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Abstract Summary (299 words) 
The aim of this thesis is to investigate the prevalence and management of bladder pain 
syndrome (BPS) amongst women with chronic pelvic pain (CPP) through a series of 
systematic reviews, a structured survey and primary study.  
 
It has been acknowledged that the diagnosis and management of BPS is a contentious 
subject. The mean prevalence of BPS in women with CPP is 61%. I initially carried 
out a patient and clinician survey to understand how BPS was being managed in the 
UK. I found wide variation in diagnostic methods and treatments of BPS used by 
clinicians and experienced by patients with no obvious consensus. Since we know the 
predominant complaint in these patients is pain (bladder or pelvic) I used patients 
with pelvic pain as my cohort.  
 
Cystoscopy is no longer used as a diagnostic test for BPS. It is possible to diagnose 
BPS through a consensus expert panel using symptom-based criteria. This method of 
deriving a reference standard is demonstrated in the primary study, since no gold 
standard diagnostic test exists for BPS. A case-control feasibility study was 
undertaken to investigate the accuracy of a group of urinary symptoms to diagnose 
BPS. While, neither index test of bladder filling pain or bladder wall tenderness can 
sensitively diagnose BPS alone, the symptoms of bladder filling pain, urinary 
frequency, pain on urination and pain on full bladder are a good predictor of the 
condition. A systematic review assessing the reporting outcomes identified five 
measures that should be included in studies; pain, urinary symptoms, general 
	   8	  
wellbeing, quality of life and bladder capacity. Of the 19 treatments used for BPS, the 
level and strength of evidence ratings overestimated quality compared to the GRADE 
ratings. BPS can be diagnosed symptomatically but there is variable reporting of 
outcome measures and poor evidence for treatment effectiveness.  
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Aims 
1. To investigate the prevalence of bladder pain syndrome (BPS) amongst 
patients with chronic pelvic pain  
2. To assess the information available to patients regarding BPS on the internet  
3. To assess patients and clinicians experiences managing BPS 
4. To evaluate the test accuracy of bladder wall tenderness and bladder filling 
pain for diagnosing BPS in patients with chronic pelvic pain  
5. To assess the role of laparoscopy and cystoscopy in the diagnosis and 
management of pelvic and bladder pain  
6. To assess the effectiveness of nerve stimulation in the treatment of pelvic and 
bladder pain  
7. To assess the relationship between quality of outcomes reported, study quality 
and journal impact factor in systematic reviews and trials of bladder pain 
syndrome. 
8. To assess the discrepancies in grading of evidence for the management of 
bladder pain syndrome  
 
Methods 
• Systematic reviews to meet objectives 1,2,6,7 
• Structured questionnaire survey to meet objective 3 
• Prospective observational study to meet objective 4 
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Results  
1. Nine studies were included with 1016 patients. Study quality and diagnostic 
assessment varied. The mean prevalence of BPS was 61% (range 11-97%, CI 
58-64%, I2 = 98%). Co-existing BPS and endometriosis was seen in 48% 
(range 16-78%, CI 44-51%, I2 = 96%). 
2. Eighteen websites were identified. The combined quality mean scores (for 
accuracy, quality, credibility and readability) ranged from 83 to 144 for 
specialist websites and 76 to 137 for non-specialist ones (a maximum possible 
score of 208). There was good inter-observer agreement for the assessments 
performed. 
3. 133 patients and 69 clinicians participated in the survey. Patients reported 
their main symptom to be pain when their bladder was full in 80% (n=107) 
and the most bothersome symptom was pelvic pain (22%, n= 29). 93% (n=64) 
of clinicians made their diagnosis by history and cystoscopy and 81% (n=108) 
of patients, reported to be diagnosed in this way. 78% (n=54) of clinicians 
treated patients with amitriptyline and 75% (n=52) by dietary modification 
while 77% (n=102) of patients reported using simple analgesia, 74% (n=98) 
dietary modification and 62% (n=83) low-dose long-term antibiotics.  
4. 46 eligible patients were recruited with a mean age of 32.8 years old. Three 
patients suffered from bladder wall tenderness and 16 from bladder filling 
pain, with 21 patients being diagnosed with BPS by expert panel diagnosis. 
The inter-observer intra-class coefficient agreement was 0.46. The sensitivity 
of bladder wall tenderness as a predictor of BPS compared to a symptom-
based diagnosis was 0.10 and the sensitivity of bladder filling pain was 0.57.   
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5. Chronic pelvic pain can be due to structural or non-structural causes and 
maybe due to multiple co-existing pathologies. Cystoscopy can be used as a 
therapeutic treatment for bladder pain syndrome. 
6. Three studies were included with 169 patients; two for CPP and one for BPS. 
There were improvements in pain, urinary and quality of life scores using both 
forms of neuromodulation. 
7. Five reporting outcomes were identified (pain, urinary symptoms, general 
wellbeing, quality of life and bladder capacity) using 19 different 
measurement scales. The correlation between reporting outcomes and study 
quality for systematic reviews was 0.73 (95% CI 0.06 - 0.95, p = 0.02) and 
0.19 (95% CI -0.22 – 0.55, p = 0.18) for RCTs. The Spearman’s rank 
correlation between impact factor and quality of reporting outcomes for RCTs 
was 0.38 (95% CI -0.06 – 0.70, p = 0.04) compared to 0.38 (95% CI -0.88 – 
0.52, p = 0.82) for systematic reviews. 
8. Of the 19 treatments for BPS that had GRADE ratings assigned, comparison 
with level of evidence ratings showed that on average the latter overestimated 
quality by 1.8 points (1.1 v 2.9; 95% CI of mean difference 1.2 to 2.3; p= 
<0.0001). Comparison of GRADE ratings with strength of evidence ratings 
showed that on average the latter overestimated quality by 1.7 points (1.1 v 
2.8; 95% CI of mean difference 1.3 to 2.1; p= <0.0001).  
 
Conclusion 
1. Almost two thirds of women presenting with CPP have BPS. Clinicians need 
to actively investigate patients for BPS, a condition that appears to co-exist 
with endometriosis. 
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2. There were for websites that filled the criteria for good quality information. 
3. There is wide variation in diagnostic methods and treatments of BPS used by 
clinicians and experienced by patients with no obvious consensus. There is a 
need for national guidance to standardise care. 
4. The absence of bladder wall tenderness can be associated with a high 
specificity and bladder filling pain with a reasonable sensitivity with high 
specificity in diagnosing BPS. A consensus expert panel was found to be a 
suitable method to achieve a symptom-based diagnosis as a reference 
standard. 
5. In view of the high incidence of co-existing pathology amongst patients with 
chronic pelvic pain (CPP), clinicians should consider performing laparoscopy 
and cystoscopy routinely to investigate CPP in order to rule out 
gynaecological or bladder causes of pain.  
6. Variable success of posterior tibial nerve stimulation (PTNS) in improving 
pain, urinary symptoms and quality of life in CPP and BPS was reported. 
There was no reported data for sacral nerve stimulation (SNS). A large multi-
centered clinical trial investigating the effectiveness of electrical nerve 
stimulation to treat BPS and CPP along with the cost-analysis of this treatment 
is recommended.   
7. Good quality RCTs tend to have better quality of outcome reporting. There is 
a need to generate consensus over a set of core outcomes in bladder pain 
syndrome.  
8. GRADE, a refined method of assigning quality to evidence, provided a more 
conservative gauge of quality of evidence, giving a realistic assessment of the 
value of recommendations for consideration in practice. 
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Synopsis 
This thesis assesses the prevalence and impact of bladder pain syndrome (BPS) 
amongst women with chronic pelvic pain (CPP), the effectiveness of 
neuromodulation, along with patients and clinicians prior beliefs about treatment and 
the levels of evidence for different treatment recommendations. It evaluates the 
diagnostic value of two index tests; bladder wall tenderness and bladder filling pain to 
diagnose BPS, as well as which outcome measures are important when reporting 
studies on BPS, along with examining the information available to patients with BPS 
and the experiences of patients and clinicians managing the disease.  
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CHAPTER 1: 
INTRODUCTION
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 Bladder Pain Syndrome	  
 
1.1 Definition  
Interstitial cystitis (IC) with ulcers was first described in 1915 by Hunner (1). By 
1978 IC had been sub-divided into disease groups with the presence of glomerulations 
and reduced bladder capacity and the ‘classical’ condition with Hunner’s ulcers (2). In 
1987 The National Institute of Digestive, Diabetes and Kidney Diseases (NIDDK) 
criteria for IC were first proposed (Appendix 2) (3). The strict inclusion criteria meant 
that many patients were under-diagnosed and the need for revisions to the definition 
were identified (4).  
 
The term ‘painful bladder syndrome’ (PBS) was introduced by the International 
Continence Society (ICS) in 2002. The condition is a differential diagnosis of chronic 
pelvic pain (CPP) with imprecise clinical characterisation, based on symptoms of 
urgency or frequency and pain in the pelvic region. PBS was defined as suprapubic 
pain related to bladder filling, accompanied by other symptoms such as increased 
daytime and night-time frequency in the absence of any identifiable pathology or 
infection (5). The ICS defined IC as a condition associated with the typical 
cystoscopic and histological features previously described (6).  
 
In 2008, The European Society for the Study of Interstitial Cystitis/Painful Bladder 
Syndrome (ESSIC), now known as the International Society for the Study of BPS, 
proposed a change in the nomenclature from IC/PBS to bladder pain syndrome (BPS) 
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describing chronic pelvic pain, bladder pressure or discomfort along with at least one 
other urinary symptom (7). The type of BPS can be further classified according to the 
cystoscopy and biopsy grading of glomerulations and the presence of Hunner’s 
lesions (Table 1). 
Table 1: The classification of bladder pain syndrome (BPS) according to 
cystoscopy and biopsy findings (7) 
 
 
 
Cystoscopy with hydrodistension 
 
 
 
      Not done       Normal  Glomerulations b Hunner’s lesions c 
 
 
Biopsy   
 
Not done XX  1X   2X   3X 
 
Normal  XA  1A   2A   3A 
 
Inconclusive XB  1B   2B   3B 
 
Positive a XC  1C   2C   3C 
 
 
 
a Histology showing inflammatory infiltrates and/or detrusor mastocytosis and/or granulation tissue 
and/or intrafasicular fibrosis. 
 
b Glomerulations: grades 2-3 (grade 2 = severe areas of submucosal bleeding, grade 3 = diffuse 
bleeding of bladder mucosa) 
 
c With or without glomerulations 
 
 
In 2009 the Japanese introduced the term hypersensitive bladder syndrome (HBS), 
which was defined as bladder hypersensitivity, usually associated with urinary 
frequency, with or without bladder pain (8). This included patients complaining of the 
IC/PBS symptoms without cystoscopic findings.  
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In 2011 the International Society for the Study of Pain (IASP) proposed a revised 
definition for BPS, acknowledging the multi-factorial nature of the disease and the 
impact on the patient’s quality of life. It defined BPS as the occurrence of persistent 
or recurrent pain perceived in the urinary bladder region, accompanied by at least one 
other symptom, such as pain worsening with bladder filling and daytime and/or night-
time urinary frequency, with no proven infection or other obvious local pathology. 
BPS can often be associated with negative cognitive, behavioural, sexual, or 
emotional consequences as well as with symptoms suggestive of lower urinary tract 
and sexual dysfunction (9). IC and BPS are now used synonymously to describe this 
disease. 
 
1.2 Epidemiology  
A variety of signs, symptoms and tests may be performed to establish a possible 
diagnosis of BPS. In view of these differences in practice, it is difficult to accurately 
calculate the prevalence of the disease. An early Finnish study in 1975 estimated the 
prevalence of BPS as 18 cases per 100,000 (0.02%) based on positive symptoms, 
negative urine infection screen and positive bladder biopsy results (10). By 2007 the 
prevalence of patients with BPS was 0.3% in Austria (11). Whereas in Japan, in 1998 
the prevalence was reported to be 2 per 100,000 and affected an older group of 
patients with a mean age of 52.9 years old, although more recently data showed that 
1.0% of the general population experienced daily symptoms of bladder pain (12-14). 
An American epidemiological survey estimated the prevalence of disease to be 
between 2.7- 6.5% of women in the United States of America (USA) who suffered 
from urinary symptoms consistent with BPS, which highlights the burden of disease 
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(15).  As the definition and diagnostic criteria for BPS has changed though the years, 
it is difficult to accurately calculate prevalence rates.  
 
1.3 Aetiology  
BPS is a chronic condition with an unknown aetiology, which is poorly understood 
pathophysiology (16). There are many theories regarding the causes of BPS. The 
glycosaminoglycan (GAG) layer protects the bladder mucosa. When this protective 
layer breaks down, the bladder mucosa is exposed to toxic substances in urine, 
leading to inflammation, which may cause symptoms such as urinary frequency and 
pain (17). The cause of this epithelial dysfunction is unknown. During the 
inflammatory process, mast cells are activated and release potent mediators, such as 
serotonin and histamine. An increased number of mast cells have been found in the 
bladder mucosa of patients (18). Studies have shown the presence of auto-antibodies 
in patients although specific ones have not been detected (19). A reduced bladder 
vascular perfusion has been noted in patients, with a decrease in the microvascular 
density of the submucosal layer and for this reason hyperbaric oxygen is believed to 
improve symptoms in affected patients (8, 20). 
 
1.4 Diagnosis  
IC was traditionally diagnosed according to the NIDDK criteria described in appendix 
2 as a clinical condition comprising of patient reported symptoms, cystoscopy 
findings of glomerulations (pinpoint petechial haemorrhages) and/or Hunner’s ulcers 
and bladder biopsies which would show inflammatory infiltrates and detrusor 
mastocytosis. Studies have shown poor correlation between cystoscopy findings and 
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diagnosis as glomerulations may be seen in asymptomatic patients and bladder 
biopsies may not confirm disease in the presence of glomerulations (8, 21). 
Cystoscopy was previously used as the ‘gold standard’ diagnostic tool but in view of 
these findings glomerulations are no longer considered diagnostic for BPS. While 
bladder biopsies are important to exclude pathology, for example carcinoma, they are 
often not performed as routine diagnostic work-up due to poor correlation with 
disease (22).  Recent American guidelines regarding the management of BPS have 
overcome these diagnostic uncertainties by recommending a symptom-based 
diagnosis, after exclusion of other confusable diseases, with cystoscopy and 
hydrodistension performed as an aid in complex presentations (8, 23, 24). It is 
important to confirm absence of a urinary tract infection. Some of the symptoms of 
BPS and overactive bladder overlap, for example, the sensation of urinary urgency so 
a careful history needs to be obtained (25). These recommendations have led to an 
over-diagnosis of symptom-based disease and under-diagnosis of Hunner’s lesions 
(formerly known as Hunner’s ulcers). It is important to identify patients with 
Hunner’s lesions as they do not respond to conservative management and need a 
different treatment course. 
 
1.5 Questionnaire tools 
Over the years, several questionnaires have been used as an aid to diagnosing affected 
patients. The two most commonly used are the O’Leary Sant (OLS) symptom and 
problem index scores and the Pelvic Pain and Urgency/Frequency (PUF) 
questionnaire (Appendix 3 and 4). In 1997 O’Leary and Sant created the OLS 
questionnaire, which was validated on 112 patients, taking into account the duration 
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of urinary and pain symptoms, and the personal impact of these symptoms on the 
patient (26). This questionnaire was shown to be a reliable measure of treatment 
outcome when comparing pre and post-treatment scores (27). In 2002, Parsons 
devised the PUF questionnaire, which was tested on 382 patients, validated against 
the outdated potassium sensitivity test (28). Unfortunately, in the PUF questionnaire 
three out of the eight questions relate to pain and are not specific for urinary 
symptoms, which cause patients to be assigned high scores. In a prospective study of 
97 patients, the PUF questionnaire was not found to be a reliable predictor of disease 
or disease severity (29). Both questionnaires tend to report a higher prevalence of 
BPS than confirmed by the clinician, therefore should not be used in isolation as a 
diagnostic tool (30).  
 
1.6 Management  
Due to the difficulty diagnosing BPS and the variety of methods used by clinicians, 
patients have often been subjected to a ‘trial and error’ approach to treatments with no 
clear evidence or guidelines regarding the effectiveness of treatment modalities.  
Through the results of systematic reviews the American Urological Association 
(AUA) published their guidelines for the diagnosis and management of BPS in 2011. 
First-line treatments comprise of conservative self-care, behavioural modification (eg 
pain management and dietary and lifestyle modification) and stress management. 
Second-line treatments include manual physical therapy (eg physiotherapy with 
internal vaginal massage), oral and intra-vesical therapies, while cystoscopy with low-
pressure hydrodistension is recommended as a third-line treatment option. The fourth-
line option is neurostimulation and fifth-line treatments include cyclosporin A and 
Botulinum toxin A while major surgery is sixth-line (Appendix 5). There are huge 
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variations in the management of BPS both locally and internationally so it is hoped 
that these guidelines will standardise diagnosis and treatment. The symptom cluster in 
BPS makes diagnosis challenging and is associated with high levels of anxiety and 
sexual dysfunction with low levels of self-esteem and quality of life amongst patients 
(11, 31).  
  
1.7 Areas of uncertainty 
There is much uncertainty around BPS from the causative bladder pathology to 
methods of diagnosis. Although the AUA guidelines have guided clinicians to 
diagnose patients and commence treatment on symptoms alone, there is still a huge 
degree of variation in practice across the UK and worldwide. The wide spectrum of 
symptoms and lack of a ‘gold standard’ diagnostic test for BPS compounds these 
difficulties. Discrepancies exist in the different international guidelines over efficacy 
of treatment and the methods of presenting this information with limited randomised 
control studies (RCTs) for many treatment options (8, 23).  Many of the first-line 
treatments are conservative, such as stress and pain management and behavioural 
modifications. These can be patient driven, so disease awareness and patient 
empowerment are an important part of management.  
 
1.8 Aims of the Study 
1.  To investigate the prevalence of bladder pain syndrome amongst patients with 
chronic pelvic pain through a systematic review (chapter 2)  
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2. To assess the information available to patients regarding bladder pain 
syndrome on the internet through a systematic review (chapter 3) 
3. To assess patients and clinicians experiences managing bladder pain syndrome 
(chapter 4) 
4. To evaluate the sensitivity of bladder wall tenderness and bladder filling pain 
in patients with chronic pelvic pain (chapter 5) 
5. To assess the role of laparoscopy and cystoscopy in the diagnosis and 
management of pelvic and bladder pain (chapter 6) 
6. To assess the effectiveness of nerve stimulation in the treatment of pelvic and 
bladder pain through a systematic review (chapter 7)  
7. To assess the relationship between quality of outcomes reported, study quality 
and journal impact factor in systematic reviews and trials of bladder pain 
syndrome (chapter 8) 
8. To assess the discrepancies in grading of evidence for the management of 
bladder pain syndrome (chapter 9) 
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1.9 Framing the research questions 
Table 2: Structured questions for each chapter of this thesis 
Chapter 
number 
Population Intervention/test Outcome Study design 
2 Women with CPP  Laparoscopy and 
cystoscopy 
Endometriosis 
BPS 
Both 
Systematic review 
of observational 
studies 
3 Websites with 
information about 
BPS 
Quality 
Readability 
Accuracy 
Credibility 
Quality assessment of 
information 
Systematic review 
4 Patients with BPS Symptoms 
Cystoscopy 
Diagnostic tests 
Treatment options 
Electronic 
structured 
questionnaires 
5 Women with CPP Bladder wall tenderness 
Bladder filling pain 
Diagnosis of BPS Prospective 
observational  
6 Patients with CPP 
and/or BPS 
Laparoscopy 
Cystoscopy 
Gynaecology 
pathology 
Bladder pathology 
Literature review  
7 Patients with CPP 
and/or BPS 
Sacral nerve stimulation 
Posterior tibial nerve 
stimulation 
Symptomatic 
improvement 
Systematic review 
of randomised 
studies 
8 Patients with BPS Outcome measures for 
treatments of BPS  
Quality of reporting 
outcomes 
Systematic review 
of systematic 
reviews 
9 Treatment options for 
BPS 
GRADE rating Discrepancy in 
quality of evidence 
score 
Literature and 
quality review of 
evidence 
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CHAPTER 2:  
PREVALENCE OF BLADDER PAIN 
SYNDROME AMONGST PATIENTS WITH 
CHRONIC PELVIC PAIN:  
A SYSTEMATIC REVIEW 
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This chapter focuses on assessing the prevalence of bladder pain syndrome amongst 
women with chronic pelvic pain (CPP). CPP is multi-factorial and the main 
gynaecology pathology is endometriosis. I have investigated the co-existence of BPS 
and endometriosis.  
 
2.1 Abstract 
Objectives: To estimate the prevalence of BPS and the co-existence of BPS and 
endometriosis in women with CPP. 
 
Data sources: The following databases were searched from inception until March 
2012: The Cochrane Library, DARE (1997-2012), EMBASE (1980-2012), Medline 
(1950-2012), PSYCHINFO (1806-2012), Web of knowledge (1900-2012), LILACS 
(1982-2012) and SIGLE (1990-2012). There were no language restrictions. 
Bibliographies and conference proceedings of the International Continence Society 
were manually hand-searched. 
 
Study selection: Observational studies of women suffering from CPP, who 
underwent a laparoscopy and cystoscopy to investigate their symptoms, were 
included. Exclusion criteria were pregnancy and a diagnosis of cancer. Study 
selection, data extraction and quality assessment was performed independently in 
duplicate. Estimates of prevalence and confidence intervals (CI) were calculated. 
 
Results: There were nine studies (1016 patients) with women with CPP. Quality and 
diagnostic assessment varied across studies. The mean prevalence of BPS was 61% 
(range 11-97%, CI 58-64%, I2 = 98%). The mean prevalence of endometriosis was 
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70% (range 28-93%, CI 67-73%, I2 = 93%) and co-existing BPS and endometriosis 
was 48% (range 16-78%, CI 44-51%, I2 = 96%).  
 
Conclusion: Almost two thirds of women presenting with CPP have BPS. There are 
large variations in prevalence, which may be due to variable study selection and 
quality. We recommend that clinicians actively investigate patients for BPS, a 
condition that appears to co-exist with endometriosis.  
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2.2 Background 
 
BPS has an unknown aetiology. The reported prevalence is between 5 and 16 per 
100,000 of the population (15, 32). Its prevalence amongst women with CPP is 
unknown. CPP can be multi-factorial in nature and the co-existence of pathology is 
not uncommonly found. Conditions such as BPS and endometriosis, described by 
Chung et al as the ‘evil twins syndrome’ can make management very difficult (33-
35). The ‘evil twin syndrome’ is not a medical definition but it this name is able to 
convey the misery of the co-existence of these two chronic pain conditions amongst 
patients.  
 
The aim of this systematic review was to estimate the prevalence of BPS in women 
suffering from CPP. The secondary objective was to estimate the prevalence of 
endometriosis and the co-existence of BPS and endometriosis within this group of 
women. 
 
2.3 Methods  
Our systematic review was prospectively conducted and reported in accordance with 
the PRISMA statement (36). 
 
Data sources 
Searches through the following databases from inception until March 2012 were 
performed: The Cochrane Library, DARE (1997-2012), EMBASE (1980-2012), 
Medline (1950-2012), PSYCHINFO (1806-2012), Web of knowledge (1900-2012) 
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and LILACS (1982-2012). Grey literature was searched through SIGLE (1990-2012) 
and there were no language restrictions imposed.  
 
Search strategy 
Medical subject headings (MeSH) and keywords for ‘chronic pelvic pain’ and 
‘chronic pain’ were combined using the Boolean operator ‘and’ with the terms 
‘interstitial cystitis’ or ‘painful bladder syndrome’ or ‘bladder pain syndrome’ or 
‘urinary frequency’ or ‘urinary urgency’. The search criteria was restricted to those 
studies involving female patients. Bibliographies from relevant articles and 
conference proceedings of the International Continence Society were manually hand-
searched in order to identify articles not electronically cited because prevalence 
studies are not well indexed in database searches.   
 
Study selection 
Relevant observational studies on CPP were identified which met the following 
eligibility criteria: 
 
Participants 
Women suffering from chronic pelvic pain with, or without, urinary symptoms 
suggestive of IC, PBS or BPS, who underwent a laparoscopy and cystoscopy to 
investigate their symptoms, were included. Exclusion criteria were pregnancy, a 
woman suffering from cancer and patients diagnosed solely on intravesical potassium 
sensitivity test (PST). CPP was defined according to the Royal College of 
Obstetricians and Gynaecologists of the United Kingdom (RCOG), as an intermittent 
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or constant pain in the lower abdomen or pelvis of at least 6 months duration that is 
not exclusively associated with menstruation, intercourse or pregnancy (37).  
 
Outcome 
As most of the studies were performed prior to the introduction of the BPS 
nomenclature, for the purpose of this review all those with IC were considered to have 
a symptom based diagnosis of BPS, as this would logically happen under the new 
disease classification. BPS was defined according to the NIDDK criteria with 
glomerulations on cystoscopy or a classic Hunner’s ulcer, and either pain associated 
with the bladder or urinary urgency. Glomerulations are punctuate petechial 
hemorrhages on the bladder wall which were diagnosed after two minutes of bladder 
distension under anaesthesia (2). At least ten glomerulations were needed in at least 
three quadrants of the bladder in order to diagnose BPS (4). 
 
Study selection 
Cross-sectional studies were included, which are neither prospective nor retrospective 
but measure the given condition at one point in time, as well as cohort studies, which 
provide prevalence figures from the baseline data collection phase. 
 
Data extraction and quality assessment 
The data were extracted independently in duplicate by two reviewers (SAT, KK). 
Patient characteristics (number of participants, age and ethnicity), study details (study 
design, location, setting, and participant recruitment as part of the study quality 
assessment to assess possible selection bias) and outcomes assessed (diagnostic tools 
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and rates of BPS, endometriosis and co-existing pathology) were collected on a pre-
designed data extraction form.  
 
Quality assessment was performed by one reviewer and checked by a second reviewer 
in order to assess the overall quality of the studies used in this systematic review. 
There were no language restrictions so studies not published in English were 
translated by individuals with command of the relevant language (38). Data from one 
study was extracted from a conference abstract where the full article could not be 
obtained (39). Quality assessment was performed using a checklist to evaluate 
internal validity using the following characteristics (40) (41): (a) Study design to 
determine if BPS assessment had been performed prospectively to minimise recall 
bias; (b) Adequacy of sampling by assessing whether participant recruitment was 
random or consecutive; (c) Sufficiently high response rate (>80%); (d) Use of 
diagnostic criteria to diagnose BPS to ensure participants response rates are a true 
representation of the underlying condition; (e) Sample size calculation so as to 
ascertain prevalence reliably. An study that complied with 3/5 quality criteria was 
considered ‘high quality’ (42). External validity was considered separately as the 
representativeness of the sample for the general population (source of sample) (35). 
 
Data synthesis 
The prevalence and 95% confidence interval (CI) was calculated for each study, along 
with heterogeniety which was assessed using I2 using the Metadisc statistical software 
package (43). Individual studies could not be combined as they were too heterogenous 
so pooled results were given for information only.  Results with I2 > 50% are 
considered highly heterogenous. 
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2.4 Results 
801 citations were identified (figure 1). 597 citations were found after all duplicate 
citations were removed and 13 of these were deemed relevant and their full papers 
were retrieved. Four studies had to be excluded for the following reasons: in one 
study only the secondary outcome of co-existing BPS and endometriosis was 
measured, one had the presenting condition of BPS rather than CPP and in two studies 
the same patient population was reported, and this was confirmed by the 
corresponding author. This systematic review included nine studies (21, 34, 38, 39, 
44-48). 
	  
Figure 1: A flow chart to represent the study selection for the prevalence of 
bladder pain syndrome amongst women with chronic pelvic pain.  	  
	  
801 records identified 
through database searching 
597 records screened 
13 full text articles screened 
for eligibility 
9 studies included in 
qualitative synthesis 
 
4 studies excluded: 
1 study – primary outcome not 
measured 
1 study – patients did not match 
inclusion criteria 
2 studies – same data used 
!
584 records excluded 
204 duplicate articles 
manually identified 
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Study characteristics 
The nine observational studies included 1016 patients. These studies were performed 
between 1990 to 2011. Table three summarises the study characteristics.  
 
Table 3: Study characteristics for papers included in the systematic review of 
bladdder pain syndrome and endometriosis. 
 
 
Study 
 
 
 
 
Country Mean age in 
years 
(age range) 
Ethnicity Number of 
patients 
Duration of 
study (months) 
Source of 
recruitment 
Cheng 2012 
 
Chung 2002 
 
Chung 2005 
 
Clemons 2002 
 
 
Paulson 2011 
 
Rackow 2009 
 
Shahmohamady 
2005 
 
Stanford 2005 
 
Villegas 2011 
 
 
Australia 
 
USA 
 
USA 
 
USA 
 
 
USA 
 
USA 
 
USA 
 
 
USA  
 
Columbia 
30 
 
19-62 
 
18-60 
 
35.2 (20-53) 
 
 
Not documented 
 
13-25 
 
36 (20-60) 
 
 
32.7 
 
32.6 (17-53) 
Not documented 
 
Not documented 
 
Not documented 
 
73% Caucasian, 16% 
Hispanic, 2% African-
American, 9% other 
 
Not documented 
 
96% Caucasian, 4% 
African-American 
 
Not documented 
 
 
Not documented 
 
Not documented 
150 
 
60 
 
178 
 
45 
 
 
284 
 
28 
 
92 
 
 
64 
 
115 
29 
 
12 
 
24 
 
7 
 
 
72 
 
168 
 
Not documented 
 
 
12 
 
26 
Specialist clinic 
 
Specialist clinic 
 
Specialist clinic 
 
Operating list 
 
 
Operating list 
 
Operating list 
 
Specialist clinic 
 
 
Community 
gynaecology clinic 
 
Specialist clinic 
 
 
All the studies diagnosed BPS using the NIDDK criteria, despite variations in the 
disease nomenclature. Between 11% (48) to 97% (34) of patients were diagnosed with 
BPS, with a mean prevalence of 61% (58-64%). Assessing study design, five studies 
were prospective. Sample size calculations were performed in one study, using Piface 
software (17). The lack of reporting on whether participants were randomly or 
purposefully recruited, made assessing external validity difficult. However, in three 
studies retrospective recruitment of women was performed from theatre operating 
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lists. Figure two shows quality assessment for all included studies with seven 
considered ‘high quality’.  
 
Figure 2: Quality assessment of included studies  
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One study reported that routine bladder biopsies were only performed when 
glomerulations were noted at cystoscopy (21). 44% of patients had normal 
histopathology results. There were two studies in which bladder biopsies were 
performed; one to rule out carcinoma and another where no cause was identified 
during cystoscopy.   
 
All nine studies reported the prevalence of endometriosis. This ranged from 28% (48) 
to 93% (34), with a mean prevalence of 70% (CI 67-73%) (Figure three). 
Endometriosis was diagnosed by visual inspection on laparoscopy with confirmatory 
biopsies performed in 3 studies (33, 34, 48). Two studies reported that biopsies were 
taken to confirm diagnosis where possible (21, 46). Seven studies documented the co-
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existence of pathology. This ranged from 16% (49) to 78% (34), with a mean 
prevalence of 48% (CI 44-51%) (Figure three).  
	  
	  
	  
Figure 3: Prevalences of  bladder pain syndrome (BPS), endometriosis and co-
existing BPS and endometriosis amongst women with chronic pelvic pain (CPP).  
 
 
3a: Prevalence of BPS amongst women with CPP 
Prevalence
0 0.2 0.4 0.6 0.8 1
Cheng, 2012 32%    (25% - 40%)
Chung, 2002 97%    (88% - 100%)
Chung, 2005 89%    (84% - 93%)
Clemons, 2002 31 %   (19% - 45%)
Paulson, 2011 81%    (76% - 85%)
Rackow, 2009 39%    (22% - 59%)
Shahmohamady, 2005 28%    (19% - 39%)
Stanford, 2005 11%    (5% - 21%)
Villegas, 2011 59%    (50% - 68%)
Prevalence (95% CI)
61% (58% to 64%)
Inconsistency (I-square) = 97.8 %
High quality
Low quality
 
 
 
3b: Prevalence of endometriosis amongst women with CPP 
Prevalence
0 0.2 0.4 0.6 0.8 1
Cheng, 2012 60%    (52% - 68%)
Chung, 2002 93%    (84% - 98%)
Chung, 2005 75%    (68% - 81%)
Clemons, 2002 47%    (32% - 62%)
Paulson, 2011 78%    (73% - 83%)
Rackow, 2009 64%    (44% - 81%)
Shahmohamady, 2005 88%    (80% - 94%)
Stanford, 2005 28%    (18% - 41%)
Villegas, 2011 65%    (56% - 74%)
70%   (67% to 73%)
Inconsistency (I-square) = 93.0 %
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3c: Prevalence of BPS and endometriosis amongst women with CPP 
Prevalence
0 0.2 0.4 0.6 0.8 1
Cheng, 2012 18%    (12% - 25%)
Chung, 2002 78%    (66% - 88%)
Chung, 2002 65%    (57% - 72%)
Clemons, 2002 16 %   (06% - 29%)
*Paulson, 2011 61%    (55% - 67%)
Rackow, 2009 25%    (11% - 45%)
*Shahmohamady, 2005 26%    (17% - 36%)
48%   (44% to 51%)
Inconsistency (I-square) = 96.4 %
* = ‘low quality’ study
 
In five (45%) studies the affected patient group was identified through their 
symptoms and clinical examination. In the other four studies (44%) validated 
questionnaires were used; one used the IC symptom index problem index (O’Leary 
Sant questionnaire, OLS) which correlated with the diagnosis of BPS in 94% of 
patients, two used the pelvic pain urgency/frequency (PUF) questionnaire, showing 
higher PUF scores in the BPS patients, and one used both questionnaires to assess the 
degree of BPS, showing higher scores in the BPS patients (mean PUF score of 8.6 and 
OLS score of 7.5) (21).  Three studies (33%) used the visual analogue scale 
questionnaire to assess pain. The mean pain score for CPP ranged from 5.3 - 8, and 
5.4 – 7 for BPS (21, 46, 49). 
 
2.5 Conclusion  
The literature reports a range of prevalence rates for BPS. There is large variation in 
rates which may be explained by variable study quality and sample selection. Patients 
recruited from specialist clinics and operating lists had the highest prevalence of BPS. 
In four out nine studies, patients suffered from CPP and urinary symptoms and some 
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of the highest prevalences of BPS (33, 34, 39, 46, 50). 67% (n=6) of studies had an 
authorship team with a special interest in urogynaecology. 
 
This systematic review was performed in accordance with PRISMA (appendix 6), 
with comprehensive data searches, selection of studies and duplicate data extraction, 
and appropriate synthesis of results. This chapter highlights the fact that almost two 
thirds of patients presenting with CPP have BPS. The diagnosis was made by the 
presence of urinary symptoms and positive cystoscopy findings in all included 
studies. However, as previously discussed, cystoscopic normality and bladder lesions 
are poorly correlated with histopathology, which is a limitation to disease 
classification (23), leading to the possibility of misdiagnosing patients. Commonly 
used questionnaires like OLS and PUF do not record symptoms such as bladder pain 
or bladder filling pain and the clinical value of such questionnaires as a diagnostic 
tool is debatable (51). The included studies had limited information about ethnicity, 
although literature shows that the prevalence of BPS does not vary with ethnicity but 
minority women appear to be symptomatic for longer than Caucasian women. 
However, the prevalence of endometriosis appears to be higher in Asian women than 
other ethnicities (52-54). 
 
The clinical presentation of BPS is similar to many other urinary conditions, making 
diagnosis challenging and can lead to delays in treatment. BPS is associated with 
chronic non-urological conditions, such as fibromyalgia, irritable bowel syndrome, 
vulvodynia and pelvic floor dysfunction, highlighting the importance of multi-
disciplinary care (55, 56). The introduction of the American Urological Association 
guidelines for the diagnosis and management of IC and BPS in 2011 recommends that 
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cystoscopy only used as a diagnostic tool in complex presentations. Thus allowing 
initiation of conservative treatments, such as pain relief, behavioural modification and 
stress management (23). Clinicians need to be aware of the existence of co-existing 
pathology and actively investigate urinary symptoms and BPS as a cause of CPP, 
allowing treatments to be initiated early.  
 
This chapter is based on the following peer-reviewed publication (57): 
The ‘evil twin syndrome’ in chronic pelvic pain: a systematic review of the 
prevalence studies of bladder pain syndrome and endometriosis. 
SA Tirlapur, K Kuhrt, C Chaliha, E Ball, C Meads, KS Khan 
Int J Surg. 2013 Feb; 233-237 
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CHAPTER 3: 
ASSESSING THE INFORMATION 
AVAILABLE TO PATIENTS REGARDING 
BLADDER PAIN SYNDROME ON THE 
INTERNET: A SYSTEMATIC REVIEW 
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This chapter discusses how information on the internet can be assessed, specifically 
looking at the quality of information related to BPS. 
 
 
3.1 Abstract  
 
Objectives: To assess sources of medical information on bladder pain syndrome 
available on the internet for quality, accuracy, credibility and readability. 
 
Methods: The meta-search engine Copernic agent was used to perform searches with 
the terms ‘pelvic pain, interstitial cystitis, painful bladder syndrome and bladder pain 
syndrome’. This meta-search engine captured websites from a range of commonly 
used search engines. We used English language websites, which were open-access. 
There were four quality assessments parameters; credibility which was based on a 10-
point scale, accuracy that was based on the American Urological Association 
guidelines, quality which used the DISCERN questionnaire and readability which was 
evaluated using Flesch reading ease scores. Intra-class coefficient (ICC) was used to 
test for inter-rater agreement. 
 
Results: We identified eighteen suitable websites; seven (39%) were specific to BPS. 
There was a wide variation in combined mean scores for the four quality parameters 
ranging from 83 to 144 for specialist BPS or urology websites and 76 to 137 for 
general or non-specialist ones. The maximum possible score was 208. We found good 
inter-observer agreement with an ICC ranging from the highest score of 0.80 for 
DISCERN to the lowest of 0.53 for readability. Specialty specific websites were 
found to have higher quality scores with a median difference of 10, p=0.07, and 
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readability scores had a median difference 5.4, p=0.05, compared to non-specialty 
websites whereas there was no difference in credibility and accuracy scores. 
 
Conclusion: Four websites were found that fulfilled our criteria for good quality 
information related to BPS. 
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3.2 Background 
 
Patients often use the internet as a source of information and for medical advice. It 
can be a useful tool, allowing patients to share experiences with others, acting as a 
support network. Unfortunately, the medical information found on the internet can be 
variable in quality and is often unregulated (58, 59). Conditions such as BPS have a 
huge impact on a patients quality of life and treatments may not adequately control 
symptoms, therefore support networks can be a valuable source of education and 
support (60). In this systematic review we assessed the quality of medical information 
related to BPS found on the internet. 
 
 
3.3 Methods 
A prospective protocol was registered with the international prospective register of 
systematic reviews (PROSPERO)(61). This included information about the search 
strategy, inclusion criteria, methodology and analysis, which was performed in 
accordance with PRISMA guidelines (62). 
 
Identification of websites 
We constructed a list of search terms most commonly used for BPS through the 
Google search engine. We used the terms ‘interstitial cystitis’, ‘painful bladder 
syndrome’ and ‘bladder pain syndrome’. In order to develop a comprehensive search 
strategy, website links for the first ten websites were evaluated.	  On 15th November 
2012 we performed the search using the meta-search engine Copernic agent. This 
engine combines several commonly used search engines to remove duplicate results, 
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store and manage the results obtained (http://www.copernic.com). The following 
search engines were used: Alta vista, ask.com, bing, blekko, Copernic, dogpile, duck 
duck go, enhance interactive, exalead, fast search, google, incywincy, lycos, 
mamma.com, open directory project, yahoo! and yippee,	   with the search terms 
‘bladder pain syndrome, interstitial cystitis, painful bladder syndrome, pelvic pain’.  
Only English language websites were included. Any websites that required a 
password or were not open access were excluded, as well as citations of scholarly 
scientific articles.	  
 
Data extraction and quality assessment  
Two reviewers (SAT, CL) independently assessed information on the websites for 
four parameters: quality, credibility, accuracy and readability. Credibility was defined 
as the ability to inspire belief. It was scored on a ten-point criteria scale: source, 
content, currency, utility, editorial review process, hierarchy of evidence, statement of 
original source, disclaimer which included ownership, sponsorship, funding and 
advertising, omissions and a feedback mechanism (63-69). A score of 0 or 1 was 
assigned to each criterion with 0 for absence and 1 for presence, which gave a score 
ranging from 0-10. Table 4 describes the criteria for accuracy, which consisted of nine 
items that were based on the American Urological Association guidelines for the 
management of BPS (23, 30). Each item was assigned a score 0, 1, 2; 0 if there was 
absence or incorrect information, 1 if the item was mentioned and 2 if the item was 
mentioned adequately. This gave a score, which ranged from 0-18.  
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Table 4: The accuracy criteria used to assess the quality of information about 
bladder pain syndrome found on the internet (23).  
 
 
  Criteria                                                       Descriptor* 
 
 
1                     Definition: ‘Chronic pelvic pain, pressure or discomfort of greater than 6 weeks duration    
                       perceived to be related to the urinary bladder accompanied by at least one other urinary   
                       symptom in the absence of any identifiable cause’             
 
2                     Assessment: history, symptom questionnaire, pain evaluation, physical examination and 
                       urine dipstick 
 
3                     First line treatment: behavioural (stress management, relaxation, dietary modification, 
                       patient education) 
 
4                    Second line treatment: physical (pelvic floor biofeedback, soft tissue massage) 
 
5                    Oral: analgesia, antihistamine, antidepressants.  
                      Intravesical: DMSO (Dimethyl sulfoxide), heparin, lidocaine 
 
6                    Cystoscopy with hydrodistension under anaesthesia 
 
7                    Neuromodulation: posterior tibial nerve and sacral nerve stimulation 
 
8                    Botulinum toxin or cyclosporin 
 
9                    Surgical management: Diversion with possible cystectomy 
 
 
 
* Each of the 18 websites were evaluated for accuracy using the 9-point scoring system above which 
was derived from the 2010 American Urological Association guidelines for the diagnosis and 
management of interstitial cystitis/bladder pain syndrome. 
 
 
 
The Flesch Reading Ease and Flesch-Kincaid grade level were used to assess 
readability. Scores for the Flesch reading ease ranged from 0-100 where the higher 
the score, the more readable the website. The Flesch-Kincaid grade level scores 
ranged from 1-12. The target was a score of <8, which meant it could be understood 
by an 8th grade school child, aged around 13-14 years old (70, 71). In order to 
calculate readability the text on the first page of the website, which usually gave a 
summary of the condition, was used. This was done using an online readability 
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calculator (www.readability-score.com). The DISCERN questionnaire was used to 
test for quality. This tool analysed the quality of information about treatment choices 
for any given condition. There are 16 questions which were rated 1- 5; where 1 = no 
(incorrect response), 3 = partial and 5 = yes (correct response), with the highest 
achievable score being 80. This DISCERN questionnaire is a validated tool which is 
used to evaluate consumer health information to critically appraise the information in 
a standardised manner by assessing the reliability and quality of information (72, 73). 
 
 
Data analysis  
Intra-class co-efficient (ICC) was used to test for agreement between inter-rater 
reliability of assessments (72). The scoring system for agreement was made in the 
following manner: less than 0.2 (poor agreement); 0.6 to 0.8 (good agreement); 
greater than 0.8 (very good agreement) (74). Analysis was performed using the two 
observers mean scores. The stats direct software package (version 2.7.9) was used to 
perform the Mann-Whitney U test in order to compare measures for specialty and 
non-specialty websites. Websites specific to BPS and bladder related conditions were 
deemed to be specialty websites, compared to non-specialty websites.  
 
 
3.4 Results 
Figure 4 shows that from 84 citations in 17 different databases, 18 websites were 
identified to be included in this review.  
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Figure 4: Study selection for assessment of information on the internet related to 
bladder pain syndrome. 
 
 
Website	  citations	  (n=84)	  
from	  17	  databases
Websites	  reviewed	  (n=56)
Websites	  included	  (n=18)
Duplicates	  (n=28)
Unsuitable	  
websites	  (n=38)
 
 
 
 
ICC was used to calculate the agreement between the two reviewers assessing the 
websites. For DISCERN the ICC was 0.75 (95% limits of agreement -14.8 to 21.8), 
0.63 for credibility (95% limits of agreement -2.48 to 4.04), 0.80 for accuracy (95% 
limits of agreement -5.86 to 2.41) and 0.53 for readability (95% limits of agreement = 
-18.3 to 21.2). 
 
The website characteristics are represented in table 5. There were 12 (67%) websites 
that were based in America; seven (39%) were specific to BPS/IC; six (33%) websites 
had a patient forum or participation function and 11 (61%) websites were linked to 
social media platforms such as Facebook and twitter.  
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Table 5: A summary of characteristics for the included websites. 
 
 
  Website address     Country Disease specific   Patient focused    Listed authors     Patient forum       Privacy statement 
 
www.niddk.nih.gov                      USA             No                        Yes                       No                                No                          Yes 
         
www.wikipedia.org                International      No                         No                        No                                No                          Yes 
 
www.essic.eu                         International      Yes                        No                        Yes                               No                          Yes 
 
www.associatedcontent.com        USA            No                         Yes                       Yes                               No                          Yes 
  
www.womenshealth.gov              USA             No                         Yes                      No                                No                          Yes 
 
www.webmd.com                         USA            No                         Yes                      No                               Yes                          Yes 
 
www.painful-bladder.org       International       Yes                       Yes                      Yes                               No                           Yes 
 
www.mayoclinic.com                   USA             No                       Yes                       Yes                               No                          Yes 
 
www.ehow.com                            USA             No                        Yes                      Yes                               No                          Yes 
 
www.bladderandbowelfoundation.org         
                                                       UK              Yes                       Yes                       No                               Yes                         Yes 
 
www.medicinenet.com                 USA             No                       Yes                       Yes                               Yes                         Yes 
 
www.ichelp.org                             USA            Yes                      Yes                       Yes                               No                          Yes 
 
my.clevelandclinic.org                  USA            No                        Yes                       No                                No                          Yes 
 
www.ic-network.com                    USA            Yes                      Yes                       Yes                               Yes                         Yes 
 
www.localhealth.com                   USA             No                        Yes                       Yes                               Yes                        Yes 
 
www.intelihealth.com                   USA             No                        Yes                       Yes                              No                          Yes 
            
www.cobfoundation.org                UK               Yes                      Yes                       Yes                              Yes                         Yes 
 
w  www.urologyhealth.org                  UK               Yes                      Yes                        Yes                              No                          Yes 
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Table 6: A summary of the outcome measures used to assess the included studies on bladder pain 
syndrome. 
 
 
Website address DISCERN*     Accuracy*                               Credibility*           Readability* 
                                  
                                  Mean       SD                 Mean         SD                         Mean        SD                                            Mean       SD      
 
www.niddk.nih.gov   68.5         0.5                 12.0            0                             8.0           1.0                                             48.2         1.75 
 
Wikipedia.org            53.2         5.0                 17.0            0                             2.0            0                                               31.7         0.35 
 
www.essic.eu            34.0         8.0                  2.5             0.5                          4.0            2.0                                            42.3         11.0 
 
www.associatedcontent.com                
                                   27.5         2.5                 5.0             1.0                          3.5            0.25                                         40.2          3.55 
       
www.womenshealth.gov                     
                                   55.0         3.0                 10.5           0.5                           6.5            0.5                                           69.1          0.05 
    
www.webmd.com     46.5          0.5                 10.5           2.5                          5.5            1.5                                            56.3           1.0 
 
 
www.painful-bladder.org                    
                                  70.0          4.0                 17.5           0.5                          7.5            0.5                                            48.9          8.95 
 
www.mayoclinic.com                         
                                   63.5        11.5                 15.0           0                            7.0           0                                                3.2          0.8 
  
www.ehow.com         40.5        4.5                   8.0           1.0                           3.0           0                                               44.2          0.6 
  
www.bladderandbowelfoundation.org      
                                   59.0        3.0                   10.5          0.5                           6.0           1.0                                           45.6           1.25 
 
www.medicinenet.com                         
                                   61.0        2.0                  11.5           3.5                          8.0            0                                              32.8          4.3 
 
www.ichelp.org         71.0        7.0                  17.5           0.5                           8.0            1.0                                          43.7           9.8 
 
my.clevelandclinic.org                         
                                   40.0        4.0                  8.0            1.0                           4.5            0.5                                          35.5           2.65 
 
www.ic-network.com                        
                                  74.5        4.5                  14.0            0                             9.0            0                                             45.0          6.2 
  
www.localhealth.com                         
                                  45.0        2.0                  10.5           1.5                           7.0           0                                              37.5          7.85 
 
www.intelihealth.com  
                                  43.5       2.5                    8.5           1.5                           7.0            0                                             39.6           0.6 
  
www.cobfoundation.org                      
                                  52.0       3.0                    10.0          2.0                          6.0           2.0                                          47.4          0.6 
   
www.urologyhealth.org                       
                                 53.0       6.0                     7.0           1.0                           5.5           0.5                                           57.8          0 
 
 
 
*DISCERN tool for quality assessment (maximum score 80), accuracy assessment based on American Urological Association 2011 
guidelines (maximum score 18), credibility based on10 criteria (maximum score 10) and readability using the Flesch reading ease 
assessment (maximum score 100). 
 
 
The quality outcome measures for the included websites are summarised in table 6 and figure 
5.  
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Figure 5: Graphical summary of the outcome measures for the included websites. 
 
5a: Websites specific to bladder pain syndrome 
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Total mean scores were calculated for the following criteria: DISCERN had a mean score of 
60 (maximum score 80), accuracy had a mean score of 11 (maximum score 18), credibility 
had a mean score of 6 (maximum score 10) and readability had a mean score of 45 
(maximum score 100). Readability scores were lower than other outcome measures. The 
complexity of medical terminology used by many websites may account for this as it did not 
make the website pages easy to read for the general public.  Several websites performed well 
with high combined quality scores, which may have been due to their high readability scores. 
The readability of a website is important but general quality, accuracy and credibility 
measures are also necessary when providing information for patients. In this systematic 
review I found the best information was provided by the following websites: www.ic-
network.com, www.ichelp.org, www.painful-bladder.org, www.niddk.nih.gov, of which 
three were specific to BPS. It was noted that specialty-specific websites tended to have higher 
DISCERN score (median difference 10, p=0.07) and readability scores (median difference 
5.4, p=0.05) with no difference in credibility (median difference = 1, p= 0.22) and accuracy 
scores (median difference = 0.5, p=0.40) compared to non-specialist websites. 
 
 
3.5 Conclusion  
This appears to be the first formal publication assessing the information available on the 
internet related to BPS. It was a robust review of all identified websites associated with BPS 
and IC. There were four websites identified as easy to navigate, which performed well across 
the outcome measurements of accuracy, quality, credibility and readability that could be 
recommended to patients as useful sources of information. Good inter-rater agreement was 
recorded for DISCERN and credibility with very good agreement for accuracy. We had to 
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exclude websites that were not written in English or where a translation tool was unavailable, 
which was a weakness of this review. 
 
Chronic pain syndromes like BPS, greatly impact on a patient’s quality of life and their 
interactions with family members so it is important, that as clinicians, we can empower 
patients to better understand their conditions in order to improve disease awareness and self-
management (75). There are guidelines for the postings on websites developed by the 
American Medical Association but their usefulness is extremely variable. For this reason it is 
important that clinicians enquire about the source and type of information patients receive 
from the internet in order to clarify any inaccuracies (65, 76-78).  
 
Self-help and conservative lifestyle modifications can have a beneficial effect on patients 
symptoms (79). Social media and the internet can help patients contact other sufferers, acting 
as a support system, as well as a constant source of information and communication. 
Clinicians should be aware of the valuable resource these websites can provide and 
recommend the good ones as an educational and support aid (80). 
 
This chapter is based on the following peer-reviewed publication (81): 
Quality of information on the internet related to bladder pain syndrome: a systematic 
review of the evidence 
SA Tirlapur, C Leiu, KS Khan 
Int J Urogyn. 2013 Aug;24(8):1257-62 
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CHAPTER 4:  
ASSESSING PATIENTS AND CLINICIANS 
EXPERIENCES MANAGING BLADDER PAIN 
SYNDROME AND THEIR PRIOR BELIEFS ON 
POSTERIOR TIBIAL NERVE STIMULATION 
	   69	  
In this chapter I explore the attitudes of urogynaecologists based in the UK towards 
diagnosing and treating BPS, as well as evaluating their thoughts on the value of PTNS as a 
therapy. I investigate patient experiences in order to compare them to clinician’s ideas to 
allow assessment of current practice.  
 
 
4.1 Abstract  
 
Background: The management of BPS varies throughout the UK with no current national 
guidance. This variation is reflected in the patient’s experience, often with delays in diagnosis 
and initiation of treatments.   
 
Objectives: To determine current practice regarding diagnosis and management of bladder 
pain syndrome (BPS) and assessment of prior beliefs on the effectiveness of percutaneous 
tibial nerve stimulation (PTNS) through a prospective electronic questionnaire based survey 
of patients and clinicians. 
 
Methods: A patient questionnaire was posted on three international patient support groups. 
The clinician survey was sent to all members on the British Society of Urogynaecology 
(BSUG) database. Methods of diagnosis, treatment options, opinions and prior beliefs on 
neuromodulation and useful internet sources were assessed, along with patient and clinician 
characteristics. 
 
Results: The survey questionnaire was completed by 133 patients and 69 clinicians. The 
main patient-reported symptom was pain when the bladder was full in 80% (n=107) with the 
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most bothersome symptom of pelvic pain in (22%, n= 29) of women. 93% (n=64) of 
clinicians relied on making their diagnosis by history and cystoscopy. 78% (n=54) of 
clinicians reported to use amitriptyline as a treatment option and 75% (n=52) used dietary 
modification.  77% (n=102) of patients reported using simple analgesia as a treatment, 74% 
(n=98) dietary modification and 62% (n=83) low-dose long-term antibiotics. 46% of 
clinicians were unsure whether PTNS was beneficial, but thought it was not harmful, while 
16% of patients were unsure whether PTNS was harmful or beneficial.  
 
Conclusion: This survey showed that there appears to be no obvious consensus in the 
management of BPS with wide variation in diagnostic methods and treatments used by 
clinicians and experienced by patients. There is a need for national guidance in order to 
standardise care.  
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4.2 Introduction 
BPS is a diagnosis of exclusion, usually derived after ruling out other possible disease 
processes, which leads to challenges in the diagnosis and management of the condition (7). 
From clinical experience and observation, I noticed an apparent variation in clinician’s 
approaches to managing this condition, which is hampered by the fact there are currently no 
national guidelines in the United Kingdom to standardise practice. The American Urological 
Association (AUA) guidelines of 2011 (23) may have helped stream-line management as this 
has encouraged clinicians to employ a symptom based diagnosis and commence treatment 
without waiting for a definite diagnosis, but this is often very hard to achieve. 
 
When a condition has imprecise clinical characterisation and its aetiology is poorly 
understood, it can be insightful to gain an understanding of the patient’s experience in the 
diagnosis and methods of treatment undertaken, along with appreciating the clinician’s 
individual beliefs and therapeutic preferences. In these situations, surveys can provide up to 
date information about current ideas and practice, which can help identify areas in need of 
improvements (82).  
 
Neuromodulation or nerve stimulation, for example percutaneous tibial nerve stimulation 
(PTNS), is used as a fourth-line treatment for BPS, which may be considered when other 
therapies have failed to offer symptomatic relief (23). There appears to be limited data on 
treatment effectiveness, and the observational studies present have low strength of evidence, 
with no randomised trials comparing PTNS and placebo (81, 83). As an individual, our prior 
beliefs in treatment effectiveness may often be guided by colleague’s experiences, study 
results and personal experience or perceived assumptions. While it is possible to alter these 
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beliefs with the results from new evidence, it can be difficult to have a ‘degree of confidence’ 
in certain treatments where uncertainty about its effectiveness exists.  (84).  
 
The aim of this study was to determine current practice regarding diagnosis and management 
of BPS through patient and clinician surveys. I also explored the prior beliefs of patients and 
clinicians on the effectiveness of PTNS as a possible treatment for BPS. In chapter 7, I 
explore the evidence for the effectiveness of PTNS in the treatment of BPS. It is a treatment 
modality not often used in the UK and rarely used for this condition, hence my interest in 
patients and clinicians experiences of it.  
 
 
4.3 Methodology  
The patient based questionnaire was posted as an online SurveyMonkey® survey on the 
websites of two UK based patient support groups; the pelvic pain network since one of the 
main symptoms of BPS is pelvic pain (http://www.pelvicpain.org.uk/) and the cystitis and 
overactive bladder foundation who support patients with cystitis, bladder pain syndrome and 
overactive active bladder (http://www.cobfoundation.org/), between December 2012 to 
November 2013, and the International Painful Bladder Foundation (www.painful-
bladder.org) in October 2013. Patients who suffer from symptoms suggestive of BPS were 
invited to participate in this survey via these three websites.  
 
The authors and institute involved in the survey were kept anonymous from the participants. 
The questionnaires explored patient’s disease symptoms, the investigations they had been 
exposed to and the treatments offered, where more than one option was possible, as many 
patients will have tried several therapies over the years. In recent years, the use of the internet 
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and social media as a source of information and support for patients and their families has 
been recognised. In order to assess this, the survey specifically asked patients about their use 
of the internet as a source of information and support.  
 
In order to establish the most useful questions, I created the clinician survey and piloted it on 
a small group of gynaecology and urogynaecology consultants and trainees to allow me to 
refine the research questions (85). Once modified these questions were reviewed by the audit 
committee for the British Society of Urogynaecology (BSUG). After approval, they were sent 
to all members on their database. The clinician survey assessed the grade and specialty of the 
clinician along with methods of diagnosing and managing BPS. I wanted to establish 
individual clinicians opinions on the value or usefulness of two simple tests for BPS; bladder 
filling pain and bladder wall tenderness, which are further assessed in chapter 5. These 
opinions were collected using a 10-point likert scale, ranging from 1 (not useful) to 10 
(useful), with responses greater than an arbitrary level of five indicating value in the test; and 
five and below indicating no value in the test.  
 
In order to explore clinician’s prior beliefs on the effectiveness of percutaneous tibial nerve 
stimulation (PTNS) a structured question was formulated (86). The same question was asked 
to patients in order to assess their prior beliefs with graphical representation of responses. 
Further questions about PTNS and assessment on patient’s willingness to participate in a 
study with this treatment were evaluated.  
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4.4 Results 
Patient survey 
There were 133 participants in the patient survey. The denominator could not be calculated, 
as the survey was not sent to individual patients. The survey was posted on the three support 
group’s websites, allowing patients with BPS to participate. The data are summarised in table 
7.  
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Table 7: Patient survey results for the management of bladder pain syndrome (BPS) 
 
 Number    %
  
  (n= 133) 
  
1. Do you suffer from any of the following symptoms? 
o Lower abdominal/pelvic pain      103  77% 
o Pain when your bladder is full      107  80% 
o Pain on passing urine       73  55% 
o Loin pain         41  31% 
o Partial relief on passing urine      71  53% 
o Iliac fossa pain         13  10% 
o Pain radiation to genitals        49  37% 
o Pain after passing urine       62  47% 
o Urethral pain        77  58% 
o Pain radiation to legs        35  26% 
o Full relief on passing urine       18  14% 
o No relief on passing urine        27  20% 
o Nocturia (waking up more than once at night to pass urine)    92  69% 
o Increased frequency (passing urine more than usual)    102  77% 
o Urinary urgency        66  50% 
 (the sensation of incontinence if unable to urinate in time) 
o Incomplete voiding       79  59% 
(the feeling of incompletely emptying your bladder when you urinate) 
 
 
2. Which symptoms do you find most problematic? 
o Lower abdominal/pelvic pain      29  22% 
o Pain when your bladder is full      15  11% 
o Pain on passing urine       4  3.0% 
o Loin pain         1  0.8% 
o Partial relief on passing urine       3  2.2% 
o Iliac fossa pain         0  0.0% 
o Pain radiation to genitals        4  3.0% 
o Pain after passing urine       6  4.5% 
o Urethral pain        18  14% 
o Pain radiation to legs        1  0.8% 
o Full relief on passing urine       0  0.0% 
o No relief on passing urine        3  2.2% 
o Nocturia (waking up more than once at night to pass urine)    9  6.8% 
o Increased frequency (passing urine more than usual)    23  17% 
o Urinary urgency        12  9.0% 
(the sensation of incontinence if unable to urinate in time) 
o Incomplete voiding       6  4.5%  
(the feeling of incompletely emptying your bladder when you urinate) 
 
 
3. Which of the following investigations were used to diagnose your BPS? 
o Symptoms alone       32  24% 
o Symptoms and cystoscopy       19  14% 
	   76	  
o Symptoms, cystoscopy and bladder biopsy     35  26% 
o Symptoms, cystoscopy and hydrodistension     20  15% 
o Symptoms, cystoscopy, hydrodistension and bladder biopsy    35  26% 
o Cystoscopy alone       1  0.8% 
o Cystoscopy and bladder biopsies      0  0.0% 
o Cystoscopy with hydrodistension      3  2.2% 
o Cystoscopy with hydrodistension and bladder biopsies    2  1.5% 
 
 
4. Which of the following treatments have you used? 
o Behavioural modification eg timed voids, decrease fluid intake   49  37% 
o Physical therapy eg pelvic floor biofeedback, soft tissue massage   28  21% 
o Stress reduction        37  28% 
o Dietary modification (avoiding caffeine, acidic foods)    99  74% 
o Simple analgesia       103  77% 
o Low-term, low-dose antibiotics      82  62% 
o Antidepressants eg. Oral amitriptyline      55  41% 
o Antihistamines eg. Oral cimetidine      47  35% 
o Immunosuppressants eg. Oral cyclosporine     6  4.5% 
o Intravesical glycoaminoglycans      5  3.8% 
o Intravesical dimethyl sulfoxide (DMSO)     20  15% 
o Intravesical hyaluronic acid       22  17% 
o Anticholinergics eg. Intravesical oxybutynin     10  7.5% 
o Botulinum toxin under cystoscopic guidance     3  2.3% 
o Cystoscopic hydrodistension      66  50% 
 
 
5. Have you ever tried to obtain information about BPS on the internet? 
o Yes         91  68% 
o No         42  32% 
 
 
6. Have you found any good websites that you would recommend to other patients? 
o Yes         70  53% 
o No         63  47% 
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The patient’s main symptom complaints were pain when the bladder is full (80%, n=107), 
lower abdominal/pelvic pain (77%, n= 103), and increased urinary frequency (77%, n= 102). 
The symptoms that caused the most bother were lower abdominal pain (21%, n=29) and 
nocturia (17%, n=23). In order to investigate their symptoms 26% (n=35) of patients were 
diagnosed by symptoms, cystoscopy and bladder biopsies, with or without hydrodistension. 
The most popular reported therapies included simple analgesia (77%, n= 103), dietary 
modifications (74%, n=99) and low dose long-term antibiotics (62%, n=82). 
 
On enquiring about the internet as a source of information, 68% (n = 90) of patients reported 
that they had tried to obtain information about BPS on the internet, while 53% (n = 71) felt 
there were useful websites that they would recommend to other sufferers.  
 
29% (n = 39) of patients had previously heard of PTNS and 0.8% (n = 1) of patients had 
previously used it. Figure 6 graphically represents patient’s prior beliefs on the effectiveness 
of PTNS to treat refractory BPS with 16% (n = 21) unsure whether the treatment is beneficial 
or harmful. 65% (n = 86) expressed their interest in participating in a clinical trial to evaluate 
the effectiveness of PTNS in the treatment of refractory BPS.  
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Figure 6: Graphical elicitation on the patient beliefs of the effectiveness of percutaneous 
tibial nerve stimulation (PTNS). 
 
 
 
Clinician survey 
There were 69 clinicians who responded to this survey (17%, n= 399; 302 consultants and 97 
trainees), 75% (n= 52) of whom were urogynaecologists and 88% (n= 61) were consultant 
grade. Table 8 summarises the clinician’s responses. The clinicians were well spread across 
the UK with 15% from both London and East of England. 93% (n = 64) of clinicians claimed 
to diagnose BPS by symptoms and cystoscopy, compared to only 12% (n = 8) who diagnosed 
the condition by symptoms alone and 48% (n = 33) of them used cystoscopy and bladder 
biopsies as a diagnostic tool. When assessing bladder filling pain as a diagnostic test, 81% (n 
= 56) of clinicians rated this as useful while 26% (n = 18) of them gave a score of 8/10 for its 
usefulness. When the sign of bladder wall tenderness was assessed, 52% (n = 36) of 
clinicians rated it as a useful test and 16% (n = 11) of them gave a usefulness score 6/10 and 
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7/10. The most commonly used treatment were antidepressants, such as amitriptyline (78%) 
and dietary modification (75%) but all treatment options had been tried by at least one 
clinician.    
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Table 8: Clinician survey results for the management of bladder pain syndrome (BPS) 
            
            
         Number   % 
         (n =69) 
1. What is your specialty? (please tick as appropriate)      
o Urogynaecology      52  75 % 
o Urology       1  1.4 % 
o General gynaecology      16  23% 
o Other – eg. Special interest in urogynaecology   3  4.3 % 
 
2. What is your level of experience? 
o Consultant       61  88 % 
o Associate specialist      1  1.4 % 
o Staff grade       2  2.9 %  
o Subspecialty trainee      0  0 % 
o Registrar       5  7.2 % 
 
3. Which of the following investigations do you use to diagnose BPS?     
o Symptoms alone      8  12 % 
o Symptoms and cystoscopy     64  93 % 
 
4. If cystoscopy is used, please state how diagnosis is made: 
o Cystoscopy alone      36  52 % 
o Cystoscopy and bladder biopsy     33  48 % 
    
5. Do you feel the symptom of ‘bladder filling pain’ is useful in making a diagnosis of BPS? 
o Yes       56  81 % 
o No       13  19 % 
        
6. Do you feel the sign of bladder base tenderness on internal examination is useful in making a diagnosis of BPS? 
o Yes       35  51 % 
o No       33  48 % 
 
7. In patients with BPS, which of the following treatments do you use?  
o Behavioural modification eg timed voids, decrease fluid intake  41  59 % 
o Physical therapy eg pelvic floor biofeedback, soft tissue massage  38  55 % 
o Stress reduction      23  33 % 
o Dietary modification      52  75 % 
o Simple analgesia      35  51 % 
o Other analgesia eg. Gabapentin, pregabalin    46  67 %  
o Low dose long-term antibiotics     48  70 % 
o Antidepressants eg. Oral amitriptyline    54  78 % 
o Antihistamines eg. Oral cimetidine    33  48 % 
o Immunosuppressants eg. Oral cyclosporine    1  1.4 % 
o Intravesical glycoaminoglycans eg. Chondroitin sulfate   32  46 % 
o Sodium pentosan polysulphate (Elmiron)    34  49 % 
o Intravesical dimethyl sulfoxide (DMSO)    24  35 % 
o Intravesical hyaluronic acid      29  42 % 
o Anticholinergics eg intravesical oxybutynin    20  29 % 
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o Intravesical heparin      9  13 % 
o Intravesical lidocaine      7  10 % 
o Botulinum toxin under cystoscopic guidance    25  36 % 
o Cystoscopic hydrodistension     23  33 % 
o Fulguration or transurethral resection of lesions   7  10 % 
o Neuromodulation      13  19%
	   82	  
On questioning clinicians about the experience with PTNS, 46% (n = 32) reported that they 
would consider using PTNS. The frequency of treatment ranged from once to twice monthly 
for up to six months. Figure 7 graphically represents the clinician’s prior beliefs on the 
effectiveness of PTNS to treat refractory BPS with 46% (n = 32) unsure whether the 
treatment is beneficial, but believed it is not harmful. 80% (n = 55) expressed their interest in 
participating in a clinical trial to evaluate the effectiveness of PTNS. 
 
Figure 7: Graphical elicitation on the clinicians beliefs of the effectiveness of 
percutaneous tibial nerve stimulation (PTNS). 
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4.5 Discussion  
This survey highlighted the national variations in the patient’s experiences and clinicians 
management of BPS. Many clinicians are still using cystoscopy as a diagnostic test. Previous 
surveys of UK clinicians have shown wide variations in the technique for hydrodistension 
with a non-standardised technique regarding timing and fluid volume used for distension 
(87). A symptom-based diagnosis is being made by only 12% of clinicians, despite current 
recommendations advising initiation of treatment using a symptom-based diagnosis. 
Cystoscopy is a third line treatment, which may be reserved for the diagnosis of complex 
cases (23).   
 
Patients suffered from a range of symptoms but the most common and problematic one being 
pelvic or lower abdominal pain, which is often highlighted in the literature as key symptoms 
in BPS (25). These findings were shared by the clinician survey, which implies there may be 
some diagnostic value in using bladder filling pain as a screening question for BPS. A variety 
of treatments are used for BPS. Unfortunately, up to 62% of patients and 70% of clinicians 
have used low-dose long-term antibiotics to treat BPS, which is not a recommended 
treatment option (23).  
 
There were variations in beliefs of treatment effectiveness of PTNS varying from unsure 
whether beneficial but not harmful to unsure whether beneficial or harmful. Both patients and 
clinicians were willing to participate in clinical trials to test this clinical equipoise.  
 
This survey was UK based inviting all clinicians registered with the British Society of 
Urogynaecology to participate with good national representation. In order to assess the 
experiences of patients, the two main UK based patient support groups were invited to 
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participate. Since patients were self-selected there was no way to directly contact them. This 
method relied on the pro-activeness of patients to participate in the survey and some 
responses may be a reflection of the patient’s own character, for example, trying several 
treatments and use of social media. As there are no specific BPS support groups in the UK, 
patient self-selection had to be used. The two surveys were both electronically conducted and 
anonymous. The low clinician response was a key weakness of this survey. However, with 
88% of respondents being consultant grade their opinions were valuable as they are 
ultimately responsible for managing these patients. Information about the type of cystoscopy, 
for example, rigid or flexible, and type of anaesthesia would have been interesting. It would 
have been useful to establish whether a cystoscopy was performed as a diagnostic test, hence 
delaying the initiation of treatment, or as a treatment. It was difficult to assess the 
demography and characteristics of the patients, as this data was not collected. Ideally a larger 
sample size would have been preferable, but it may have not added any further information to 
the overall results.  
 
It may have been useful to collect data on lifestyle, for example smoking and caffeine intake 
of patients, along with possible alternative and conservative therapies such as acupuncture or 
massage. Pelvic pain is an over-riding symptom in BPS and is known to be multi-factorial in 
cause, hence more information about patients comorbidities may have been valuable (88). 
Other useful data may have been quality of life and psychological assessments in order to 
understand disease impact since patients with BPS and associated comorbidities often have 
poor quality of life (55, 89, 90). In order to keep the questionnaire short and user friendly 
limited additional questions were asked as the survey focused on the diagnosis and 
management of patients. 
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The complexity of BPS is evident by the range of symptoms associated with the condition. 
Since pelvic pain is a key symptom, it is important that general gynaecologists are aware of 
the clinical presentations of BPS as these patients may initially present to their clinics rather 
than to a urogynaecologist if the patient is referred with pelvic pain. 
 
While many surveys about BPS have focused on patients quality of life and related 
comorbidities, mine focused on its management (55, 88). It showed that clinicians still appear 
to be using cystoscopy as a diagnostic tool, implying that the American Urological 
Association guidance to commence treatments on symptoms alone have not been followed. 
Clinicians often struggle to diagnose BPS due to the cluster of non-specific symptoms, which 
may cause difficulty implementing initial community-centred care without referral to 
secondary care (91). The general lack of consensus about the management of BPS, along 
with the variety of treatments used implies difficulty achieving symptomatic control (92). 
 
This chapter highlights the variations in clinical practice, suggesting there is a need for 
national guidance on the management of BPS in order to offer patients consistent care. This 
has been acknowledged by the RCOG in the UK, who have recently a commissioned such a 
guideline which aims to help clinicians provide a minimum standard of care.  
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CHAPTER 5: 
EVALUATING THE SENSITIVITY OF 
BLADDER WALL TENDERNESS AND 
BLADDER FILLING PAIN IN PATIENTS 
WITH CHRONIC PELVIC PAIN  
(A CASE-CONTROL FEASIBILITY STUDY)  
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In this chapter I evaluate the usefulness of using two index tests, bladder wall tenderness and 
bladder filling pain, as diagnostic markers of BPS in women with CPP. I also explore the 
possibility of using an expert consensus panel to achieve a symptom-based diagnosis for 
BPS, in the absence of a gold standard test.  
 
 
5.1 Abstract  
 
Introduction: Patients with BPS often suffer from a cluster of urinary symptoms. This study 
aimed to validate the use of two simple tests for BPS, bladder wall tenderness and bladder 
filling pain, in women with CPP.  
 
Methods: In this multi-centre study women with unexplained CPP were recruited from 
gynaecology clinics across the UK between August 2012 and July 2013. Data on particular 
signs and symptoms were collected. The diagnosis of BPS was made by expert consensus 
panel, made up of three urogynaecology consultants, using the complete patient history and 
examination data, without the index (tests to avoid incorporation bias), as there is no gold 
standard diagnostic tool. The panel achieved a moderately high level of agreement (intra-
class coefficient agreement of 0.46). We computed sensitivity (true positive result) and 
specificity (true negative result) with 95% confidence intervals. 
 
Results: There were 46 eligible women with a mean age of 30.8 years (n=21, SD 7.20) in the 
BPS group (cases) and 34.6 years (n=25, SD 9.51) in the control group. The most sensitive 
symptom was bladder filling pain (sensitivity = 0.57, 95% CI = 0.3-0.8, specificity = 0.84, 
95% CI = 0.6-1.0). The most specific test was bladder wall tenderness (sensitivity = 0.10, 
95% CI = 0.1-0.3, specificity = 0.96, 95% CI = 0.8-1.0).   
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Conclusion: In women with unexplained CPP, absence of bladder wall tenderness can be 
associated with a high specificity and bladder filling pain with a reasonable sensitivity with 
high specificity. A large multi-centre study is needed to validate these tests in order to aid 
clinicians diagnose this debilitating condition. 
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5.2 Introduction 
 
BPS is an often forgotten cause of CPP. Its unknown aetiology, along with the range of 
symptoms experienced by patients, usually comprising of bladder/pelvic pain, urgency, 
frequency and nocturia make diagnosis challenging, especially as these symptoms may be 
present in several other urinary conditions and are not discriminating of BPS (93). There is 
no gold standard test for BPS, with the recommendation of a symptom-based diagnosis (23), 
which causes difficulty in the choice of study design for a diagnostic accuracy study.  
 
In practice, the symptom of bladder filling pain and the sign of bladder wall tenderness on 
vaginal examination have been shown to be present in a high number of patients with BPS, 
but these have not been incorporated into existing diagnostic tools (46, 94). In a recent survey 
of clinicians, described in chapter 4, 81% believed the symptom of bladder filling pain was 
useful in the diagnosis of BPS. In this chapter I assess the usefulness of these tests, while also 
identifying if other symptoms may be sensitive markers of BPS. I have attempted to show 
that expert panel diagnosis can be a successful option when no reference standard exists for a 
given condition.  
 
 
5.3 Methods  
This study evaluated diagnostic accuracy in the absence of a reference standard (95). I 
assessed the correlation of bladder filling pain, and bladder wall tenderness with the Pelvic 
Pain Urgency/ Frequency (PUF) questionnaire (and several component questions within it). 
This should enable an estimation of the accuracy with which a certain combination of signs 
and symptoms (index tests) can identify the diagnosis of BPS in women with CPP. BPS is 
often a diagnosis of exclusion, with no validated questionnaires, although several 
	   91	  
questionnaires may be used to identify baseline symptoms (23). The PUF questionnaire, 
rather than the O’Leary Sant Interstitial Cystitis Problem Index/Symptom Index (ICSI/PI), 
was used because it also captures information about symptoms in relation to sexual 
intercourse (26, 28). Both the PUF and ICSI/PI questionnaires enquire about pain, which is a 
key symptom of BPS. Pain was assessed using likert visual analogue scales and pain specific 
tools like the McGill short form questionnaire. The aim of this questionnaire was to capture 
pain and urinary symptoms, and not enquire about quality of life, which was not assessed in 
this study.  
 
This was a case-control study, which was part of the MEDAL trial (MRI to Establish 
Diagnosis Against Laparoscopy), which is a multicentre study in the United Kingdom 
assessing women with unexplained CPP. Patient inclusion criteria were: women presenting to 
secondary care with unexplained CPP, aged 16 or older with the ability to understand 
adequate English in order to give informed consent. Exclusion criteria were pregnancy, a 
previous hysterectomy, a proven urinary tract infection on urine dipstick and a previous 
diagnosis of BPS. Eligible women were recruited from gynaecology outpatient clinics in the 
United Kingdom between August 2012 and July 2013 with consecutive recruitment of all 
eligible patients to minimise selection bias. 
 
Since there is no gold standard test for BPS, an expert consensus panel was used for 
diagnosis (95). The panel comprised of three consultant specialists in urogynaecology. The 
diagnosis determined by the panel used patient self-reporting symptoms and signs captured in 
a range of items from several questionnaires (figure 8) (28).  
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Figure 8: Consensus panel assessment form for diagnosis of bladder pain syndrome. 
 
 
 
1. Negative urine dipstick?   Yes / No 
2. Duration of pain    Answer in months  
3. Location of pain and severity?  Description of location with pain score 1-10 
4. Superficial dyspareunia   Yes / No 
5. Deep dyspareunia?    Yes / No  
6. Pain on full bladder?    Yes / No 
7. Pain on urination?    Yes / No 
8. Urinary frequency?    Score 0 (3-6 times) to 4 (over 20 times) 
9. Nocturia?     Score 0 (never) to 3 (always) 
10. Post void urgency?    Yes / No 
11. Degree of urgency?    Mild/ moderate/ severe 
12. Pain associated with bladder, urethra, Never/occasionally/usually/always 
 vagina, perineum, pelvis? 
13. PUF score     0 – 35 
14. Do you think this patient has BPS?  Yes / No  
15. How certain are you? (0 = uncertain to 10 = very certain) 
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 In order to avoid incorporation bias, we did not include the index tests as part of the 
symptom based diagnosis made by the expert panel. A diagnosis was made if two out of three 
consultants felt the patient suffered from BPS. Disease certainty scores from 0-10 were 
assigned to each case. All recruited patients were allocated into the case or control group 
depending on the presence or absence of BPS. These scores were used to calculate the intra-
class coefficient (ICC), which was moderately high at 0.46.  
 
The two index tests performed were: bladder-filling pain, which was assessed through a 
clinical history, and bladder wall tenderness on examination, which was assessed by 
specialists in gynaecology as part of a routine vaginal examination, as the sensation of pain 
when the bladder wall was palpated. Data were collected on a pre-designed collection form 
and inputted into a central database as part of the main MEDAL study. Quality assurance 
included double data entry, visual cross validation, data completeness checks and protocol 
adherence in accordance with good clinical practice guidance. One of the missing data, 
limiting recruitment was urine dipstick testing. Manual checking of data collection forms, GP 
referral letters and patient notes was performed to find missing data.  
 
Data analyses included patient characteristics with descriptive statistics, ranges and standard 
deviations as appropriate. Statistical analysis of sensitivity, specificity and predictive values 
was calculated using the StatsDirect software programme version 2.8.0. Data recruitment fell 
short of an ideal sample size of 100 patients since the main study ended as funding and 
recruitment deadlines were met and further recruitment was futile as the main study 
objectives had been met.  
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5.4 Results 
There were 46 eligible patients recruited over an 11-month period. Table 9 shows the 10 
centres where patients were recruited from within the United Kingdom.  
 
Table 9: Hospitals within the United Kingdom where individual patients were 
recruited.  
 
 
Number of patients     Name of Hospital  
            2                                                               Cumberland Infirmary, Cumberland 
            1                                                               Edinburgh Royal Infirmary, Edinburgh 
            1                Furness General Hospital, Cumbria 
            5                                                               Homerton University Hospital, London 
            2                                                               Musgrove Park Hospital, Taunton 
            5                                                               Royal Hallamshire Hospital, Sheffield 
            1                                                               Royal Preston Hospital, Preston 
           24                                                              Royal London Hospital, London 
            3                                                             Southend University Hospital, Southend              
            2                     University Hospital Of North Staffs        
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Table 10 shows the study characteristics for the case and control groups of patients.  
 
Table 10: Study characteristics of patients with and without bladder pain syndrome 
(BPS) 
 
 
Patient characteristics                              Case group                              Control group 
                                                                    (BPS present)              (BPS absent)   
                                                                    (n = 21)                                     (n = 25) 
 
Mean age (years)                                        30.8                                            34.6 
Mean body mass index (kg/m2)                  26.5                                            25.1 
Ethnicity –   Caucasian                               14 (70%)                                    13 (54%) 
- Asian                                       4 (20%)                                      6 (25%)  
- Afro-Caribbean                       0                                                 2 (8%) 
- Mixed race                              1 (5%)                                        1 (4%)  
- Other                                       1 (5%)                                        2 (8%) 
Mean duration of symptoms (months)       59.2                                            39.2 
Mean highest pelvic pain score (0-10)       8.64                                            9.12 
Superficial dyspareunia                             18 (86%)                                     7 (28%) 
Deep dyspareunia                                      19 (90%)                                     9 (36%) 
 
 
 
There were 21 patients who suffered from BPS (case group). Their mean age was 30.8 years 
(SD 7.20) compared to 34.6 years (SD 9.51) in the control group. The mean body mass index 
(BMI) was 26.5kg/m2 in the BPS group and 25.1kg/m2 in the control group. There was 
variation in ethnicities; Caucasian 70% in the BPS group and 54% in the control group, Asian 
20% in the BPS group and 25% in the control group, Afro-Caribbean 8% in the control 
group, mixed race Caucasian and Afro-Caribbean 5% in the BPS group and 4% in the control 
group and other 5% in the BPS group and 8% in the control group. 
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In the disease group, bladder wall tenderness was present in 2/21 (9.5%) and bladder filling 
pain in 12/21 (57%). In the disease-free group bladder wall tenderness was present in 1/25 
(4.0%) and bladder filling pain in 4/25 (16%) (figure 9).  
 
Figure 9: Study flow chart in accordance with the STARD reporting guidelines (96) 
 
a. Bladder wall tenderness 
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In the BPS group, the highest mean pain scores were 8.6/10 with a mean duration of 
symptoms of 59 months. 18 (86%) patients suffered from superficial dyspareunia and 19 
(90%) from deep dyspareunia. In the control group the highest mean pain scores were 9.1/10 
with a mean duration of symptoms of 39 months. 2 (28%) patients suffered from superficial 
dyspareunia and 9 (36%) from deep dyspareunia. 
 
29 patients (63%) had a calculable PUF questionnaire score with a mean score of 15.2 in the 
BPS group and 9.5 in the control group. Table 11 shows the relationship between the 
presence of individual urinary symptoms and a diagnosis of BPS. Bladder filling pain had a 
sensitivity of 0.57 and specificity of 0.84, and bladder wall tenderness had a sensitivity of 
0.10 and specificity of 0.96. The most sensitive additional symptoms were urinary frequency, 
and pain on urination (0.57) and the most specific additional tests were post-void urgency 
(1.00), pain on urination (0.91) and pain in the urethra, vagina and bladder (0.91).   
 
 
Table 11: The accuracy of tests for the diagnosis of bladder pain syndrome (BPS)  
 
 
Test                                          BPS present      BPS absent     Sensitivity        Specificity           Odds Ratio 
                                                     (n = 21)          (n = 25)            (95% CI)         (95% CI)             (95% CI) 
         
Index test 
Bladder wall tenderness               2                    1               0.10 (0.1-0.3)          0.96 (0.8–1.0)     2.53 (0.1-155) 
Bladder filling pain                     12                   4               0.57 (0.3-0.8)          0.84 (0.6-1.0)      7.00 (1.5-37) 
 
Additional tests 
Urinary frequency                       12                   4               0.57 (0.3-0.8)           0.84 (0.6-1.0)     7.00 (1.5-37) 
Nocturia                                       11                   3              0.52 (0.3-0.7)            0.88 (0.7-1.0)     8.07 (1.6- 52) 
Pain on urination                         12                   2               0.57 (0.3-0.8)           0.92 (0.7-1.0)     15.3 (2.5-156) 
Post-void urgency                        5                    0               0.24 (0.1-0.5)           1.00 (0.9-1.0)      *     (1.2- ∞) 
Pain in urethra, bladder, vagina   7                    2               0.33 (0.1-0.6)            0.92 (0.7-1.0)     5.75 (0.9-62) 
Pain on full bladder                     1                    5                0.05 (0.0-0.2)            0.80 (0.6-0.9)     0.20 (0.0-2.1) 
 
 
Urinary frequency = voiding ≥ 7 times per day 
Nocturia = ≥ 1 occasion per night 
Post-void urgency = present if patient reported presence usually or always 
Pain in urethra, bladder or vagina = present if patient reported presence usually or always 
Pain on full bladder = patient reported score of ≥ 5 
 
95% CI = 95% confidence interval 
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A cystoscopy was performed on four patients; three in the BPS group where only one 
cystoscopy identified pathology showing grade 2 submucosal bleeding and one in the control 
group which showed grade 2 submucosal bleeding. A laparoscopy was performed on 43 
patients with bladder pathology (anterior bladder wall endometriosis or dense adhesions 
affecting the anterior bladder wall) seen in 2/20 (10%) patients in the BPS group and 3/23 
(13%) patients in the control group.   	  	  
5.5 Discussion 
 
Urinary symptoms may be discriminatory of BPS. The two primary index tests used in this 
study were bladder wall tenderness and bladder filling pain. Both tests were simple and easy 
to assess. Bladder wall tenderness had a poor sensitivity but high specificity. Bladder filling 
pain had a reasonable sensitivity but high specificity. Bladder filling pain is often thought of 
as a hallmark symptom for BPS (25). The symptoms that had the best sensitivity and 
specificity were bladder filling pain, urinary frequency, nocturia and pain on urination. There 
were low levels of PUF questionnaire completion due to missing data. Despite the limitations 
of the PUF questionnaire, it discriminated between BPS and disease-free patients with higher 
scores in the BPS group (15.2 versus 9.5).  
 
This study has successfully demonstrated that BPS can be diagnosed by symptoms alone. An 
expert panel was favourably used to obtain a consensus diagnosis, as no gold standard 
diagnostic tool exists. Using a case-control study design, we demonstrated that the absence of 
several urinary symptoms may aid ruling out a diagnosis of BPS. 
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The patients in the case and control group had similar demographic backgrounds. There was 
consecutive recruitment using standardised reporting forms and questionnaires to minimise 
bias. All three members of the expert panel were all urogynaecologists and were not involved 
in patient recruitment. They were not aware of the index test results when making their 
diagnosis of BPS, thus avoiding incorporation bias. The major study weakness was the small 
sample size. During the data collection process it became apparent that some centres did not 
routinely test patients urine or perform internal vaginal examinations so did not fulfil the 
inclusion criteria. Despite attempts to remind all recruiting centres of the study inclusion 
criteria there were high levels of missing data, accounting for the low sample size. 
 
The results of this study have several clinical implications. One recommendation would be 
that all patients have urine dipstick testing routinely on first presentation to gynaecology 
clinics, as a urine infection is easy to treat and may explain pelvic pain and urinary 
symptoms. Clinicians should feel confident making a symptom-based diagnosis of BPS by 
asking a few salient questions that are part of a routine urogynaecology consultation. Only 
14% of patients with BPS had a cystoscopy and only one patient’s revealed pathology, 
showing that symptoms and cystoscopy findings often do not correlate. The duration of 
symptoms in BPS patients was on average 20 months more than non-BPS patients. There was 
a higher prevalence of superficial and deep dyspareunia suffered in the BPS group, 
suggesting sexual dysfunction is associated with the BPS phenotype (97). This highlights the 
burden of disease and need for prompt initiation of treatment. The symptoms of BPS can be 
easily elicited as part of a routine history and allow immediate treatment to be commenced. 
Literature shows that the prevalence of BPS in women with chronic pelvic pain is 61%, 
hence should be considered as a differential diagnosis of CPP (57).  
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We successfully undertook a feasibility study to assess if a group of urinary signs and 
symptoms could be used to diagnose BPS. The impact of BPS on quality of life has been well 
documented (98). Patients with BPS are known to utilise healthcare resources more than non-
sufferers which adds to the burden of the economy so any beneficial treatments would not 
only benefit sufferers but the healthcare economy (99). A large multi-centre study is needed 
to validate these tests in order to aid clinicians diagnose this debilitating condition. This has 
already been described as the Bravado study but in order to validate these tests a large sample 
size would be needed, requiring funding and adequate time to recruit (100). This may be 
possible if the study was recruited in primary care where large volumes of symptomatic 
patients initially present and could be commenced on conservative treatments. In future 
research, an asymptomatic control group could be recruited, possibly patients that present to 
gynaecology clinics requesting laparoscopic sterilisation who usually do not have any urinary 
or pelvic pain symptoms so would make an ideal cohort group. 
 
This work is supported by the National Institute for Health Research Health 
Technology Assessment (NIHR HTA) (ref: 09/22/50) with ethic approval for the NIHR 
MEDAL Study from East Midlands Research Ethics Committee - Nottingham 1 (Ref 
11/EM/0281), which covers this sub-study.  
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CHAPTER 6: 
THE ROLE OF LAPAROSCOPY AND 
CYSTOSCOPY IN THE DIAGNOSIS AND 
MANAGEMENT OF PELVIC AND BLADDER 
PAIN 
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In this chapter I explore the role of invasive diagnostic tests to investigate chronic pelvic pain 
and bladder pain syndrome as most patients with BPS usually present to gynaecology clinics 
with CPP as their primary complaint.  
 
6.1 Background 
We are aware that the prevalence of CPP in women is comparable to that of lower back pain 
and asthma with a huge negative impact on quality of life and causing a large financial 
burden on the economy due to days off work and the time spent managing and treating these 
patients (101). This chapter explores the role of laparoscopy as a diagnostic and therapeutic 
tool in the management of these patients. Bladder pain syndrome (BPS) may be a 
manifestation of CPP where cystoscopy can have a diagnostic and therapeutic role. I will also 
explore other causes of CPP and evaluate the most effective methods of diagnosing these.  
 
6.2 What is chronic pelvic pain (CPP)?  
The RCOG definition of CPP is ‘an intermittent or constant pain in the lower abdomen for at 
least 6 months that is not associated with pregnancy and not occurring exclusively with 
menstruation or sexual intercourse’ (102). The International Association for the Study of Pain 
and the European Association of Urology have revised this definition to include both men 
and women, including pain perceived in structures related to the pelvis and have 
acknowledged the negative impact of pain on cognition, behaviour, sexual and emotional 
well-being, along with its possible association with urinary, bowel, sexual, pelvic floor or 
gynaecological dysfunction (9, 103). 
  
It is often difficult to diagnose the cause of CPP, as there may be several causes and co-
existing pathologies, which makes identification of a single diagnosis sometimes impossible. 
	   103	  
The estimated prevalence of CPP ranges between 8-81% worldwide according to a recent 
systematic review with an extensive range of causes (35). There are a variety of 
investigations to diagnose each with differing diagnostic accuracy and patient acceptability. 
Table 12 shows the most common gynaecological causes of CPP, which include 
endometriosis, adenomyosis, ovarian cysts, uterine fibroids, pelvic congestion syndrome, 
chronic pelvic inflammatory disease and adhesions. Adhesions may be secondary to 
endometriosis, pelvic inflammatory disease or previous surgery. There may be non-
gynaecological causes of CPP, which include irritable bowel syndrome, BPS, musculo-
skeletal, neuropathic and psychological factors, such as a history of sexual abuse and 
psychosexual difficulties. 
 
6.3 The role of laparoscopy in CPP 
Initially management for patients with CPP is a careful clinical assessment consisting of 
thorough history, physical examination and imaging, usually in the form of a pelvic 
ultrasound or possibly pelvic magnetic resonance imaging, if needed (102). A diagnostic 
laparoscopy has traditionally been seen as the ‘gold standard’ diagnostic test. Unfortunately, 
as many as 40% of diagnostic laparoscopies fail to detect any pathological cause of the pain 
(104). It has been well documented that a laparoscopy can successfully diagnose the type and 
location of adhesions and several types of endometriosis (104, 105). The gynaecological 
causes of CPP along with the diagnostic accuracy of laparoscopy as a diagnostic tool are 
shown in table 12.  
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Table 12: The gynaecological causes of chronic pelvic pain and the accuracy of laparoscopy as a 
diagnostic tool (106).  
 
 
 
Target condition   Diagnostic criteria   Role of laparoscopy 
 
 
Adenomyosis   Presence of islands of  Uncertain value – appearance  
    ectopic endometrial   bulky ‘boggy’ uterus  
    tissue within the 
    myometrium confirmed 
    histologically 
 
Adhesions   Visual inspection during Gold standard - visual 
    laparoscopy, or by   inspection 
    absence of movement 
    between adjacent organs 
 
Endometriosis   Visual inspection during  Gold standard – negative 
laparoscopy, noting  laparoscopy can exclude 
appearance, size and  disease but positive findings 
depth of endometrial  cannot accurately confirm 
 implants disease (107) 
 
Fibroids   Size and location noted  Uncertain – visual inspection  
during pelvic ultrasound  of size and location of   
    subserosal fibroids 
 
Ovarian cysts   Pelvic magnetic resonance Uncertain value – visual  
    imaging to define size,   inspection of size and 
    location and nature of cyst,  location of cyst 
    confirmed histologically 
 
Pelvic congestion syndrome Definitive diagnosis on  Uncertain value – appearance 
    catheter-directed venography, of pelvic varicosities 
    showing uterine venous 
    engorgement and ovarian  
    complex congestion (108) 
 
Pelvic inflammatory disease Visual inspection during Uncertain value – may identify 
    laparoscopy or histology salpingitis, adhesions and Fitz- 
    from fimbrial biopsy (109) Hugh-Curtis syndrome 	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During laparoscopy, visual inspection of the fallopian tubes and assessment for tubal patency 
may be performed, along with assessment of disease severity, for example, the presence of 
severe endometriosis, which may indicate that management in a specialist endometriosis 
centre may be most appropriate. Regardless of the peritoneal entry technique, up to 57% of 
surgeons have described major bowel and vascular injures (110). ‘See and treat’ therapeutic 
laparoscopies are more preferable in order to avoid multiple operations and the risks 
associated with repeat surgery (111).    
 
Different imaging modalities, such as pelvic ultrasound scans can be extremely useful in 
identifying site-specific adnexal pain, decreased ovarian mobility, as well as the presence of 
endometriomas and hydrosalpinges (112). These findings may be in keeping with the 
presence of endometriosis and can allow the surgeon to effectively plan surgery with suitably 
skilled staff, appropriate surgical instruments and possibly transfer to a tertiary centre if 
severe endometriosis is suspected (111).  
 
Endometriosis  
 
Endometriosis is one of leading causes of CPP, which often affects areas of the pelvis, such 
as the uterosacral ligaments, pouch of Douglas and rectovaginal septum, which can be 
difficult to assess by clinical examination (113). Literature shows that while a negative 
laparoscopy can accurately exclude visually diagnosed endometriosis, a positive laparoscopy 
needs histological confirmation of disease, with a sensitivity of 94% for laparoscopic 
diagnosis compared to histological diagnosis (107) . The role of the assisting surgeon is 
crucial in providing adequate anteversion using the uterine manipulator to allow for 
anteversion and anteflexion of the uterus in order to thoroughly inspect the pouch of Douglas. 
Up to 42% of general gynaecologists have reportedly failed to recognise rectovaginal 
	   106	  
endometriosis during visual inspection at primary laparoscopy (114). Laparoscopy is still 
regarded as the ‘gold standard’ diagnostic investigation for superficial endometriosis. The 
optimal method of treating superficial endometriosis is debatable as diathermy or excision of 
disease is usually dependent on surgical preference. Excision of endometriosis allows a 
biopsy to be obtained for histological disease confirmation but this requires surgical skill to 
avoid trauma. Ablative therapy with diathermy poses the risk of thermal injury to nearby 
structures, such as the bowel or ureter. When ablation was compared to excision using 
monopolar diathermy in patients with mild endometriosis (stage 1 or 2 revised American 
Fertility Score) in a small RCT, both treatments produced symptomatic relief and there was 
no difference in six-month symptom questionnaire scores (115). A large-scale randomised 
trial is needed to obtain more reliable results for these two treatment options. The added 
advantage of a laparoscopy is the opportunity to visualise and dissect adhesions that may be 
present and perform a tubal patency test if the woman has fertility desires. 
 
Adhesions 
Adhesions may be present as a result of endometriosis, exposure to infection or previous 
surgery. They can distend or stretch organs causing pain (102). Adhesions may be fine and 
filmy or dense and vascular. There is uncertainty over the symptomatic benefits of 
adhesiolysis in CPP with trials showing substantial pain relief reported in groups where 
adhesions were treated with adhesiolysis compared to no treatment one year post surgery	  
(116). Smaller, observational studies have shown similar results two years after surgery in 
45% of patients (117). These results imply there may be a psychologically beneficial effect in 
performing adhesiolysis with a perceived improvement in pain (118).  
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Adenomyosis 
Adenomyosis is defined by the presence of islands of ectopic endometrial tissue within the 
myometrium, causing smooth muscle hypertrophy (119). It is a common condition, which is 
usually reported on ultrasound scans showing a cystic myometrial appearance or seen on 
laparoscopy with the classical appearance of a bulky ‘boggy’ uterus. There may be an 
association with endometriosis and endometrial hyperplasia and patients often present with 
menorrhagia and dysmenorrhea. The value of laparoscopic or ultrasound diagnosis is 
questionable since definitive diagnosis is by histology, which is impractical so imaging in the 
form of an MRI or ultrasound allows initiation of medical treatment and may sometimes 
avoid the need for surgery. 
 
6.4 Uncertainties of laparoscopy 
Diagnostic laparoscopies are useful at evaluating some of the causes of CPP. Unfortunately 
40% of laparoscopies show no pathology, which leaves clinicians with the dilemma of 
weighing up the possible surgical benefits against the risks, as many causes of CPP do not 
involve gynaecological pathology. Chronic pelvic pain syndrome (CCPS) is the term for the 
occurrence of chronic pelvic pain where there is no proven infection or other obvious local 
pathology that may account for the pain, where pain may be focused around a single organ or 
multiple pelvic organs (9). A ‘negative’ laparoscopy where no pathology is seen can also 
have a reassuring effect on the patient (120).  
 
6.5 What is bladder pain syndrome (BPS)?  
 
Patients suffering from BPS can often present with CPP. It has been well documented that 
due to the wide spectrum of pain and urinary symptoms associated with the condition, 
diagnosis is challenging leading to inaccurate prevalence rates.  
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6.6 The role of cystoscopy  
 
The role of cystoscopy has been previously discussed in the introduction, along with the 
uncertainties of this procedure. Cystoscopy can differentiate between BPS with a normal 
bladder mucosal appearance from grade 2 and 3 disease with the presence of petechial bleeds, 
glomerulations and Hunner’s lesions/ulcers (121). In the presence of Hunner’s ulcers, the 
clinician may choose to offer alternative treatments such as fulguration at an early stage, 
rather than persevering with conservative treatments. While hydrodistension during 
cystoscopy can allow visualisation of petechial haemorrhages, it can also provoke petechial 
bleeds that are thought to be pathognomonic and prolonged hydrodistension is not 
recommended due to the rare side effect of bladder rupture (23).  
 
 
6.7 The uncertainties of cystoscopy  
 
Cystoscopy and histology of bladder biopsies have often been seen as the ‘gold standard’ 
diagnosis for BPS as they may confirm disease presence and enable disease classification (7). 
Cystoscopy has a level A recommendation as a method of diagnosis while bladder biopsies 
are level B, where guidelines recommend or highly recommend the treatment option based on 
information from well-conducted studies with or without randomisation (121). Poor 
correlation has been seen in some studies between cystoscopy findings and diagnosis since 
glomerulations may be seen in asymptomatic patients and bladder biopsies may not confirm 
disease in the presence of glomerulations (8, 21). For this reason, the results of cystoscopy or 
bladder biopsies are unreliable and clinicians are advised to treat symptomatic patients in 
accordance with the recommendations of AUA guidelines using clinical history and 
examination to make a symptom- based diagnosis (23).  
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6.8 Conclusion  
 
CPP may be multi-causal with several identifiable risk factors, such as a history of drug, 
alcohol and sexual abuse, pelvic inflammatory disease, anxiety and depression (122). 
Invasive procedures such as a laparoscopy and cystoscopy may be useful diagnostic tools as 
well as having therapeutic effects. The degree of sensitivity of each test varies with the target 
condition, but patients must be aware that no obvious cause of pain is always identified (120). 
For this reason a thorough history, examination and imaging, where appropriate, are essential 
to correctly plan and offer treatments. Therapeutic ‘see and treat’ laparoscopies are 
recommended, rather than purely diagnostic procedures to avoid the need for multiple 
operations and the risks associated with them.  
 
Worldwide, CPP and BPS affect large numbers of people where the etiology is often 
unknown and symptoms overlap with possible co-existing disease pathology, which makes 
the management of such patients difficult (57) (123). These difficulties suggest the need for 
integrated management between primary and secondary care clinicians (124). Both 
conditions may have non-specific symptoms but pain is usually the main complaint. It may 
be prudent for clinicians to consider performing both a laparoscopy and cystoscopy in cases 
of persistent CPP in order to rule out co-existing gynaecological and bladder pathology.  
 
This chapter is based on the following publication as a book chapter: 
The role of laparoscopy and cystoscopy in the diagnosis and management of chronic 
pelvic and bladder pain. 
SA Tirlapur, KS Khan, E Ball 
Recent	  advances	  in	  obstetrics	  and	  gynaecology	  25	  
(Edited	  by	  William	  Ledger	  and	  Justin	  Clark)	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CHAPTER 7: 
 ASSESSING THE EFFECTIVENESS OF 
NERVE STIMULATION IN THE TREATMENT 
OF PELVIC AND BLADDER PAIN: A 
SYSTEMATIC REVIEW OF THE EVIDENCE 
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In this chapter I will explore the effectiveness of posterior tibial nerve stimulation (PTNS) 
and sacral nerve stimulation (SNS) as treatments for CPP and BPS. 
 
 
7.1 Abstract  
 
Background: Both syndromes of CPP and BPS are associated with poor quality of life. In 
cases of refractory pain, neuromodulation, or nerve stimulation, has been suggested as a 
possible treatment option.   
 
Objectives: To assess the effectiveness of posterior tibial nerve and sacral nerve stimulation 
in the treatment of BPS and CPP. 
 
Data sources: The Cochrane Library, EMBASE (1980-2012), Medline (1950-2012), Web of 
knowledge (1900-2012), LILACS (1982-2012) and SIGLE (1990-2012) databases were 
searched until July 2012 with no language restrictions. Manual searches through 
bibliographies and conference proceedings of the International Continence Society were 
performed. 
 
Study selection: Included studies were randomised and prospective quasi-randomised versus 
sham nerve stimulation treatment or usual (standard) care of patients with CPP and BPS who 
underwent sacral or tibial nerve stimulation. Studies that involved transcutaneous electrical 
stimulation (TENS) were excluded. The outcome measure was a cure or symptomatic 
improvement.  
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Results: There were three eligible studies with 169 patients; two for CPP and one for BPS. 
Symptomatic improvements were reported for pain, urinary and quality of life questionnaire 
scores using both tibial and sacral neuromodulation. 
 
Conclusion: There is very limited available literature on neuromodulation, which reports 
variable success of posterior tibial nerve stimulation (PTNS) in improving pain, urinary 
symptoms and quality of life in CPP and BPS. There was no available data for the 
effectiveness of sacral nerve stimulation (SNS). In view of the absence of quality literature, a 
large multi-centered clinical trial is recommended to investigate the effectiveness of nerve 
stimulation to treat BPS and CPP. Cost-analysis of these treatments is recommended to assess 
the feasibility of wide-scale introduction of treatment into hospitals.   
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7.2 Introduction 
BPS and pelvic pain are both chronic pain syndromes known to have a negative impact on 
quality of life and sexual function (60). As both conditions have an unknown etiology, 
symptomatic management is the mainstay of treatment. Unfortunately, standard conservative 
and pharmacological treatments frequently fail (125). Nerve stimulation, or neuromodulation, 
of the posterior tibial or sacral nerves is minimally invasive and has been described as a 
treatment for refractory BPS and CPP. Both methods of neuromodulation have been shown to 
be effective in other bowel and bladder disorders such as overactive bladder and faecal 
incontinence (126) (127) (128). During posterior tibial nerve stimulation (PTNS) there is 
insertion of a fine needle 5cm cephalad from the medial malleolus and posterior to the margin 
of the tibia to the site of the posterior tibial nerve. There is a weekly treatment regime, 
usually for 10-12 weeks (129). In sacral nerve stimulation (SNS) there is an initial test phase 
with insertion of a test lead which is tunneled under the skin and transmitted onto the nerve 
roots exiting the S3 foramen, which causes stimulation of the pelvic and pudendal nerves and 
this is connected to a stimulator. This is exchanged for a permanent implant if successful 
(130, 131). Published data about the effectiveness of neuromodulation is contradictory so the 
aim of this chapter is to assess the effectiveness of PTNS and SNS to treat BPS and CPP by 
systematically reviewing the available literature.  
 
 
7.3 Methods  
This systematic review was prospectively conducted using a protocol based on contemporary 
methods, which was registered on the international register of systematic reviews 
(PROSPERO) registration number CRD42012002465. It was reported in accordance with the 
PRISMA statement (36). 
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Data sources 
The Cochrane Library, EMBASE (1980-2012), Medline (1950-2012), PSYCHINFO (1806-
2012), Web of knowledge (1900-2012), and LILACS (1982-2012) databases were searched 
from inception to July 2012. Grey literature was searched through SIGLE (1990-2012). No 
language restrictions were used. The MeSH headings and keywords used were ‘chronic 
pelvic pain’ or ‘pelvic pain’ or ‘interstitial cystitis’ or ‘painful bladder syndrome’ or ‘bladder 
pain syndrome’ which were combined using the Boolean operator ‘and’ with the terms ‘tibial 
nerve’ or ‘sacral nerve’ or ‘nerve stimulation’ or ‘neuromodulation’. All bibliographies from 
relevant articles and conference proceedings of the International Continence Society were 
hand searched to identify any articles that were not electronically cited.   
 
Study selection 
Studies that had a randomised and prospective quasi-randomised trial design and used sham 
nerve stimulation treatment or usual care of patients as a comparator on patients with CPP 
and BPS who underwent sacral or tibial nerve stimulation were included. Studies using 
transcutaneous electrical stimulation (TENS) were excluded, as this was not considered direct 
nerve stimulation. The patients were men and women suffering from BPS and/or CPP who 
were not pregnant or suffering from cancer (7, 102). The outcome measured was a cure or 
symptomatic improvement.  
 
Data extraction and quality assessment 
There was independent data extraction by two reviewers (SAT, AV) who used a pre-designed 
data collection form, which captured study characteristics, information about participants, 
intervention, comparator and outcomes. Quality assessment of studies was performed using 
two published indexes (132) (133). These assessed the reporting, external validity, internal 
	   116	  
validity (Jadad scale) and power of each study.  Each study was assigned a quality score; 
poor quality (score <14), fair quality (score 15-19) or good quality (score >20) for the Downs 
and Black quality index. The Jadad scale rated a study as good quality with a score of ≥3 
(134). A third assessment of study quality was performed using the Grading of 
Recommendations, Assessment, Development and Evaluations (GRADE) approach in order 
to assess the quality of evidence for each outcome (135, 136). 
  
 
Data synthesis 
The results were tabulated and graphically represented where possible, although it was not 
possible to perform statistical analysis on the data due to the variation in outcome scoring 
systems used.  
 
 
7.4 Results 
There were three included studies in this review with 169 patients (137-139). A summary of 
the selection of papers is shown in figure 10.  
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Figure 10: A flow chart for study selection in the systematic review on the effectiveness 
of neuromodulation in the treatment of chronic pelvic pain (CPP) and bladder pain 
syndrome (BPS). 
 
Total	  citations	  identified	  by	  
electronic	  and	  hand	  searches	  
(n=1404)	  
Manual	  removal	  of	  duplicate	  citations	  (n=468)
Total	  citations	  reviewed	  (n=936)
Citations	  excluded	  after	  screening	  titles	  
and/or	  abstracts	  (n=926)
Studies	  identified	  (n=10)
7	  papers	  excluded:
6-­‐ No	  controls	  included
1	  – Different	  technique	  for	  
sacral	  nerve	  stimulation	  
Studies	  included	  (n=3)
2	  for	  chronic	  pelvic	  pain	  
(113	  patients	  – 24	  women,	  89	  men)
1	  for	  bladder	  pain	  syndrome
(56	  women)
 
Table 13 shows the characteristics of included studies.  
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Table 13: Characteristics and summary of results for studies included in a systematic review of the 
effectiveness of neuromodulation for BPS and CPP.  
 
 
Primary    Participants Methods and duration       Treatment regimen Outcome  Effectiveness 
Author,               & follow-up  measures  & complicatons 
Date, 
Locaton 
 
Gokyildiz  24 women CPP           PTNS versus routine           30 mins x 12 weeks Pain,  Improvements  
2012 Exclusion criteria Ethics approval    QoL  Pain & QoL 
Turkey No reported ages Informed consent    Sexual function in treatment  
   No blinding, ITT      group 
   2 drop outs      1 haematoma 
 
 
 
 
Kabay 89 men CPP PTNS versus sham         30 mins x 12 weeks Pain scores Reduction in  
2009 Mean age 37.9 Ethics approval         Sham had no electrical  QoL score  pain & urgency 
Turkey Exclusion criteria Informed consent         stimulation  Urinary  in treatment  
   Unknown blinding, 
   Randomisation, ITT 
    
 
 
 
O’Reilly 56 women IC Transdermal  PTN       30 secs x 12 weeks  Pain scores        Improved QoL 
2004 No reported ages laser versus sham       Inactivated sham   QoL scores Decreased 
Australia Exclusion criteria Ethics approval    Urinary  symptoms  
   Informed consent  
   Unknown blinding, 
   Randomisation, ITT 
 
          
      
 
CPP  = chronic pelvic pain, UTI = urinary tract infection, PTNS = posterior tibial nerve stimulation, VAS = visual analogue scale, ITT = 
intention to treat, QoL = quality of life, RCT = randomized controlled trial, FSFI = female sexual function index, NIH CPSI = chronic 
prostatitis symptom index, BPS = bladder pain syndrome, IC = interstitial cystitis, ICPI/SI = interstitial cystitis problem index/symptom 
index
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One paper was excluded (140), Lee et al, who described an alternative method of sacral 
neuromodulation which used electroacupuncture, where acupuncture points in the second and 
third posterior sacral foramen of the sacrum are stimulated with a frequency of 4Hz and an 
intensity of 5-10mA. Continuous pulse generator stimulation is produced, along with a 
deeper stimulation that reaches the myofascial trigger point of the piriformis muscle.  
 
The quality assessment of included studies is graphically represented in figure 11. There were 
no ‘good’ quality studies when the Downs and Black quality index was used. One study was 
found to be ‘good quality’ when the Jadad criteria was used (137, 140). Non-homogeneous 
populations were studies. There was variation in the duration of treatment and the number of 
neuromodulation sessions undertaken per week, as well as the electrical parameters that were 
used. Hence, a meta-analysis could not be performed. 
 
Figure 11: A quality assessment graph of included studies in a systematic review of the 
effectiveness of neuromodulation for BPS and CPP. 
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11b: Jadad scale 
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There were two studies where patients had CPP and one with BPS. PTNS was used in three 
studies and no studies with SNS. In two of the studies a sham treatment was used, while one 
study had usual care as the comparator. The outcome measure symptoms used were pain, 
urinary symptoms and quality of life. Each of the studies used different outcome 
measurements. The McGill questionnaire (137), visual analogue scale (137, 139) and chronic 
prostatitis symptom index (NIH CPSI) were used to assess pain scores (139, 140). The 
interstitial cystitis symptom index (ICSI) (138) and NIH CPSI  were used to measure urinary 
symptoms (139, 140). The SF 36 questionnaire (138), female sexual function index (FSFI) 
(137) and NIH CPSI were used to measure quality of life (139, 140).  
 
The GRADE quality assessment is shown in table 14. Limitations were noted in the study 
design, directness and precision, with different interventions and questionnaires being used in 
each study. The emotional component of the quality of life outcome measure performed best 
as it was reported using the same questionnaire in two papers. This evidence was rated as 
‘moderate’ quality, which indicates that further research may be likely to have an important 
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impact on the confidence of findings. There was one complication related to nerve 
stimulation; a needle insertion site hematoma experienced by one patient but there were no 
reported serious adverse effects. 
 
Table 14: A GRADE assessment table for the evidence presented by outcomes in the 
included studies in a systematic review of the effectiveness of neuromodulation for BPS 
and CPP (141, 142).  
 
Quality assessment No of patients Importance 
Outcome 
(No of 
studies) 
Design Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations Neuromodulation 
Sham or 
no 
treatment 	  
Pain 
(3) 
Randomised 
trials 
Serious
1 
No serious 
inconsistency 
Serious2 Serious3 None 86  
 
83 
 
⊕ΟΟΟ 
VERY 
LOW 
Urinary 
symptoms 
(2) 
Randomised 
trials 
Serious
1 
No serious 
inconsistency 
Serious2 Serious3 None 74  
 
71  
 
⊕ΟΟΟ 
VERY 
LOW 
Quality of 
Life 
(general) 
(3) 
Randomised 
trials 
Serious
1 
No serious 
inconsistency 
Serious2 Serious3 None 86  
 
83  
 
⊕ΟΟΟ 
VERY 
LOW 
Quality of 
Life 
(emotional
) 
(2) 
Randomised 
trials 
Serious
1 
No serious 
inconsistency 
Serious2 Serious2 None 41  
 
                  
39  
 
⊕ΟΟΟ 
VERY 
LOW 
 
1 Study design limitations - lack of blinding, no description of randomization, failure to document intention to treat analysis 
2 Indirectness - indirect comparisons between interventions, comparators, outcome measurement tools  
3 Imprecision - wide confidence intervals, few patients in studies	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7.5 Discussion  
There is limited available literature on the effectiveness of PTNS in improving pain, urinary 
symptoms and quality of life in patients with chronic pelvic and bladder pain syndromes, 
which shows variable success. No studies were found for SNS. 
 
The small number of studies assessing the intervention with a comparator was the main 
limitation of this systematic review. This limits the inferences that can be drawn. The 
literature search performed was thorough and imposed no language restrictions.  There were 
at least 30 studies found that did not have a comparator, these were excluded as no 
meaningful assessment could be performed. There were a variety of different questionnaires 
that were used to assess outcomes between the included studies. This made it difficult to 
directly compare scores for each symptom. The treatment follow up period was limited to 12 
weeks, which was the duration of treatment, which meant meaningful long-term effectiveness 
of neuromodulation could not be assessed. 
 
The benefit of posterior tibial nerve stimulation is that it is minimally invasive and can be 
performed in an outpatient setting (143). The frequency of repeat treatments and the 
frequency necessary to maintain good symptom control are uncertain. Lead avulsion in sacral 
nerve stimulation is a recognised complication which can cause sudden loss of function of the 
neuromodulator after trauma, as has been documented in case reports (144).  Both PTNS and 
SNS are generally well tolerated, although they may cause transient needle site pain, tingling 
in the legs and local infection as possible side effects. These are usually transient or resolve 
with removal of the neuromodulator (145).  
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Neuromodulation is recommended as a fourth-line treatment for BPS, once lifestyle, oral and 
intravesical treatments as well as cystoscopy with hydrodistension have been tried. The 
evidence for treatment efficacy of nerve stimulation is level 2, according to both the 
American and Japanese BPS guidelines. This level of evidence was drawn from well-
designed non-randomised or quasi-experimental studies. It was given a recommendation 
grade of C, which indicates that no clear recommendation for treatment is possible, (8, 23). 
Recent guidelines are recommending treatment initiation after careful clinical history and 
physical assessment, which can avoid delays in management and does not rely on diagnosis 
by cystoscopy, which can be unreliable (23). In order to fully evaluate the effectiveness of 
treatments, we need to understand the natural course of BPS but this is poorly understood 
(146).  
  
The Food and Drug Administration (FDA) board approves medical devices in the United 
States of America. It has not approved the use of nerve stimulation for the treatment of BPS. 
The American Urological Association guidelines for the management of BPS recommend a 
trial of nerve stimulation if conservative measures have failed (23, 147). Although the precise 
mode of action of neuromodulation is unknown, it has the benefits of being minimally 
invasive and has the possibility to greatly improve the quality of life for patients with 
refractory pelvic pain (129, 148). This systematic review highlights the lack of good quality 
evidence for neuromodulation and the recommendation of a thorough investigation of the 
therapeutic and cost effectiveness needs to be undertaken. Sham treatments have previously 
been validated in a feasibility study (149). The importance of a prospective, large multi-
centered clinical trial to investigate the effectiveness of PTNS and SNS to treat BPS and CPP 
in order to adequately assess treatment efficacy, long-term effects and produce reliable high 
quality evidence has been suggested in several studies (128, 150-152).  
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This chapter is based on the following peer-reviewed paper (81): 
Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic 
review 
SA Tirlapur, A Vlismas, E Ball, KS Khan 
Acta Obstet Gynecol Scand 2013 Aug;92(8):881-7 
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CHAPTER 8: 
ASSESSING OUTCOME MEASURES FOR 
TREATMENTS OF BLADDER PAIN 
SYNDROME: A SYSTEMATIC REVIEW OF 
THE LITERATURE 
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In this chapter I will discuss what are the core outcome measures for treatment effectiveness 
studies in BPS, along with how they are assessed and whether the impact factor of the journal 
influences the quality of outcome reporting. 
 
8.1 Abstract  
Background: The reporting of quality of outcomes in systematic reviews and randomised 
controlled trials (RCTs) is variable.  
 
Objectives: To evaluate the quality of outcomes reported in systematic reviews and RCTs of 
BPS, along with the possible relationship with study quality and journal impact factor.  
 
Data sources: The following databases were searched from inception until August 2013: the 
Cochrane Library, EMBASE, Medline, CINAHL, LILACS and SIGLE, without any 
language restrictions.  
 
Study selection: A six-point scale was used to assess the quality of outcomes that were 
reported in systematic reviews and constituent RCTs. AMSTAR and Jadad scoring systems 
were used to calculate study quality. Each journals impact factor in the year of publication 
was recorded and Spearman rank correlation was calculated.  
 
Results: A total of 28 RCTS with 1732 patients were reported in eight systematic reviews. 
Five outcome measures were described, which used 19 different measurement scales. These 
outcome measures were urinary symptoms (100%), pain (64%), quality of life (39%), general 
wellbeing (36%) and bladder capacity (36%). The quality of all outcomes was measured, and 
the mean score was 1.63 (95% CI 0.29 – 2.96) for systematic reviews and 3.25 (95% CI 2.80 
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– 3.70) for RCTs. There was a correlation between the quality of outcomes and the overall 
study quality (0.90, 95% CI 0.79 - 0.95, p <0.0001) but no correlation with journal impact 
factor (0.07, 95% CI -0.31 – 0.43, p = 0.35).  Multivariable linear regression was calculated 
for quality of outcome reporting and study quality, showing a positive relationship (β = 0.05, 
p < 0.0001), with an adjustment for the effects of study type, impact factor and journal type.  
 
Conclusion: These results highlight the need to generate a consensus to develop a core set of 
outcomes in bladder pain syndrome, which use standardised reporting tools that can be 
disseminated through good publication practice.  
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8.2 Introduction 
Outcome measures are examined by effectiveness studies. There are inconsistencies in the 
reporting of outcomes and the tools that are used to measure these. There can also be missing 
outcome data along with outcome reporting bias, which is often seen across studies (153). It 
is essential to have consistency in the reporting of outcomes in order to allow direct 
comparison of effects. Inconsistency at any stage can delay or hinder evidence syntheses and 
limit the usefulness of study results and may ultimately have a negative impact on care 
quality. The development of core study outcomes is needed to improve the translation of 
evidence into practice (154).  
 
In this chapter, I explored if the quality of reporting outcome measures was linked to other 
publication features, such as impact factor in the year of publication, study quality etc. There 
are many studies and reviews evaluating various treatments to achieve symptomatic control 
in BPS. A range of scores, scales and validated tools were used to measure these outcomes.  
 
There was identification of primary and secondary study outcome measures used to assess 
BPS treatments in published systematic reviews and their constituent trials along with 
assessment of the variation and quality of these outcome measures. The relationship between 
the quality of outcomes that were reported and overall study quality and journal impact factor 
was performed in a controlled analysis with adjustment for the year of publication and factors 
like the presence of commercial funding, study design and the journal type. 
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8.3 Methods  
There was prospective adherence of a protocol based on contemporary methods and reported 
in accordance with the PRISMA guidelines for this systematic review (62). 
 
Search strategy 
The Cochrane Library, EMBASE (1980-2013), Medline (1950-2013), CINAHL (1981-2013) 
and LILACS (1982-2013) were searched for relevant citations from the date of inception to August	   2013, along with searches in the grey literature in SIGLE (1990-2013), with no 
language restrictions. The following MeSH headings were used ‘interstitial cystitis’ or 
‘painful bladder syndrome’ or ‘bladder pain syndrome’, along with their keywords and 
variants, which were combined using the Boolean operator ‘and’ with the term ‘systematic 
review’ within the title or abstract. There was hand searching of the bibliographies from 
relevant articles and conference proceedings of the International Continence Society in order 
to capture any references not found through electronic database searches.  
 
Study selection and data extraction 
I used the definition of a systematic review to be one in which at least two databases were 
used to perform literature searches, along with the PRISMA guidance for reporting and 
evaluating treatments for BPS. I noted whether primary and secondary outcomes had been 
described and recorded, as well as the measurement tools or questionnaires, which had been 
used to collect this information. This usually took the form of patient-rated improvement 
scores (23). In order to evaluate a possible relationship between quality of outcome reporting 
and journal type, I recorded the type of journal (general or specialist) that studies were 
published in, the journal impact factor in the year of publication, along with any recorded 
sources of pharmaceutical funding and whether any sample size calculations had been 
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performed for randomised controlled trials (RCTs). As for other systematic reviews, all data 
were extracted in duplicate by two independent researchers (SAT, RNR) using an electronic 
pre-designed data extraction form and any disagreements in results were resolved through 
consensus after discussion.  
 
Quality assessments  
All outcomes reported in systematic reviews and RCTs were assessed for quality. A six-point 
scoring system was used with the following questions (155): if a primary outcome was stated 
(1-point), if a clear definition was provided for reproducible measurement (1-point), if a 
secondary outcome was stated (1-point), if a clear definition was provided for reproducible 
measurement (1-point), if the authors explained the use of the outcomes (1-point) and if 
methods were used to enhance quality of measures, for example repeating measures or 
training in use of measurement tools (1-point). As measuring the quality of core outcomes is 
a relatively new concept, there is no rating system for these questions. Therefore, an arbitrary 
level of ≥ 4 was used to represent ‘good’ quality. The six questions have been used in 
published literature on core outcome development and hence were used to assess quality, as 
there does not appear to be any alternative tool (155). 
 
The 11-point AMSTAR (assessment of multiple systematic reviews) measurement tool was 
used to assess study quality for systematic reviews. This served as a standardised checklist, 
which evaluated study methodology, study characteristics, quality assessment, publication 
bias assessment and any conflict of interest declaration. All of the 11 questions were 
answered with yes, no, cannot be answered or not applicable. Scores of eight to 11 were 
designated as ‘high’ quality, scores of four to seven were ‘medium’ quality and 0 to three 
were ‘low’ quality (156). Quality assessment of RCTS was performed using the Jadad 
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criteria, which evaluates the methodology used, while taking into account patients who drop 
out of the study, scoring all five questions with an answer of yes or no. The scores can range 
from 0-5, where ‘good’ quality is assigned to scores ≥ 3 (134). Both the AMSTAR and Jadad 
quality assessment scores were transformed into a 0-100 scale in order to graphical display 
results and perform analysis.  
 
Data synthesis 
Study characteristic were represented in tabular form and Spearman’s rank correlation was 
calculated with 95% confidence intervals (CI) for the quality of reporting outcomes versus 
overall study quality assessment, and for the quality of reporting outcomes versus journal 
impact factor in the year of publication. A multiple regression analysis was performed to 
assess a possible relationship between quality of reported outcomes and study quality, using 
StatsDirect version 2.7.9. It was adjusted for the following factors: impact factor, year of 
publication, commercial funding and study and journal type.   
 
8.4 Results 
The selected articles are summarised in figure 12. There were eight systematic reviews with a 
total of 1732 patients (157-164). I excluded four articles as three of them did not adhere to 
the definition of a systematic review and one did not affect patients with the target condition 
of BPS (127, 165-167).  
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Figure 12: Flow chart of systematic review selection 
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Manual	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  of	  duplicate	  citations	  (n=25)
Total	  citations	  reviewed	  (n=73)
Citations	  excluded	  after	  screening	  titles	  
and/or	  abstracts	  (n=61)
Reviews	  identified	  (n=12)
4	  reviews	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3-­‐ Not	  systematic	  reviews	  using	  at	  least	  2	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  and	  PRISMA	  guidance
1	  – No	  patients	  with	  target	  condition
8	  Systematic	  reviews	  included,	  
comprising	  of	  28	  RCTs:
1	  review	  and	  3	  RCTs	  had	  no	  	  
impact	  factor	  information
4	  RCTs	  were	  abstract	  only	  and	  
excluded	  from	  outcome	  reporting	  
analysis
7	  reviews	  and	  21	  RCTs	  were	  
used	  in	  multiple	  regression	  analysis	    
 
 
 
Table 15 identifies all the different outcomes reported and the types of measurement tools 
used in each RCT and systematic review. 
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Table 15: Characteristics of systematic reviews for treatments of bladder pain 
syndrome. 
 
Author Impact factor Treatment No. of RCTs  No. of studies Outcome Tool No RCTs per  
(Year) (AMSTAR)   (no. patients) (total patients)   outcome 
 
Srivastava Not documented SNS  1 (22)        11 (480) Pain VAS  1 
(2012)  (3)       QoL GRA, SF 36, BDI 0 
        Urinary ICPI, PUF               0 
        Bladder capacity ND          0  
       
Dawson  4.65  Intravesical 8 (586)        9 (616) Pain VAS, NRS 3 
(2009) (11)  treatments    QoL ICSI, Rand 36 5 
        Urinary ICSI, GRA, PUF     4 
        Bladder Diaries, UDS 4 
        Economic ND 0 
   
 
Dimitrakov  8.39  Pharmacological 21 (1470)        21 (1470) Urinary ICSI/PI, diary 21 
(2007)  (6)       Global status ND 0  
 
 
Mangera 8.49  Botulinum toxin A 1 (20)        9 (231) Pain VAS  1 
(2011) (4)       Urianry freq ND 1 
        Nocturia  ND          1 
        Bladder  UDS                 0 
        Global QoL    1 
         CPSI, PSS, GICS, AUA SI 
 
Matsuoka 2.17  Intravesical 5 (596)        5 (596) Pain VAS, PUF               3 
(2012) (5)  treatments    QoL SF 36, Rand 36       0  
        Bladder  UDS  3 
 
 
Mourtzoukou 2.38  Intravesical 3 (203)       6 (225) Pain VAS, PUF 3 
(2008) (2)  resiniferatoxin    QoL  ND 0 
        Urinary  GRA, ICSI, voiding 3 
 
 
Tirlapur 1.85  Neuromodulation 1 (56)       1 (56)  Pain ICSI/PI  1 
(2013) (7)       QoL ICSI/PI  1 
        Urinary  SF 36  1 
 
 
Tirumuru 1.73  Intravesical 3 (155)      10 (260) Pain VAS  2 
(2012) (7)   Botulinum toxin     Urinary  BFLUTS, GRA,  2 
         IIQ, ICSI, KHQ  
        Bladder  UDS  2 
        QoL IPPS, UDI 2 
 
 
 
SNS: sacral neuromodulation; QoL: quality of life; ND: not documented; UDS: urodyanmics 
AMSTAR: Assessment of multiple systematic reviews; VAS: visual analogue scale; GRA: global response 
assessment; SF 36: short-form 36 quality of life survey; BDI: Beck’s depression inventory; ICPI: interstitial 
cystitis problem index; PUF: pelvic pain urgency/frequency; NRS: numeric rating scale; ICSI: interstitial 
cystitis symptom index; RAND 36: Research and development health survey; CPSI: chronic prostatitis 
symptom index; PSS: perceived stress scale; GICS: global interstitial cystitis score; AUA SI: American 
Urological Association symptom index; BFLUTS: Bristol female lower urinary tact symptoms; IIQ: 
incontinence impact questionnaire; KHQ: King’s health questionnaire; IPPS: International prostate symptom 
score; UDI: urogenital distress inventory 
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In the 28 unique RCTs that were identified (138, 168-192), there were five outcomes, which 
were; urinary symptoms, pain, quality of life, general wellbeing and bladder capacity. Every 
RCT (100%) had the outcome of urinary symptoms, which were measured with seven 
different tools. In 18 RCTs (64%) five different tools were used to measure pain. In 11 RCTs 
(39%) six different tools were used to measure quality of life. In 10 RCTS (36%) only one 
tool was used to measure general wellbeing and in 12 RCTs (43%) one tool was used to 
measure bladder capacity. For the outcome of quality of life, the general or ‘physical’ 
component of the measurement tool was used, rather than the emotional or ‘mental’ 
component, which is referred to in the SF 36 questionnaire. The mean AMSTAR score of 
5.63 (95% CI 3.26 – 7.99) was calculated for quality of systematic reviews. The mean Jadad 
score of 3.13 (95% CI 2.58 – 3.67) was calculated for quality of RCTS.  
 
On analysing the type of journal, I found that half of the systematic reviews were published 
in specialists’ urology or urogynaecology journals (n= 4), 13% (n = 1) were published in a 
general obstetrics and gynaecology journal and 38% (n = 3) in non-women’s health journals. 
It was noted that 100% of RCTs were published in specialty urology or urogynaecology 
journals (n = 28). The sample size was only calculated in 46% (n = 15) of RCTS. There was 
no pharmaceutical company funding in any of the of systematic reviews but was present in 
33% (n = 8) of RCTs.  
 
In 21 RCTs and seven systematic reviews the quality of outcomes was assessed (figure 13). 
Despite several attempts to contact the authors, the full text for four RCTs could not be 
obtained so these were excluded from this analysis, since it was not possible to accurately 
assess quality from the limited information provided in the study abstract (174, 181, 193, 
194). 
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Figure 13: Quality of outcomes reported for systematic reviews and randomised 
controlled trials (RCTs)  
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Systematic reviews had a mean score of 1.63 (95% CI 0.29 – 2.96) for quality of outcomes 
and RCTs had a mean score of 3.25 (95% CI 2.80 – 3.70). There was good quality of 
reported outcomes in 13% (n = 1) of systematic reviews and in 33% (n = 8) of RCTS, which 
is represented in figure 13. There was no difference in the reporting of primary outcomes (4 
versus 21, 50% versus 88%, p = 0.51), however, I did find that secondary outcomes were 
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reported more frequently in RCTs compared to systematic reviews (1 versus 11, 13% versus 
46%, p = 0.003).                      
 
The relationship between the quality of reported outcomes with impact factor in the year of 
publication and study quality in all the included systematic reviews and RCTs is represented 
in figure 14. There was an exclusion of one systematic review and three RCTs because the 
information about the journal impact factor in the year of publication could not be obtained 
(162, 168, 180, 190). There was a positive correlation between the quality of outcomes 
reported and the study quality (0.90, 95% CI 0.79 - 0.95, p = <0.0001) but there was no 
correlation with journal impact factor (0.07, 95% CI -0.31 – 0.43, p = 0.35) when the 
Spearman’s rank coefficient was calculated.   
 
Figure 14: Relationship of quality of outcomes reporting with journal impact factors at 
publication and overall study quality.  
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The positive correlation between quality of outcome reporting and study quality was 
confirmed using multivariable linear regression analysis (β= 0.05, p < 0.0001) with 
adjustment for effects of study type, impact factor and journal type (table 16). There was an 
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association between the quality of reporting outcomes and systematic reviews versus RCTs 
(β = -1.24, p < 0.0001), specialist versus general journals (β = -0.41, p = 0.03), and lower 
versus higher impact factor (β = -0.07, p = 0.02). 
 
Table 16: Multiple linear regression analysis to determine factors associated with 
quality of outcome reporting.  
 
Factor      Univariable   Multivariable* 
      β p   β p 
  
Study quality+     0.05 <0.0001   0.05 <0.0001 
Impact factor at publication   -0.08 0.02   -0.07 0.02 
Type of study (systematic review/RCT) -1.20 <0.0001  -1.24 <0.0001 
Journal type (specialist/general)  -0.40 0.05   -0.41 0.03 
Year of publication    -0.01 0.70   - - 
Commercial funding    -0.01 0.93   - - 
 
 
+ measurement details in methodology section 
* Based on best sub-set regression 
 
 
8.5 Discussion 
In this chapter I have shown that studies use several outcomes as reporting endpoints, and 
these are measured using various tools to assess treatment effectiveness in BPS. Most studies 
on treatment effectiveness are observational with a lack of RCTs, possibly due to the 
difficulty using placebo or sham procedures for surgical interventions. The quality of 
reporting outcomes was poor. I found that the reporting of secondary outcomes was better in 
individual RCTs compared to systematic reviews. Generally, the quality of individual 
systematic reviews and RCTs was variable. Dawson et al had the best quality systematic 
review, assessing intravesical treatments for BPS. This paper clearly described the primary 
and secondary outcomes and performed well using the quality assessment tools.  However, 
this study was a Cochrane collaboration publication which needs to adhere to the Cochrane 
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guidance and hence incorporates all expected elements of reporting a systematic review, 
which may explain its high quality (157). Surprisingly, Mangera et al had the publication 
with the highest impact factor but this had the lowest quality assessment score because it did 
not describe the primary or secondary outcomes (159). A positive relationship was noted 
between the quality of outcomes reported and the quality of a study. Contrary to belief, there 
was no relationship between quality of outcomes and journal impact factor, which may 
suggest the authors with good quality studies do not aim to publish in high impact journals, 
resorting to speciality specific journals, which are often lower ranking.   
 
The five outcomes of urinary symptoms, pain, quality of life, bladder capacity and general 
wellbeing were assessed using a variety of patient-reported questionnaires. These 
questionnaires were composed of a composite symptom and sign scores and visual analogue 
scales. There was a lot of heterogeneity, which made it impossible to compare the effects on 
treatment as I was unable to evaluate their impact on disease (195). The problem with many 
patient-reported questionnaires is that they lack the ability to be truthful. They are often 
difficult or unfeasible to replicate and do not have discriminative power to gauge the 
reliability and sensitivity of the measurement tool (196). The patient populations varied as 
RCTs were international with so no meaningful comparisons could be made relating to 
ethnicity, disease effects on different patient groups and treatment effectiveness.  
 
The five outcome measures identified in this chapter may serve as a starting point for the 
development of a core outcome set. In order to develop and prioritise a finalised set of 
outcomes, a Delphi consensus panel survey of stakeholders, including patient representatives 
would need to be undertaken (197). The Grading, Recommendations, Assessment, 
Development and Evaluation (GRADE) working group recommendation scale allows 
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outcome measures to be prioritized, in order to improve standardisation and transparency of 
results by rating outcomes from ‘critically important’ to ‘not important’ (141, 198).  
 
In the field of urogynaecology, there are attempts to standardise terminology (199, 200). In 
order for this to happen, we need standardised, validated tools, which give clear reporting on 
time of testing to allow repeatable results. This will allow the development of an inventory of 
core outcomes (155). Many common gynaecological conditions need core outcomes to be 
developed, with intended primary and secondary outcomes explicitly described, to facilitate 
and improve the transparency of results in trials, reviews and guidelines. Symptom severity 
and general physical and mental quality of life are the ‘soft markers’ often forgotten but so 
important to patients as a means of evaluating treatment effectiveness. Although there are 
many validated disease-specific questionnaires that can be used for BPS, there is no single 
internationally adopted one. Delphi panels of specialists may be used to develop a single 
symptom-based questionnaire, which incorporates the five core outcomes identified in this 
paper. This is especially important in diagnosing a condition, which has no gold standard 
diagnostic criteria and often depends on recognition of patient symptoms.  
 
In order to minimise reporting bias, it is necessary to have methods of measuring outcomes, 
and the reporting of frequency of incomplete outcomes in results to improve the reliability of 
outputs from evidence syntheses (201-203). The CROWN (CoRe Outcomes in WomeN’s 
health) initiative is a working group, which has been recently set up, led by journal editors in 
obstetrics and gynaecology to minimise inconsistencies in the reporting of outcomes and 
avoid reporting bias in women’s health (204).  
 
This chapter is based on the following peer-reviewed publication (205): 
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Variations in the reporting of outcomes used in systematic reviews of treatment 
effectiveness research in bladder pain syndrome 
SA Tirlapur, R Ni Riordain, KS Khan in collaboration with EBM-CONNECT 
Eur J Obstet Gynecol Reprod Biol. 2014 Jun 13;180C:61-67 
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CHAPTER 9: 
ASSESSING THE DISCREPANCIES IN 
GRADING OF EVIDENCE FOR THE 
MANAGEMENT OF BLADDER PAIN 
SYNDROME 
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In this chapter I explore the different rating systems to evaluate the quality of evidence 
available on the management of BPS.  
 
 
 
9.1 Abstract  
 
Background: There are a variety of international clinical guidelines on bladder pain 
syndrome (BPS). These rate quality of evidence, which is based on the study design. Along 
with the quality of evidence described in current BPS guidelines, we used the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system, which 
accounts for several domains to assign quality ratings apart from the limitations of study 
design.  
 
Methods: We reviewed clinical guidelines and all existing systematic reviews on the 
management of BPS along with the evidence included, which was rated according to 
GRADE on a four-point scale (1- 4, from very low to high). The GRADE ratings were 
compared to the other two reported quality assessments; level of evidence 1- 4, from meta-
analysis of randomised studies to expert opinion; strength of evidence 1- 4, from very low to 
high.  
 
Results: 19 treatments were identified for BPS where GRADE ratings were assigned. In 
comparison with level of evidence ratings, the latter overestimated quality by 1.8 points (1.1 
v 2.9; 95% CI of mean difference 1.2 to 2.3; p= <0.0001). In comparison with strength of 
evidence ratings, the latter overestimated quality by 1.7 points (1.1 v 2.8; 95% CI of mean 
difference 1.3 to 2.1; p= <0.0001).  
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Conclusion: The GRADE quality scoring system is a refined method of assigning quality to 
evidence, which provides a more conservative measurement of quality of evidence that can 
give a realistic assessment of the value of recommendations, which can be considered in 
practice. 
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9.2 Introduction  
There have been numerous treatments suggested for BPS with varying evidence about their 
effectiveness.  
 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
system assesses the quality of evidence using several domains which include: study design, 
indirectness, imprecision, inconsistency and risk of bias (206, 207). This system was 
developed allowing clinicians to evaluate the evidence and strength of recommendations in 
systematic reviews and guidelines by creating transparency over the reporting of evidence. 
The quality of evidence is usually summarised focusing on the study design in existing 
guidelines (8, 23). Hence, traditionally high quality was assigned to randomised controlled 
trials (RCTs) without a distinction to whether the RCT was high and low quality. In these 
situations the GRADE evaluation can be helpful (208).  
 
The different methods of evaluating evidence and recommendations for BPS in current 
guidelines are assessed and I explore how recommendations may be affected if the GRADE 
approach were to be adopted. 
 
 
9.3 Methodology  
Medline and EMBASE databases were searched from inception to May 2013 using the 
following search terms and word variants: ‘chronic pelvic pain’ OR ‘interstitial cystitis’ OR 
‘painful bladder syndrome’ OR ‘bladder pain syndrome’ combined with the Boolean operator 
AND with ‘guideline’ OR ‘systematic review’. Hand searching for additional articles not 
identified through electronic database was performed. Quality of evidence in recent 
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guidelines was compared using the GRADE approach versus standard quality measures. The 
2009 Japanese guidelines for IC used level of evidence scores ranging from 1-4 where 1 was 
assigned to an RCT and 4 was assigned to expert opinion, along with strength of evidence 
scores A, B, C or D where A represented highly recommended treatments with evidence from 
good quality studies and D represented treatments that were not recommended (8). In 2011 
the AUA produced their guidelines on the management of BPS which used strength of 
evidence assessments (23). In addition to these two guidelines, information from 2012 
European Association of Urology guidelines on the management of chronic pelvic pain, 
which used both level and strength of evidence scores, a 2008 review and 2012 systematic 
review on the management of the painful bladder were obtained in order to incorporate all 
available sources of information (127) (24, 103). 
 
GRADE methodology 
The evidence was assessed for each treatment option according to GRADE, incorporating 
five domains, which were study design, inconsistency, indirectness, imprecision and risk of 
bias. Historically, randomised trials have been considered as ‘high’ quality studies and 
observational studies are ‘low’ quality. Downgrading of evidence occurs when assigning a 
score for study design (207). Inconsistency is associated with relative treatment effects, 
where scores may be downgraded if there are different point estimates, overlapping 
confidence intervals and lack of heterogeneity (209). The domain of directness compares 
important interventions in applicable populations with patient-related primary outcomes. 
There is indirectness when a study does not correctly address these (210). There may be 
imprecision within a study when large confidence intervals, small sample sizes or numbers of 
events are observed (211). The limitations in study design can lead to a high risk of bias, 
which includes failure of adequate concealment, blinding, adherence to intention to treat 
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analysis and accountability of losses to follow up in RCTs, as well as selective reporting and 
inappropriate use of controls in observational studies (142). 
 
Downgrading of evidence occurs every time there is a deficiency; by one level, ranging from 
no deficiency to serious to very serious deficiencies. These assessments are dependent upon 
the reviewer’s subjectivity. The quality of evidence may also be subject to downgrading from 
high quality where further research is unlikely to change our confidence in the effect, 
moderate, low and very low evidence where any estimate of effect is very uncertain (208). 
 
Comparison of GRADE with level of evidence in guidelines 
I compared the recommendations and levels of evidence in guidelines on the diagnosis and 
management of BPS from the United States of America (23), Japan (8), Europe (24) and a 
recent systematic review (127) to GRADE assessment. Quality ratings in the guidelines used 
four-point ordinal scale for level of evidence; level 1a was meta-analysis of a randomised 
control trial and level 4 was expert opinion and in strength of evidence ratings, A represented 
a highly recommended treatment to D for a treatment that was not recommended. Definitions 
of GRADE, level and strength of evidence scores are summarised in table 17. If any 
discrepancies arose regarding the rating scores between guidelines, there was a review of the 
evidence and the most accurate score was awarded.  
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Table 17: Quality assessment methods used in different guidelines for the management 
of bladder pain syndrome (23, 103).  
 
 
 
Quality assessment method            Numerical scale assigned for analysis 
 
 
 
Level of evidence* 
 
1a Meta-analysis of randomised control trials (RCT)       4 
1b Evidence obtained from a single RCT         4 
2a Evidence obtained from one well-designed, controlled study without randomization   3 
2b  Evidence obtained from one other type of well- designed quasi-experimental study   3 
3 Evidence obtained from non-experimental studies (comparative, correlation or case-reports)  2 
4 Evidence obtained from expert committees, expert opinions or clinical practice    1 
 
 
 
Strength of evidence**       
  
A Highly recommended – Clinical studies of good quality and consistency including at one RCT  4 
B Recommended – Well-conducted clinical studies without randomised trials    3 
C  No clear recommendation possible – Absence of directly applicable clinical studies of good quality  2 
D Not recommended          1 
 
 
 
Grading, Recommendations, Assessment, Development and Evaluation (GRADE) ***   
      
 
4 High           4  
3 Moderate           3 
2 Low           2 
1 Very low           1 
 
 
 
* e.g. Japanese guidelines for interstitial cystitis, European Urology Association guidelines for chronic pelvic pain 
** e.g. American Urology Association guidelines for bladder pain syndrome 
*** See methodology for details and table 2 for a worked example of a GRADE table 
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Stats direct software programme were used for statistical analysis in order to calculate the 
mean and median differences and 95% confidence interval for strength of evidence versus 
GRADE and level of evidence versus GRADE. 
 
9.4 Results 
Three suitable guidelines were identified from 88 citations. These were: The 2009 Japanese 
Urology Association clinical guidelines for interstitial cystitis, the AUA guidelines for the 
diagnosis and management of IC/BPS in 2011 and the 2012 European Urology Association 
guidelines on chronic pelvic pain (8, 23, 103) (figure 15). 
 
Figure 15: A flow chart identifying suitable guidelines for bladder pain syndrome. 
 
  
 
 
First line treatments (conservative management): 
Self-care and behavioural modifications: In a 2012 published survey involving 1,982 
patients, it was revealed that 87.6% reported a symptomatic improvement with an elimination 
diet and 86.1% by completely avoiding certain items. Treatment durations were not indicated. 
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65.2% of patients reported a symptomatic improvement by participating in regular exercise 
(212).  
 
Stress management: In the same 2012 survey, there was symptomatic improvement in 76.4% 
of patients using relaxation techniques, 66.8% reported improvement using meditation, 
64.5% when listening to music and 80.5% reported improvement while employing stress 
reduction to their lifestyle (212).  
 
Second line treatments: 
Manual physical (massage) therapy: The effectiveness of massage therapy was assessed in 
an electronic questionnaire which revealed that 74.2% of patients experienced symptomatic 
improvement with this treatment, 61.5% with physical therapy and 66.1% through a 
combination of physical therapy with internal treatment (212).  
 
Analgesia: There is no available data about the efficiency of different forms of analgesia in 
the treatment of BPS. 
 
Oral Amitriptyline: This H1 receptor antagonist can modify pain transmission in the central 
nervous system to relieve symptoms in BPS. In one prospective randomised control double-
blind study, which was undertaken on 50 patients, they were treated with a self-titrating dose 
of amitriptyline over 4 months, to a maximum dose of 100mg. There was a reported decrease 
in the mean scores for the O’Leary-Sant symptom questionnaire of 8.5 points in the treatment 
group and 3.5 in the control group. There was a demonstratable improvement in pain and 
urgency symptoms that was statistically significant (182). The commonly noted side effects 
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of amitriptyline are dry mouth and weight gain. In long-term follow up studies of 19 months, 
46% patient satisfaction was observed with treatment (213).   
 
Oral Cimetidine: A placebo-controlled randomised double blind study, which compared 36 
patients treated with a three-month course of 400mg oral cimetidine versus placebo twice 
daily, showed a marked improvement in the treatment group in pain and urinary symptoms, 
especially in nocturia. More than ten years ago, it was reported that post treatment cystoscopy 
and bladder biopsies showed no histological changes, which would not be a surprising 
finding in this day (185). 
 
Oral Hydroxyzine: There is one reported randomised study comparing a treatment group of 
31 patients who were treated with a three week course of 10-50 mg hydroxyzine daily then 
were on he highest dose for 21 weeks compared to a placebo group. In 31% of treated 
patients a response rate was found compared to 20% of the control group (187).  
 
Oral Pentosan polysulfate sodium (PPS): PPS is thought to repair the damaged 
glycosaminoglycan (GAG) layer of the bladder mucosa, which acts as a protective 
mechanism (8). There are two prospective double-blind studies evaluating the effectiveness 
of PPS. In the first one 115 patients were treated with a four month course of 200mg PPS 
twice daily but showed no difference in scores for pain or urinary symptoms in the treatment 
and placebo arms. The second study had 148 patients who were treated with 100mg PPS 
three times daily.  There was a 32% improvement in symptoms in the treatment group 
compared to a 16% improvement in the placebo group (193, 214). 
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Intra-vesical dimethyl sulfoxide (DMSO): DMSO has a combination of effects. It acts as an 
analgesic, anti-inflammatory and muscle relaxant (8). In one prospective cross-over study it 
was reported that 33 patients who were randomised into treatment with 50% DMSO or 
placebo (normal saline) for a two week period with two treatment sessions each week had a 
93% objective improvement in the treatment group and 35% in the placebo group (174). The 
main side effects of DMSO are a garlic-like odour and bladder spasm.  
 
Intra-vesical Heparin: 48 patients were treated with 10,000 units of heparin in 10mls sterile 
water in one observational study. This was instilled three times a week for three months. 
Over a three month period, 56% of patients achieved clinical remission and after one year 
50% of patients had symptomatic control (215). 
 
Intra-vesical Lidocaine: Lidocaine is a local anaesthetic which blocks sensory nerve fibres in 
the bladder. 102 patients were treated in one randomised double-blind study with 200mg 
intravesical lidocaine with alkalinised instillation of 8.4% sodium bicarbonate to a final 
volume of 10mls versus a placebo treatment over a five-day course. In the treatment group 
30% of patients reported a moderate or marked symptom improvement, whereas only 9.6% 
of the placebo group reported improvement over a 29 day follow up period (160).  
 
Third line: 
Cystoscopy with short-duration low-pressure hydrodistension: Cystoscopy used to be used 
solely as a diagnostic tool but is nowadays also used as a treatment if conservative treatment 
measures have failed. There are effectiveness data from three observational studies, which 
describe variable symptomatic improvement after treatment in a total of 265 patients but the 
effects are short-lived and within six months symptoms had recurred in the majority of 
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patients (216-218). A recognised but rare complication of prolonged bladder distension is 
rupture, therefore low-pressure distension is advised (219).  
 
Fulguration +/- triamcinolone for Hunner’s lesions: There are two observational studies 
which report successful outcomes when using Nd:YAG laser under cystoscopic control in 
BPS with Hunner’s ulcers. In 51 patients who were treated in this way, 88% expressed 
symptomatic relief within 2-3 days of treatment. However, 45% needed additional treatment 
within 23 months of initial treatment (220, 221).  
 
Fourth line: 
Neurostimulation: There is limited data on the effectiveness of sacral and posterior tibial 
nerve stimulation (neuromodulation) for the treatment of BPS. There are no randomised trials 
that compare these treatments with a placebo. There is one observational study that reported 
efficacy of posterior tibial nerve stimulation in 18 patients. There are six studies that have 
reported effectiveness of sacral nerve stimulation in a total of 150 patients, both showing 
improvements in symptoms and quality of life scores (222-227). While both forms of nerve 
stimulation are effective, they are minimally invasive procedures that need frequent repeat 
treatment to sustain the treatment effect, which may deter patients. 
 
Fifth line: 
Cyclosporin A: There have been two RCTs evaluating the effectiveness of cyclosporine A. 
Both of them compared a six-month course of oral cyclosporin A versus oral pentosan 
polysulfate sodium (228-230). In the treatment group, 75% of patients had a symptomatic 
improvement, compared to 19% of the PPS group but it is difficult to directly compare results 
as the intervention was not compared to a placebo.  The urinary marker, epidermal growth 
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factor (EGF), has been shown to be higher in BPS patients, and EGF levels were found to be 
significantly reduced in the treatment group.  
 
Botulinum toxin A: This is a treatment, which is administered when other treatments have 
failed to control symptoms. There is one systematic review that evaluated botulinum toxin A 
in the treatment of BPS, which included data from three RCTs and seven prospective cohort 
studies with a total of 260 patients. In eight studies there was a symptomatic improvement, 
even though although 7% of patients needed post-treatment self-catheterisation (231). 
 
Sixth line: 
Major surgery: This is often considered the last resort for refractory BPS.  Surgical 
management takes the form of a total cystectomy and urinary diversion will lead to self-
catheterisation. Patients also need to be aware of the complications of persistent pelvic pain 
and pouch pain post-surgery (8). 47 patients who had reconstructive surgery for BPS were 
reviewed in a retrospective observational study, which found that 82% of patients with 
Hunner’s ulcerations had symptomatic relief after surgery. This compared with 23% of 
patients with non-ulcer disease after an average of 89 months follow up period (232). 
 
Treatments that should not be offered (not recommended): 
Long-term oral antibiotics: The practice of using long-term rotating antibiotics to treat BPS 
is not recommended. There was one RCT, which compared sequential antibiotics versus 
placebo but showed no significant benefit, with a high proportion of adverse effects reported. 
(184). In the study 50 patients were randomised to receive an 18-week course of antibiotics. 
These were rifampicin plus a sequence of doxycycline, erythromycin, metronidazole, 
clindamycin, amoxicillin and ciprofloxacin for three weeks each, or a placebo. In the 
154	  	  
	  	  
treatment group, 48% reported overall improvement compared to 24% in the placebo group 
(p = 0.14), but 10 (20%) patients in the treatment group and five (10%) in the placebo group 
noticed improvement in pain and urgency (p = 0.22). 80% of patients in the antibiotic 
treatment group suffered from had adverse effects, in comparison to 40% in the placebo 
group (p = 0.009).  
 
Intravesical instillation of Bacillus Calmette-Guerin (BCG): No clinical benefit has been 
reported using BCG instillation treatment, although serious adverse effects are anticipated 
and have been reported in studies. There are two RCTs, which compared intravesical BCG 
with placebo in 282 patients over a six-week period (171, 175). There was no reported 
statistical difference for symptomatic outcomes for patients in the BCG treatment arm but 
there were a large number of adverse outcomes, which included arthralgia, headaches and 
infection. A 68 week extended follow up period was undertaken for 86% of the treatment 
group and 75% of the placebo group who felt there was a marked or moderate symptomatic 
improvement (233). The second smaller RCT of 30 patients observed a 60% improvement in 
symptoms within the treatment group compared to 27% in the placebo group (P = 0.065).  
 
High-pressure, long-duration hydrodistension: Hydrodistension is performed at the time of 
cystoscopy where high-pressure water of greater than 80-100cm, stretches the bladder for a 
prolonged duration of greater than 10 minutes. This may cause adverse effects, with the most 
serious being bladder rupture or sepsis. Three observational studies have reported outcomes 
for this intervention. They showed variable efficacy rates, ranging from 22-67% with at least 
one case of bladder rupture in each study (23, 234, 235). Guidelines have recommended 
avoiding this treatment option as the risks far outweigh the benefits. 
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Oral long-term glucocorticoid: The side effects associated with use of long-term steroids, 
such as prednisolone, have led to this treatment not being recommended as a therapy for BPS. 
Limited data exists on the therapeutic effectiveness with only one observational study, which 
treated patients with prednisolone and hydrodistension simultaneously so meaningful 
comparisons of efficacy could not be evaluated (236). 
  
Rating of evidence with GRADE versus strength of evidence in guidelines 
An example of a GRADE table is seen in table 18, which uses second-line treatments for BPS 
as an exemplar, created using GRADE software.  
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Table 18: A sample GRADE table: Second-line treatments for bladder pain syndrome. 
 
 
 
 
Quality assessment Quality 
Treatment No of 
studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations  
Oral analgesia 0 n/a n/a n/a n/a n/a n/a n/a 
Oral 
hydroxyzyine 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias ⊕ΟΟΟ 
VERY 
LOW 
Manual physical 
therapy 
1 observational 
studies 
very serious1 very serious no serious 
indirectness 
no serious 
imprecision 
reporting bias2 ⊕ΟΟΟ 
VERY 
LOW 
Oral 
amitriptyline 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias2 ⊕⊕ΟΟ 
LOW 
Oral cimetidine 1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias2 ⊕⊕ΟΟ 
LOW 
Oral pentosan 
polysulfate 
sodium (PPS) 
2 randomised 
trials 
serious1 no serious 
inconsistency 
serious3 no serious 
imprecision 
reporting bias2 ⊕ΟΟΟ 
VERY 
LOW 
Intravesical 
dimethyl 
sulfoxide 
(DMSO) 
1 randomised 
trials 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias2 ⊕ΟΟΟ 
VERY 
LOW 
Intravesical 
heparin 
1 observational 
studies 
very serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias2 ⊕ΟΟΟ 
VERY 
LOW 
Intravesical 
lidocaine 
1 randomised 
trials 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias2 ⊕⊕ΟΟ 
LOW 
 
 
1 Lack of blinding, failure to report intention to treat, method of randomisation, lack of allocation or concealment 
2 Evidence based on less than 10 trials 
3 Variations in outcome assessment tools, populations compared 
 
 
In figure 16, the scores for the level of evidence score were compared to GRADE, to show 
any overestimations in the scores. There were 19 comparable treatment options, which were 
all downgraded with six of these options being downgraded by three points, from ‘high’ to 
‘very low’, four options were downgraded by two points and nine of them by one point. 
There was a mean over estimation score of 1.8 (1. v 2.9, with a 95% CI of mean difference of 
2.3 to 1.2; p = <0.0001 using an unpaired t test. Using the Wilcoxon’s signed rank test the 
median difference was 2 (95% CI of 2.0 to 1.0). 
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Figure 16: Graphical representation of the level of evidence score versus GRADE for 
the management of bladder pain syndrome 
 
   
Level	  of	  evidence	  score:
4	  =	  meta-­‐analysis	  or	  randomized	  controlled	  trials
3	  =	  well-­‐designed	  quasi-­‐experimental	  or	  non-­‐
randomised	  studies	  
2	  =	  non-­‐experimental	  studies	  (comparative,	  
correlation	  or	  case-­‐reports)
1	  =	  expert	  committees,	  expert	  opinions	  or	  clinical	  
practice
GRADE:
4	  =	  High
3	  =	  Moderate
2	  =	  Low
1	  =	  Very	  low
0 1 2 3 4
Behavioural modification	  (bladder	  training,	  diet)
Stress	  management
Manual	  physical	  therapy
Multimodal	  pain	  management
Oral	  amitriptyline
Oral	  cimetidine
Oral	  hydroxyzine
Pentosan polysulfate	  (PPS)
Intra-­‐vesical	  DMSO
Intra-­‐vesical	  heparin
Intra-­‐vesical	  lidocaine
Cystoscopy	  with	  hydrodistension
Fulguration	  and/or	  injection	  of	  tri-­‐amcinolone
Neurostimulation
Oral	  cyclosporine	  A
Intradetrusor botulinum toxin	  A
Major	  surgery
Long-­‐term	  oral	  antibiotics
Intravesical	  instillation	  of	  BCG
No	  high-­‐pressure,	  long-­‐duration	  hydrodistension
No	  oral	  long-­‐term	  glucocorticoid
Level	  of	  evidence	  score	  
Tr
ea
tm
en
t	  O
pt
io
ns
0 1 2 3 4
GRADE
3 2 1 0
Overestimation	  of	  level	  of	  
evidence	  by	  score	  versus	  
GRADE
 
Figure 17 shows the overestimation in GRADE versus strength of evidence. Out of the 21 
treatment options, 19 were assigned GRADE scores. In all 19, the GRADE and strength of 
evidence scores could be compared. 18 treatment options were downgraded using GRADE 
with a mean over estimation score of 1.7 (1.1 v 2.8), with a 95% CI mean difference of 2.2 to 
1.3; p = <0.0001 using unpaired t test and the median difference was 1.5 (95% CI of 2.0 to 
1.0) using Wilcoxon’s signed rank test. There was downgrading of nine treatment options by 
one mark, for example this changed the evidence quality from low to very low, downgrading 
by two marks occurred for seven treatment options and by three marks for two treatment 
options. Intravesical lidocaine was the only treatment that had the same strength and GRADE 
scores. 
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Figure 17: Graphical representation of the strength of evidence score versus GRADE 
for the management of bladder pain syndrome  
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9.5 Conclusion  
Main findings 
The literature for treatment effectiveness of BPS is variable in its quality of evidence ratings 
depending on which guideline you consult. This can cause much confusion for clinicians who 
may not know the difference between the rating scales that have been used or how they were 
derived. In this chapter I have reviewed all the available evidence for BPS treatment options 
and evaluated the discrepancies between strength and level of evidence and GRADE ratings. 
The majority of treatment options were downgraded when compared to GRADE, giving them 
lower overall quality scores.  
 
 
159	  	  
	  	  
Strengths and weaknesses 
This was a thorough literature review of all the available data, which incorporated several 
international guidelines and clinical reviews. I believe the GRADE approach provides an 
opportunity to combine information across five domains in order to create the most 
comprehensive scoring system to assess evidence quality.  A notable limitation of GRADE 
scoring system is the computer software programme, which automatically assigns 
randomised studies a GRADE quality of evidence rating, which is not done for observational 
studies. The formation of GRADE tables is subjective with assignment of bias for study 
design, inconsistency, indirectness, imprecision and publication bias being assessor 
dependent (136). The use of GRADE tables allows assessment of several randomised studies 
across all five domains. However, the overall quality of the information obtained is 
dependent on the combined data from all studies, which means a very good quality study may 
be downgraded by combining its data with a poor quality study. This chapter shows that 
clinicians and readers of guidelines need to understand how data and study quality is derived 
and exercise caution when reading guideline recommendations.   
 
Recommendations 
I would propose that a single method of reporting quality ratings is used to allow for 
transparency of results. The GRADE reporting system would be an ideal option, as it does 
not limit its assessment of a study solely on the study design, as is common to most other 
quality evidence scores. Clinicians could be helped to understand guidelines if a single 
standardised reporting methodology was employed, which would enable them to 
communicate best treatment options to their patients. 
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This chapter is based on the following peer-reviewed paper (237): 
Discrepancies in the grading of evidence for bladder pain syndrome: A comparative 
review of quality assessment methods 
SA Tirlapur, KS Khan 
Int	  Urogynecol	  J.	  2014	  Aug;25(8):1005-­‐13
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CHAPTER 10: 
 DISCUSSION AND PERSPECTIVES 
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10.1 Summary of findings 
 
 
10.11 Prevalence of BPS in women with chronic pelvic pain 
Nine studies (1016 patients) were identified with varying quality of data. The mean 
prevalence of BPS was 61% and co-existing BPS and endometriosis was 48%. With almost 
2/3 of patients presenting with CPP suffering from BPS, basic urinary symptoms need to be 
assessed in these patients. Almost 50% of patients have co-existing pathology so multi-
disciplinary care should be considered.  
 
 
10.12 Assessing the information on the internet related to BPS 
Eighteen websites were identified; seven (39%) were specific to BPS. There was a wide 
variation in combined mean scores for the four quality parameters of accuracy, quality, 
credibility and readability. There was good inter-observer agreement with an ICC ranging 
from the highest score of 0.80 for DISCERN to the lowest of 0.53 for readability. Four 
websites were selected that fulfilled the criteria for good quality information related to BPS. 
This showed that good sources of information are available on the internet but caution is 
needed when recommending websites to patients.  
 
 
10.13 Assessing patients and clinicians experiences managing bladder pain syndrome and 
their prior beliefs on posterior tibial nerve stimulation 
The survey questionnaire was completed by 133 patients and 69 clinicians. The main patient-
reported symptom was pain when the bladder was full in 80% with the most bothersome 
symptom of pelvic pain in 22% of women. 93% of clinicians relied on making their diagnosis 
163	  	  
	  	  
by history and cystoscopy. 77% of patients reported using simple analgesia as a treatment, 
74% dietary modification and 62% low-dose long-term antibiotics. This variation highlights 
the need for national guidance in order to standardise care.  
 
 
10.14 Assessing the sensitivity of bladder pain syndrome and bladder wall tenderness for 
BPS in women with chronic pelvic pain 
46 eligible women were recruited, with a mean age of 30.8 years (n=21, SD 7.20) in the BPS 
group (cases) and 34.6 years (n=25, SD 9.51) in the control group. An expert panel was 
successfully used to obtain a consensus diagnosis, as no gold standard diagnostic tool exists. 
The most sensitive symptom was bladder filling pain (sensitivity = 0.57, 95% CI = 0.3-0.8, 
specificity = 0.84, 95% CI = 0.6-1.0). Other sensitive symptoms were urinary frequency, 
nocturia and pain on urination. The most specific test was bladder wall tenderness (sensitivity 
= 0.10, 95% CI = 0.1-0.3, specificity = 0.96, 95% CI = 0.8-1.0). A large multi-centre study is 
needed to validate these tests in order to aid clinicians diagnose this debilitating condition. 
 
 
10.15 The role of cystoscopy and laparoscopy in pelvic and bladder pain 
BPS may be a manifestation of CPP where cystoscopy can have a diagnostic and therapeutic 
role. CPP may be multi-causal with several identifiable risk factors. Invasive procedures such 
as a laparoscopy and cystoscopy may be useful diagnostic tools as well as having therapeutic 
effects, where the degree of sensitivity of each test varies with the target condition. 
Therapeutic ‘see and treat’ laparoscopies, rather than purely diagnostic procedures may help 
avoid the need for multiple operations and the risks associated with them.  
 
164	  	  
	  	  
 
10.16 Assessing the effectiveness of nerve stimulation in the treatment of pelvic and bladder 
pain 
Three eligible studies were identified with 169 patients; two for CPP and one for BPS. 
Symptomatic improvements were reported for pain, urinary and quality of life symptoms 
using posterior tibial nerve stimulation (PTNS). There was very limited available literature on 
neuromodulation, as most studies were observational, rather than randomised against a sham 
treatment, so they did not allow meaningful comparison. There was no available data for the 
effectiveness of sacral nerve stimulation (SNS). A large multi-centered clinical trial is 
recommended to investigate the effectiveness of nerve stimulation to treat BPS and CPP, 
along with cost-effectiveness analysis to assess the feasibility of wide-scale introduction of 
this treatment.   
 
 
10.17 Assessing outcome measures of treatments for BPS 
A total of 28 RCTS with 1732 patients were reported in eight systematic reviews. Five 
outcome measures were described, using 19 different measurement scales. These were 
urinary symptoms (100%), pain (64%), quality of life (39%), general wellbeing (36%) and 
bladder capacity (36%). The quality of all outcomes were measured with scores ranging from 
0-6 and a mean score of 1.63 (95% CI 0.29 – 2.96) for systematic reviews and 3.25 (95% CI 
2.80 – 3.70) for RCTs. These results highlight the need to generate a consensus to develop a 
core set of outcomes in BPS. 
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10.18 Assessing the evidence of GRADE ratings for BPS 
From all the international guidelines, 19 treatments were identified for BPS where GRADE 
ratings were assigned. Comparing GRADE and level of evidence ratings (1-4), the latter 
overestimated quality by 1.8 points (1.1 v 2.9; 95% CI of mean difference 1.2 to 2.3; p= 
<0.0001). Comparing GRADE and strength of evidence ratings (A-D), the latter 
overestimated quality by 1.7 points (1.1 v 2.8; 95% CI of mean difference 1.3 to 2.1; p= 
<0.0001). The GRADE quality scoring system is a refined method of assigning quality to 
evidence, which provides a more conservative measurement of quality of evidence that can 
give a realistic assessment of the value of recommendations for practice. 
 
 
10.2 Strengths and limitations  
In attempting to understand how BPS is managed, a series of systematic reviews was 
undertaken. All the included systematic reviews (chapters 2, 3, 7 and 8) had robust 
methodology with prospective protocols adhering to the PRISMA guidance (appendix 6). 
The limitation is the sparse literature available on treatment effectiveness for BPS with a 
sham or standard/no treatment comparator.  
 
The survey of clinicians and patients was an anonymous questionnaire (chapter 4). Although 
there was a low response rate of clinicians, it did sample urogynaecologists practicing in the 
UK who are on the British Society of Urogynaecology (BSUG) database in order to gain an 
idea of current opinions and practice. Patients were invited to participate but this may have 
only been the proactive ones and those who are computer literate. The survey gave insight 
into their experiences, without knowledge of who treated them. 
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In the feasibility study (chapter 5) there was prospective recruitment to minimise missing 
data and selective recall. Despite the weakness of a small sample size, a case-control 
feasibility study successfully proved that expert panel consensus diagnosis could be used to 
make a symptom-based diagnosis of BPS. It also showed that bladder filling pain was a 
useful symptom to aid diagnosing BPS.  
 
 
10.3 Implications on clinical practice  
• The realisation that the prevalence of BPS in women with CPP was high, along with 
my experiences of clinical practice and the results from the clinician survey on the 
management of BPS, as well as the lack of UK based guidelines for BPS inspired my 
work with members of BSUG, patient support groups and the RCOG to develop 
national RCOG green-top guidelines on the management of BPS (appendix 7). I hope 
these will aid general practitioners and clinicians to diagnose and initiate conservative 
treatments and avoid long delays trying to find a definitive diagnosis.  
 
• Given the prevalence of CPP and BPS, policy makers need to consider the disease 
burden when designing referral pathways and improving pelvic pain and gynaecology 
services.   
• The benefit of conservative treatments, patient awareness and self-management 
should be highlighted when counselling patients in order to empower them about the 
disease. 
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10.4 Implications for future research  
When planning research projects, clear definitions of BPS and methods of diagnosis need to 
be used. It is important to identify study outcomes and use validated assessment tools. Since 
so many questionnaires for pain and urinary symptoms are used and these are usually patient 
reported, standardisation and comparability between studies is difficult.  
 
My review of RCTs and systematic reviews identified key outcomes for studies in BPS. The 
development of a validated questionnaire to aid in the analysis of a symptom-based diagnosis 
would be beneficial in both the clinical and research settings.     
 
Given the disease burden of CPP and BPS with a significant number of patients suffering 
from refractory pain, neuromodulation, in the form of PTNS may be a possible treatment 
modality. As part of the clinician and patient survey, we asked specifically about PTNS. 
Clinicians expressed an interest in a clinical trial and affected patients expressed an interest in 
participating in such a study. An RCT to assess the effectiveness of PTNS in the treatment of 
CPP and BPS in a large multi-centre study will help reduce uncertainty about its 
effectiveness.   	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Appendix 1: Contribution to each chapter 
 
• Chapter 1 – I wrote this chapter in its entirety. 
• Chapter 2 – I conceived the idea for the study, performed searches, selected studies, 
designed the data extraction form, extracted and synthesised data, performed quality 
assessment of studies, created figures and drafted the manuscript.   
• Chapter 3 – I devised the protocol, performed searches, selected studies, designed the 
data extraction form, extracted and synthesised data, performed quality assessment of 
studies, created figures and drafted the manuscript.   
• Chapter 4 – I drafted, piloted and distributed surveys, analysed data and prepared the 
manuscript. 
• Chapter 5 – I refined the study design, drafted and revised the protocol, recruited 
patients, collected, collated and analysed data and prepared the manuscript. 
• Chapter 6 – I researched and prepared the manuscript and created the tables of 
information. 
• Chapter 7 - I conceived the idea for the study, performed searches, selected studies, 
designed the data extraction form, extracted and synthesised data, performed quality 
assessment of studies, created figures and drafted the manuscript.   
• Chapter 8 – I devised the review protocol, performed searches, data extraction, 
quality assessment, data analysis, created figures and tables and drafted the 
manuscript. 
• Chapter 9 – I reviewed the evidence, prepared figures and tables, researched and 
wrote the manuscript. 
• Chapter 10 – I wrote this chapter in its entirety. 
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Appendix 2: National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) 
diagnostic criteria for Interstitial Cystitis (4) 
Diagnostic criteria: 
• Glomerulations on cystoscopy or classic Hunner’s ulcer AND pain associated with bladder or urinary 
frequency 
• Examination for glomerulations should be undertaken after hydrodistension under anaesthesia to 80-
100cm water pressure for 1-2 minutes 
• Glomerulations must be diffuse, present in at least 3 quadrants of the bladder, and there must be at least 
10 glomerulations per quadrant and not along the path of the cystoscope as they may be an artifact 
 
Exclusion criteria: 
1. Bladder capacity ≥ 350cc on awake cystometry using either a gas or liquid filling medium 
2. Absence of an intense urge to void with the bladder filled to 100cc gas or 150cc water during 
cystometry, using a fill rate of 30 to 100cc per minute 
3. The demonstration of phasic involuntary bladder contractions on cystometry using the fill rate above 
4. Duration of symptoms < 9 months 
5. Absence of nocturia 
6. Symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics or antispasmodics 
7. A frequency of urination, while awake, of less than 8 times a day 
8. A diagnosis of bacterial cystitis or prostatitis within a 3 month period 
9. Bladder or urethral calculi 
10. Active genital herpes 
11. Uterine, cervical, vaginal or urethral cancer 
12. Urethral diverticulum 
13. Cyclophosphamide or any type of chemical cystitis 
14. Tuberculosis cystitis 
15. Radiation cystitis 
16. Benign or malignant bladder tumours 
17. Vaginitis 
18. Age less than 18 years 
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Appendix 3: O’Leary Sant (OLS) Symptom and Problem Index Questionnaire 
(26) 
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Appendix 4: Pelvic Pain and Urgency/Frequency (PUF) Questionnaire (28) 
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Appendix 5: The management summary for bps according to the American 
Urological Association guidelines (23) 
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Appendix 6: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) reporting checklist (238) 
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Appendix 7: Draft RCOG Green-top guideline on the management of bladder pain 
syndrome (included with permission from the RCOG).  
Green-­‐top	  Guideline	  No.	  XX 
First	  Draft	  –	  Summer	  2014	  
	  
The	  Management	  of	  Bladder	  Pain	  Syndrome	  (BPS)	  
	  
	   [Edition	  statement]	   	  
	   This	  is	  the	  first	  edition	  of	  this	  guideline.	   	  
1	   Purpose	  and	  scope	   	  
	   This	   guideline	   aims	   to	   provide	   information,	   based	   on	   clinical	   evidence,	   to	  
clinicians	   in	   primary	   and	   secondary	   care	   settings	   in	   order	   to	   recognise	   the	  
symptoms	  of	  bladder	  pain	  syndrome	  (BPS)	  and	  the	  possible	  treatments	  for	  this	  
condition,	  along	  with	  appreciating	  the	  current	  uncertainties	  that	  exist	  around	  
the	  condition.	  	  	  
	  
2.	  	  	   Introduction	  and	  background	  epidemiology	   	  
	   Bladder	   pain	   syndrome	   (BPS)	   has	   been	   defined	   in	   2008	   by	   the	   European	  
Society	  for	  the	  Study	  of	  Interstitial	  Cystitis/Painful	  Bladder	  Syndrome	  as	  ‘pelvic	  
pain,	  pressure	  or	  discomfort	  perceived	  to	  be	  related	  to	  the	  bladder,	  lasting	  at	  
least	  6	  months,	  and	  accompanied	  by	  at	   least	  one	  other	  urinary	  symptom,	  for	  
example	   persistent	   urge	   to	   void	   or	   frequency,	   in	   the	   absence	   of	   other	  
identifiable	  causes.’	  (1)	  
	  
The	   term	   BPS	   has	   been	   recommended	   rather	   than	   previous	   names	   for	   this	  
condition:	   interstitial	  cystitis	  (IC)	  was	  first	  described	  in	  1915	  and	  criteria	  were	  
defined	   in	   1987	   by	   the	   National	   Institutes	   of	   Health	   National	   Institute	   of	  
Diabetes	   and	   Digestive	   and	   Kidney	   Diseases	   (NIDDK),	   with	   the	   following	  
inclusion	   criteria:	   pain	   associated	   with	   bladder	   or	   urinary	   frequency	   and	  
glomerulations	   on	   cystoscopy	   or	   classic	   Hunner’s	   ulcer	   seen	   after	  
hydrodistension	   under	   anaesthesia	   to	   80-­‐100cm	   water	   pressure	   for	   1-­‐2	  
minutes,	   where	   the	   glomerulations	   must	   be	   diffuse,	   present	   in	   at	   least	   3	  
quadrants	   of	   the	   bladder,	   and	   there	  must	   be	   at	   least	   10	   glomerulations	   per	  
quadrant	  and	  not	  along	  the	  path	  of	  the	  cystoscope	  as	  there	  may	  be	  an	  artefact	  
(2).	   This	   strict	   criteria	  meant	  many	   patients	  were	   under-­‐diagnosed	   so	   a	   new	  
term,	   painful	   bladder	   syndrome	   was	   proposed	   in	   2002	   by	   the	   International	  
Continence	  Society	  as	  ‘suprapubic	  pain	  related	  to	  bladder	  filling,	  accompanied	  
by	  other	  symptoms	  such	  as	  increased	  daytime	  and	  night-­‐time	  frequency	  in	  the	  
absence	  of	  any	  identifiable	  pathology	  or	  infection	  with	  typical	  cystoscopic	  and	  
histological	  features’	  (2-­‐4).	  	  
	  
BPS	  is	  a	  chronic	  condition	  with	  unknown	  aetiology.	  As	  the	  definition	  of	  BPS	  has	  
constantly	   evolved,	   it	   has	   been	   seen	   as	   a	   diagnosis	   of	   exclusion	   with	   no	  
definitive	  diagnostic	  test,	  hence	  it	  is	  difficult	  to	  estimate	  prevalence,	  which	  can	  
be	   dependent	   on	   whether	   symptoms	   are	   clinician-­‐assigned	   or	   patient	  
reported.	  A	   large	  American	   study	   found	  prevalence	   rates	   of	   2.3%	   to	   6.5%	  of	  
women	  (5).	  BPS	  is	  between	  2-­‐5	  times	  more	  common	  in	  women	  than	  men	  (6-­‐8).	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There	  is	  very	  limited	  data	  on	  BPS	  in	  the	  United	  Kingdom	  but	  a	  recent	  survey	  of	  
urogynaecologists	   has	   showed	   variable	   practice	   regarding	   the	   diagnosis	   and	  
management	  of	  BPS	  (9).	  	  
3.	   Identification	  and	  assessment	  of	  evidence	   	  
	   [RCOG	  staff	  to	  complete]	   	  
4.	  	  	   What	  is	  the	  effect	  of	  BPS	  on	  quality	  of	  life?	   	  
	   Recommendation:	  
Patients	  with	  BPS	  can	  have	  low	  self-­‐esteem,	  sexual	  dysfunction	  and	  reduced	  
quality	  of	   life.	   It	   is	   important	   to	  enquire	  about	   the	  effects	  on	  quality	  of	   life	  
and	  refer	  as	  appropriate.	  
Grade:	  
C	  
	   Supporting	  Text:	  
Patients	   will	   often	   be	   highly	   anxious	   about	   their	   symptoms	   and	   possible	  
diagnosis	  with	  low	  self	  esteem	  and	  poor	  quality	  of	  life	  (QoL)	  (10).	  	  Women	  with	  
BPS	  can	  have	  high	  levels	  of	  sexual	  dysfunction	  (11).	  Spousal	  and	  family	  support	  
are	   important	   and	   referral	   to	   a	   clinical	   psychologist	   should	   be	   considered	   if	  
symptoms	  are	  persistent	  or	  for	  refractory	  BPS.	  	  	  	  	  	  	  
Evidence	  
Level:	  	  
2+	  
	  
	   Recommendation:	  
Patients	  with	  BPS	  may	  have	  other	  co-­‐existent	  conditions	   impacting	  on	  their	  
quality	  of	  life.	  
Grade:	  
C	  
	   Supporting	  Text:	  
	  One	   of	   the	   key	   symptoms	   of	   BPS	   is	   chronic	   pelvic	   pain,	   which	   may	   be	  
associated	   with	   other	   organic	   and	   non-­‐organic	   causes,	   for	   example	  
endometriosis,	  fibromyalgia,	  depression	  and	  irritable	  bowel	  syndrome	  (12,	  13).	  
This	   co-­‐existence	   can	   make	   diagnosis	   and	   management	   of	   BPS	   particularly	  
challenging.	  	  
Evidence	  
Level:	  	  
2+	  
	  
5.	   Diagnosis	  of	  BPS	   	  
5.1	   How	  is	  BPS	  diagnosed?	   	  
	   Recommendation:	  
Diagnose	  bladder	  pain	  syndrome	  on	  the	  basis	  of	  symptoms	  of	  pain,	  pressure	  
or	  discomfort	  perceived	  to	  be	  related	  to	  the	  bladder	  accompanied	  by	  at	  least	  
one	   other	   lower	   urinary	   tract	   symptom	   such	   as	   urgency,	   frequency	   or	  
nocturia,	  for	  at	  least	  6	  months	  in	  the	  absence	  of	  other	  identifiable	  causes.	  
Grade:	  
B	  
	   Supporting	  Text:	  
A	  systematic	   literature	  review	  found	  the	  most	  commonly	  reported	  symptoms	  
of	   BPS	   to	   be	   bladder/pelvic	   pain,	   urgency,	   frequency	   and	   nocturia	   (14).	   	   A	  
number	   of	   expert	   panels	   including	   ESSIC	   (European	   Society	   for	   the	   study	   of	  
IC/PBS),	   AUA	   (American	   Urological	   Association),	   EAU	   (European	   Urological	  
Association)	   and	   ICI	   (International	   Consultation	   on	   Incontinence)	   have	  
published	  symptom	  based	  diagnostic	  criteria	  for	  BPS.	  All	  include	  the	  symptoms	  
of	  pain	  related	  to	  the	  bladder,	  at	  least	  one	  other	  urinary	  symptom,	  absence	  of	  
identifiable	  causes	  and	  minimum	  duration	  of	  symptoms	  of	  6	  weeks	  (AUA)	  or	  6	  
months	  (15-­‐17).	  
Evidence	  
Level:	  	  
2++	  
	  
	   Recommendation:	  
Cystoscopy,	  bladder	  biopsies	  and	  hydrodistension	  are	  not	  recommended	  for	  
the	   diagnosis	   of	   BPS.	   Clinicians	   should	   consider	   cystoscopy	   to	  
diagnose/exclude	  other	  conditions,	  which	  may	  mimic	  BPS.	  
Grade:	  
C	  
	   Supporting	  Text:	  
Cystoscopy	   without	   hydrodistension	   is	   expected	   to	   be	   normal	   (except	   for	  
discomfort	  and	  reduced	  bladder	  capacity)	  in	  most	  patients	  with	  BPS.	  	  
	  
Characteristic	   cystoscopic	   findings	   have	   been	   ascribed	   to	   BPS,	   including	   post	  
Evidence	  
Level:	  	  
2+	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distension	  glomerulations	  (pinpoint	  petechial	  haemorrhages),	  reduced	  bladder	  
capacity	   and	   bleeding.	   Cystoscopy	   findings	   correlate	   poorly	   with	   symptoms.	  
150	  women	   in	   the	   Interstitial	   Cystitis	   Database	   Study	   underwent	   cystoscopy	  
and	  hydrodistension.	  There	  was	  no	  correlation	  between	  severity	  of	  symptoms	  
and	  the	  finding	  of	  glomerulations	  or	  bleeding	  following	  hydrodistension.	  Pain,	  
urgency	   and	   reduced	   bladder	   capacity	  were	   associated	  with	   the	   presence	   of	  
Hunner’s	   lesions	   in	   11.7%	   (18).	   Similar	   findings	   have	   been	   seen	   in	   other	  
studies,	  along	  with	  glomerulations	  in	  asymptomatic	  women	  (19,	  20).	  
	  
Pathological	   features	   have	   been	   described	   in	   patients	   with	   BPS	   including	  
inflammatory	  infiltrates,	  detrusor	  mastocytosis,	  granulation	  tissue	  and	  fibrosis	  
but	  these	  are	  non-­‐specific.	  The	  diagnosis	  of	  BPS	  cannot	  be	  made	  or	  excluded	  
on	   the	   basis	   of	   any	   specific	   finding	   on	   bladder	   biopsy	   and	   these	   are	   not	  
required	   for	   the	  diagnosis.	   In	  a	   study	  of	  108	  people	  with	  BPS,	  no	   correlation	  
was	   found	   between	   histological	   and	   cystoscopic	   findings	   (21).	   In	   an	   earlier	  
study	   of	   50	   patients,	   there	  was	   a	   correlation	  with	   reduced	   bladder	   capacity,	  
inflammation	  and	  mast	   cell	   count	  however,	  both	  cystoscopic	  and	  histological	  
findings	   showed	   large	   variation	   (22).	   Bladder	   biopsy	   may	   be	   indicated	   to	  
exclude	   other	   pathologies	   such	   as	   carcinoma	   in	   situ,	   if	   suspected	   by	   a	   focal	  
lesion	  or	  abnormal	  cytology.	  	  
	  
	   Recommendation:	  
Potassium	   sensitivity	   test,	   urodynamic	   assessment	   and	   urinary	   biomarkers	  
should	  not	  be	  used	  in	  the	  diagnosis	  of	  BPS.	  
Grade:	  
C	  
	   Supporting	  Text:	  
The	  potassium	  chloride	  bladder	  permeability	   test	   is	  not	   recommended	   in	   the	  
diagnosis	  of	  BPS	  as	  specificity	  and	  sensitivity	  are	  poor,	  adding	  no	   information	  
over	  standard	  diagnostic	  techniques	  (23).	  
	  
Pain	  on	  bladder	   filling,	  a	   reduced	   first	   sensation	  to	  void	  and	  reduced	  bladder	  
capacity	   are	   consistent	  with	   BPS,	   however,	   there	   are	   no	   urodynamic	   criteria	  
that	   are	   diagnostic	   for	   BPS.	   The	   presence	   of	   detrusor	   overactivity,	   which	   is	  
seen	   in	   approximately	   15%	   of	   patients	   with	   BPS,	   should	   not	   preclude	   a	  
diagnosis	  of	  BPS.	  Pressure	   flow	   studies	  may	  be	   considered	   in	  patients	  where	  
there	   are	   coexistent	   voiding	   symptoms	   but	   are	   not	   recommended	   in	   the	  
diagnosis	  of	  BPS	  (23).	  
	  
Evidence	  
Level:	  	  
2+	  
	  
5.2	   How	  can	  we	  classify	  the	  severity	  of	  BPS?	   	  
	   Recommendation:	  
Clinicians	   should	  use	  a	  validated	  symptom	  score	   to	  assess	  baseline	   severity	  
of	  BPS	  and	  assess	  response	  to	  treatment.	  
Grade:	  
B	  
	   Supporting	  Text:	  
Symptoms	   scores	   for	  BPS	   should	  be	  used	   to	   grade	   the	   severity	   of	   symptoms	  
and	   assess	   response	   to	   treatment.	   There	   are	   3	   published	   BPS	   symptom	  
questionnaires:	  the	  University	  of	  Wisconsin	  IC	  Scale	  (UW-­‐IC),	  the	  O’Leary-­‐Sant	  
IC	   Symptom	   Index	   and	   IC	   Problem	   Index	   (ICSI/PI),	   and	   the	   Pelvic	   Pain	   and	  
Urgency/Frequency	   (PUF)	   Scale	   (24-­‐26).	   All	   have	   been	   validated	   in	   patients	  
with	  BPS	   and	   the	  UW-­‐IC	   and	   ICSI/ICPI	   have	   shown	   responsiveness	   to	   change	  
over	   time	   (23).	   In	   a	   comparison	  of	   questionnaires	   used	   for	   the	   evaluation	  of	  
chronic	  pelvic	  pain,	  there	  was	  moderate	  to	  good	  correlation	  between	  the	  ICSI	  
and	  PUF	  symptoms	  scores	  for	  bladder	  complaints	  and	  the	  ICPI	  and	  PUF	  bother	  
Evidence	  
Level:	  	  
2++	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scores	  for	  quality	  of	  life.	  
	   Recommendation:	  
The	   use	   of	   visual	   analogue	   scales	   for	   pain	   should	   be	   considered	   to	   assess	  
severity	  of	  pain	  in	  BPS.	  
Grade:	  
D	  
	   Supporting	  Text:	  
A	  number	  of	  different	  rating	  scales	  have	  been	  devised	  to	  measure	  pain.	  They	  
rely	  on	  a	  subjective	  assessment	  of	  the	  pain	  and	  therefore	  make	  inter-­‐individual	  
comparisons	   difficult.	   A	   1	   to	   10	   Likert	   style	   visual	   analogue	   scale	   (VAS)	   is	   an	  
easily	   administered	   instrument	   to	   capture	   pain	   intensity	   and	   should	   be	  
considered	  to	  measure	  baseline	  pain	  and	  response	  to	  treatment.	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
The	  use	  of	  bladder	  diaries	  are	  recommended	  to	  assess	  severity	  of	  BPS.	  
Grade:	  
D	  
	   Supporting	  Text:	  
A	   bladder	   diary	   is	   recommended	   to	   document	   voiding	   frequency	   and	  
functional	   capacity.	   	   It	   aids	   assessment	   of	   severity	   of	   storage	   symptoms	   and	  
can	  be	  used	  to	  measure	  progress	  with	  treatment.	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
Consider	  cystoscopy	  and	  bladder	  biopsy	  to	  identify	  the	  presence	  of	  Hunner's	  
ulcer	  (and	  assess	  bladder	  capacity).	  
Grade:	  
C	  
	   Supporting	  Text:	  
Whilst	  cystoscopy	  is	  not	  recommended	  for	  the	  diagnosis	  of	  BPS	  it	  may	  be	  used	  
to	   identify	   and	   treat	   patients	   with	   more	   severe	   disease	   by	   the	   presence	   of	  
Hunner's	  lesions	  and	  reduced	  bladder	  capacity	  (18).	  	  	  
Evidence	  
Level:	  	  
2+	  
	  
5.3	   What	  are	  the	  differential	  diagnoses?	   	  
	   Recommendation:	  
Exclude	   or	   diagnose	   other	   disorders	   that	   could	   be	   the	   cause	   of	   the	  
symptoms.	  	  
Grade:	  
D	  
	   Supporting	  Text:	  
ESSIC	  has	  published	  a	  list	  of	  confusable	  diseases,	  by	  expert	  consensus	  (17)	  
These	  include:	  
•	   Malignancy	   e.g.	   bladder	   carcinoma	   /	   carcinoma	   in	   situ,	   cervical,	  
urterine	  or	  ovarian	  cancer	  
•	   Infection	  of	  urinary	  or	  genital	  tract	  
•	   Overactive	  bladder	  
•	   Radiation	   cystitis	   or	   drug	   mediated	   cystitis	   e.g.	   cyclophosphamide,	  
ketamine	  
•	   Bladder	  outlet	  obstruction	  or	  incomplete	  bladder	  emptying	  
•	   Calculus	  of	  bladder	  or	  lower	  ureter	  
•	   Urethral	  diverticulum	  
•	   Prolapse	  
•	   Endometriosis	  
•	   Pudendal	  nerve	  entrapment,	  pelvic	  floor	  muscle	  related	  pain	  
	  
Evidence	  
Level:	  	  
4	  
	  
6.	   Initial	  assessment	   	  
6.1	   What	  initial	  clinical	  assessment	  should	  be	  performed?	   	  
	   Recommendation:	  
BPS	  is	  a	  chronic	  pain	  syndrome	  and	  the	  principles	  of	  management	  of	  chronic	  
pelvic	  pain	  apply	  to	  the	  initial	  assessment	  of	  this	  condition	  too.	  	  
	  
Adequate	   time	   should	   be	   allocated	   to	   allow	  women	   to	   feel	   they	   are	   being	  
listened	   to	   and	   believed.	   Some	   women	   will	   have	   preconceived	   theories	  
Grade:	  
B	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regarding	  the	  origins	  of	  the	  pain	  and	  the	   initial	  consultation	  should	  address	  
these.	  	  	  
	   Supporting	  Text:	  
The	   initial	   consultation	   is	   aimed	  at	  generating	   trust	  between	   the	  patient	  and	  
the	  caregiver.	  In	  chronic	  pain	  syndromes	  it	  is	  well	  recognised	  that	  a	  favourable	  
patient	  rating	  of	  the	  initial	  consultation	  was	  associated	  with	  greater	  likelihood	  
of	  complete	  recovery	  at	  follow-­‐up	  (27).	  Patients	  should	  be	  encouraged	  to	  talk	  
about	   their	   symptoms	   and	   any	   theories	   they	   have	   about	   the	   origins	   of	   the	  
pain.	   This	   allows	   engagement	   in	   further	   investigations	   and	   management	   of	  
their	  condition	  (28,	  29).	  	  	  
Evidence	  
Level:	  	  
2+	  
	  
	   Recommendation:	  
The	   symptoms	   should	   be	   assessed	   systematically	   and	   where	   possible	   a	  
validated	  questionnaire	  should	  be	  used	  (see	  section	  5.2).	  
Grade:	  
B	  
	   Supporting	  Text:	  
Symptom	  assessment	  forms	  the	  basis	  of	  the	  initial	  assessment.	  The	  location	  of	  
the	  pain	  has	  been	  described	   in	   several	   studies	   and	   the	   commonest	   reported	  
sites	  are	   the	  bladder,	  urethra	  and	  vagina.	  The	  description	  of	   the	  pain	   ranged	  
from	  pressure,	  aching	  to	  a	  burning.	  A	  study	  of	  565	  patients	  with	  the	  condition	  
was	  used	  to	   identify	  factors,	  which	  can	  aggravate	  and	  alleviate	  the	  condition.	  
Voiding	  was	  found	  to	  relieve	  the	  pain	  in	  57-­‐73%.	  Pain	  was	  aggravated	  by	  stress	  
(61%),	   sexual	   intercourse	   (50%),	   constrictive	   clothing	   (49%),	   acidic	   beverages	  
(54%)	  coffee	  (51%)	  and	  spicy	  foods	  (46%).	  In	  the	  EPIC	  study	  (Events	  preceding	  
interstitial	   cystitis)	   of	   158	   women	   with	   BPS,	   found	   that	   pain	   worsened	   with	  
certain	   food	   or	   drink	   and/or	   worsened	   with	   bladder	   filling	   and/or	   improved	  
with	  urination	  in	  97%	  of	  patients	  (24,	  30,	  31).	  
Evidence	  
Level:	  	  
2++	  
	  
	   Recommendation:	  
A	   thorough	   medical	   history	   should	   be	   taken	   and	   physical	   examination	  
including	  pain	  mapping	  performed.	  	  	  	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
As	   the	  diagnosis	  of	  BPS	   is	   a	  diagnosis	  of	   exclusion	   it	   is	   important	   to	   rule	  out	  
other	  possible	  causes	  of	  bladder	  pain	  in	  that	  area.	  
	  
The	   history	   should	   include	   details	   of	   previous	   pelvic	   surgery,	   UTIs,	   STDs,	  
bladder	   disease	   and	   autoimmune	   disease.	   The	   location	   of	   the	   pain	   and	  
relationship	   to	   bladder	   filling	   and	   emptying	   should	   be	   established.	   The	  
characteristics	  of	  the	  pain	  including	  trigger	  factors	  and	  onset,	  correlation	  with	  
other	   events	   and	   description	   of	   the	   pain	   should	   be	   recorded.	   A	   history	   of	  
physical	   and	   sexual	   abuse	   should	   be	   elicited,	   as	   it	   is	   a	   recognised	   cause	   of	  
pelvic	   pain	   (32).	   Enquire	   about	   prior	   or	   current	   use	   of	   oral	   contraception,	  
which	   a	   recent	   systematic	   review	   has	   found	   to	   be	   associated	   with	   BPS	  
symptoms	  (33).	  
	  
The	  physical	  examination	  should	  be	  aimed	  at	  ruling	  out	  bladder	  distension	  due	  
to	   retention,	   hernias	   and	   trigger	   points	   abdominally.	   A	   genital	   examination	  
should	   be	   performed	   to	   rule	   out	   atrophic	   changes,	   prolapse,	   vaginitis,	  
vulvodynia	   and	   trigger	   point	   tenderness	   over	   the	   urethra,	   vestibular	   glands,	  
vulvar	   skin	   or	   bladder.	   Features	   of	   dermatosis	   including	   vulvar	   or	   vestibular	  
disease	   should	   be	   looked	   for.	   An	   evaluation	   of	   the	   introitus	   and	   tenderness	  
during	  insertion	  or	  opening	  of	  the	  speculum	  should	  be	  made.	  Superficial/deep	  
vaginal	  tenderness	  and	  tenderness	  of	  the	   levator	  muscles	  should	  be	  assessed	  
during	  the	  course	  of	  the	  examination.	  Cervical	  pathology	  should	  be	  excluded.	  A	  
Evidence	  
Level:	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bimanual	   pelvic	   examination	   is	   helpful	   to	   rule	   out	   abdominal,	   cervical	   or	  
adnexal	  pathology.	  	  	  	  	  
6.2	   What	   baseline	   investigations	   should	   be	   performed	   before	   deciding	   on	  
treatment?	  
	  
	   Recommendation:	  
A	  bladder	  diary	  (frequency	  volume	  chart)	  should	  be	  completed.	  	  
Grade:	  
B	  
	   Supporting	  Text:	  
A	   3	   day	   diary	  with	   input	   and	  output	   is	   useful	   for	   initial	   assessment.	   Patients	  
with	  BPS	  classically	  void	  small	  volumes	  so	  this	  is	  useful	  to	  identify	  the	  severity	  
of	   the	   storage	   symptoms.	   The	   first	   morning	   void	   is	   a	   useful	   guide	   to	   the	  
functional	   capacity	   of	   the	   bladder.	   The	   bladder	   diary	   can	   also	   be	   used	   to	  
reinforce	   behavioural	   therapy	   and	   where	   necessary	   pharmacological	  
treatment.	  
Evidence	  
Level:	  	  
2+	  
	  
	   Recommendation:	  
A	   food	   diary	   may	   be	   used	   to	   identify	   if	   specific	   foods	   cause	   a	   flare	   up	   of	  
symptoms.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
Maintaining	  a	  food	  diary	  and	  its	  association	  with	  pain	  can	  be	  useful	  to	  identify	  
if	  certain	  types	  of	  food	  cause	  symptoms	  to	  flare	  up.	  	  	  	  	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
Urine	   should	   be	   tested	   to	   rule	   out	   a	   UTI	   as	   this	   is	   a	   prerequisite	   for	   a	  
diagnosis	  of	  BPS.	  
	  
Investigations	  for	  ureaplasma	  and	  chlamydia	  should	  be	  considered	  
	  
Grade:	  
C	  
	   Supporting	  Text:	  
A	   dipstick	   should	   be	   performed	   and	   where	   there	   is	   a	   suggestion	   of	   a	   UTI	   a	  
culture	  and	  sensitivity	  should	  be	  obtained	  with	  consideration	  given	  to	  testing	  
for	  acid-­‐fast	  bacilli	  where	  there	  is	  sterile	  pyuria.	  Ureaplasma	  is	  not	  isolated	  in	  
routine	  culture	  tests,	  so	  needs	  to	  be	  specifically	  looked	  for.	  	  
	  
A	   study	   of	   92	   patients	   diagnosed	  with	   BPS	   demonstrated	   that	   the	   condition	  
itself	  was	  not	  associated	  with	  persistence	  of	  bacterial	  or	  viral	  DNA	  on	  bladder	  
biopsy	  and	  all	  biopsies	  were	  negative	  for	  adenovirus,	  cytomegalovirus,	  herpes	  
simplex	  virus	  types	  I	  and	  II,	  human	  papillomavirus	  (all	  subtypes)	  and	  Chlamydia	  
trachomatis	   in	   all	   samples	   (34).	   These	   findings	   exclude	   a	   chronic	   infective	  
etiology	  for	  the	  condition.	  A	  separate	  study	  looking	  at	  clinical	  characteristics	  of	  
87	  women	  with	  the	  condition,	  found	  that	  12%	  had	  a	  past	  history	  of	  chlamydia,	  
which	  is	  higher	  than	  the	  national	  average.	  It	  is	  therefore	  important	  to	  rule	  this	  
out	  with	  appropriate	  cultures	  (35).	  	  	  
Evidence	  
Level:	  	  
2–	  
	  
	   Recommendation:	  
In	  high-­‐risk	  groups,	  urine	  cytology	  should	  be	  tested.	  
Grade:	  
C	  
	   Supporting	  Text:	  
In	  the	  presence	  of	  persistent	  microscopic	  haematuria	  urine	  cytology	  is	  usually	  
indicated.	   In	   a	   study	   of	   148	   patients	   with	   BPS,	   at	   least	   one	   episode	   of	  
haematuria	  was	  reported	  in	  41%	  of	  BPS	  over	  the	  preceding	  18	  months	  (36).	  In	  
this	   group,	   of	   those	  who	   agreed	   to	   a	   full	   evaluation,	   no	   cases	   of	  malignancy	  
were	   identified.	   No	   statistically	   significant	   differences	   were	   found	   in	   age,	  
bladder	   capacity,	   and	   the	   presence	   of	   Hunner's	   ulcers	   or	   glomerulations	  
between	  patients	  with	  hematuria	  and	  those	  without.	  Cytology	  is	  also	  indicated	  
Evidence	  
Level:	  	  
2+	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when	  there	  are	  other	  risk	  factors	  for	  urothelial	  carcinoma,	  for	  example	  those	  
who	   smoke,	   have	   a	   family	   history	   or	   have	   received	   radiotherapy	   or	  
chemotherapy.	  
	   Recommendation:	  
Laboratory	  investigation	  for	  urinary	  markers	  of	  inflammation	  is	  of	  no	  proven	  
value.	  
Grade:	  
C	  
	   Supporting	  Text:	  
Urine	   IL-­‐6	   levels	   (37),	   anti-­‐proliferative	   factor	   (APF)	   (38),	   inter-­‐α-­‐trypsin	  
inhibitory	  heavy	  chain	  H4	  (39)	  were	  found	  to	  be	  elevated	  in	  some	  women	  with	  
interstitial	   cystitis/BPS	   and	   uromodulin	   and	   kininogen	   were	   found	   to	   be	  
reduced.	   These	   were	   tested	   in	   relatively	   small	   cohorts	   of	   populations	   and	  
corresponded	  to	  different	  stages	  of	  disease	  progression.	  There	   is	  however	  no	  
evidence	   that	   laboratory	   testing	   of	   these	   urinary	   markers	   is	   of	   any	   proven	  
value	  in	  the	  initial	  assessment	  or	  diagnosis	  of	  BPS.	  
Evidence	  
Level:	  	  
2+	  
	  
7.	   What	  is	  the	  initial	  management?	   	  
7.1	   Conservative	  treatments	  (efficacy	  and	  safety)	   	  
	   Recommendation:	  
Dietary	  modification	  can	  be	  beneficial	  and	  avoidance	  of	  caffeine,	  alcohol	  and	  
acidic	  foods	  should	  be	  suggested	  to	  patients.	  	  
Grade:	  
D	  
	   Supporting	  Text:	  
A	  survey	  of	  1,982	  participants	   revealed	  87.6%	  of	  patients	  had	  a	  symptomatic	  
improvement	   with	   an	   elimination	   diet	   and	   86.1%	   by	   complete	   avoidance	   of	  
these	  items,	  although	  treatment	  duration	  was	  not	  indicated	  (40).	  Certain	  foods	  
that	   worsen	   pain	   are	   alcohol,	   citrus	   fruits,	   coffee,	   carbonated	   drinks,	   tea,	  
chocolate,	  and	  tomatoes	  (30).	  
Evidence	  
Level:	  	  
3	  
	  
	   Recommendation:	  
Regular	  exercise	  can	  be	  beneficial.	  
Grade:	  
D	  
	   Supporting	  Text:	  
65.2%	  of	  patients	  gained	  symptomatic	  improvement	  with	  regular	  exercise	  (40).	  	  
Evidence	  
Level:	  	  
3	  
	  
	   Recommendation:	  
Stress	  management	  should	  be	  recommended.	  	  
Grade:	  
D	  
	   Supporting	  Text:	  
76.4%	   of	   patients	   reported	   symptomatic	   improvement,	   through	   a	   patient	  
survey,	  using	  relaxation	  techniques,	  66.8%	  using	  meditation,	  64.5%	  listening	  to	  
music	  and	  80.5%	  with	  stress	  reduction	  (40).	  	  
Evidence	  
Level:	  	  
3	  
	  
	   Recommendation:	  
Physical	  therapy	  and	  massage	  can	  help	  relieve	  symptoms.	  
Grade:	  
C	  
	   Supporting	  Text:	  
An	   electronic	   questionnaire	   revealed	   that	   74.2%	   of	   patients	   experienced	  
symptomatic	  improvement	  with	  massage	  therapy,	  61.5%	  with	  physical	  therapy	  
and	   66.1%	   through	   physical	   therapy	   with	   internal	   treatment	   (40).	   A	  
randomised	   study	  of	  10	   scheduled	   treatments	  of	  myofascial	  physical	   therapy	  
versus	  global	  therapeutic	  massage	  on	  81	  women	  showed	  a	  reduction	   in	  pain,	  
frequency	   and	   urgency	   in	   both	   groups	   with	   no	   significant	   difference	   in	  
therapies	  (41).	  
Evidence	  
Level:	  	  
2–	  
	  
	   Recommendation:	  
Analgesia	   is	   recommended	   for	   the	   key	   symptom	   of	   pelvic	   or	   bladder	   pain,	  
suffered	  by	  most	  patients.	  
	  
	  
Grade:	  
GPP	  
	   Supporting	  Text:	   Evidence	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Between	  30-­‐61%	  of	  patients	  presenting	  with	   chronic	  pelvic	  pain	  have	  BPS	   so	  
although	   there	   is	  no	  data	  available	  about	   the	  efficiency	  of	  different	   forms	  of	  
analgesia	   in	   the	   treatment	   of	   BPS,	   analgesia	   is	   useful	   at	   treating	   the	   key	  
symptom	  of	  pain	  in	  this	  condition	  (12,	  42).	  
Level:	  	  
4	  
	  
	   Recommendation:	  
There	  is	  limited	  data	  on	  the	  benefit	  of	  acupuncture.	  	  
Grade:	  
C	  
	   Supporting	  Text:	  
A	  systematic	  review	  of	  3	  small	  observational	  studies	  with	  a	  total	  of	  22	  patients	  
showed	   that	   acupuncture	   provided	   moderate	   symptomatic	   improvement,	  
however,	   a	   large	   randomised	   trial	   is	   needed	   to	   properly	   evaluate	   treatment	  
effectiveness	  (43).	  
Evidence	  
Level:	  	  
2–	  
	  
7.2	   Pharmacological	  treatments	  (efficacy	  and	  safety)	   	  
	   Recommendation:	  
Oral	   Amitriptyline	   should	   be	   considered	   when	   first-­‐line	   conservative	  
treatments	  have	  failed.	  
Grade:	  
A	  
	   Supporting	  Text:	  
A	  meta-­‐analysis	  of	  2	  RCTs	  showed	  improvements	  in	  urinary	  urgency,	  frequency	  
and	   pain	   scores	   (44).	   A	   total	   of	   281	   patients	   were	   treated	   with	   increasing	  
titrated	  doses	  of	  amitriptyline	  between	  10-­‐100mg	  over	  a	  4-­‐month	  period	  (45,	  
46).	  Compliance	  is	  often	  affected	  by	  the	  side	  effects,	  which	  include	  dry	  mouth,	  
constipation,	  sedation,	  weight	  gain	  and	  blurred	  vision.	  
Evidence	  
Level:	  	  
1+	  
	  
	   Recommendation:	  
Oral	  cimetidine	  should	  be	  considered	  when	  first-­‐line	  conservative	  treatments	  
have	  failed.	  
Grade:	  
A	  
	   Supporting	  Text:	  
A	  meta-­‐analysis	  of	  1	  RCT	  compared	  36	  patients	  treated	  with	  a	  3-­‐month	  course	  
of	   400mg	   of	   cimetidine	   orally	   versus	   placebo	   twice	   daily	   (44).	   All	   treated	  
patients	   had	   symptomatic	   improvements,	   especially	   in	   pain	   and	   nocturia,	  
however,	   no	   histological	   changes	   in	   post-­‐treatment	   cystoscopy	   or	   bladder	  
biopsies	  were	  noted	  (47).	  	  	  
Evidence	  
Level:	  	  
1–	  
	  
	   Recommendation:	  
Oral	   hydroxyzine	  does	  not	   appear	   to	  be	  an	  effective	   second-­‐line	   treatment	  
for	  BPS.	  
Grade:	  
A	  
	   Supporting	  Text:	  
A	  meta-­‐analysis	  of	  1	  RCT	  of	  31	  patients	  treated	  with	  oral	  hydroxyzine	  10-­‐50mg	  
daily	  in	  titrated	  doses	  for	  3	  weeks,	  then	  treated	  on	  the	  highest	  effective	  dose	  
for	  21	  weeks	  was	  compared	  to	  a	  placebo	  group	  (44).	  There	  was	  no	  significant	  
response	   rate	   in	   the	   treatment	   group	   (31%)	   versus	   the	   control	   group	   (20%)	  
(48).	  
Evidence	  
Level:	  	  
1+	  
	  
	   Recommendation:	  
Oral	   Pentosan	   Polysulfate	   Sodium	   (PPS)	   (Trade	   name	   Elmiron®)	   may	   be	  
considered	  when	  first-­‐line	  conservative	  treatments	  have	  failed.	  
Grade:	  
A	  
	   Supporting	  Text:	  
Pentosan	   polysulfate	   sodium	   (PPS)	   is	   thought	   to	   repair	   the	   damaged	  
glycosaminoglycan	  layer,	  which	  acts	  as	  a	  protective	  mechanism	  for	  the	  bladder	  
mucosa	  (49).	  A	  meta-­‐analysis	  of	  3	  RCTs	  with	  a	  total	  of	  379	  patients	  compared	  
100mg	  oral	  PPS	  three	  times	  daily	  to	  placebo	  (44).	  All	  3	  studies	  showed	  variable	  
effectiveness	  with	   a	  mean	   symptom	   improvement	   of	   31%	   versus	   15%	   in	   the	  
placebo	   group	   (48,	   50,	   51).	   Recognised	   side	   effects	   include	   gastrointestinal	  
upset,	  headaches	  and	  mood	  swings.	  	  This	  treatment	  may	  not	  be	  offered	  in	  all	  
hospitals	  in	  the	  UK.	  	  
Evidence	  
Level:	  	  
1+	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   Recommendation:	  
Long-­‐term	   antibiotics,	   intravesical	   Resiniferatoxin,	   intravesical	   Bacillus	  
Calmette-­‐Guerin	   (BCG),	   high-­‐pressure	   long-­‐duration	   hydrodistension	   and	  
long-­‐term	   oral	   glucocorticoids	   are	   treatments	   that	   should	   not	   be	  
recommended	  for	  BPS.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
Long-­‐term	  antibiotics	  should	  not	  be	  used	  as	  a	  treatment	  option.	  1	  RCT	  reports	  
on	   50	   patients	   randomised	   to	   receive	   an	   18-­‐week	   course	   of	   antibiotics	  
(rifampicin	   plus	   a	   sequence	   of	   doxycycline,	   erythromycin,	   metronidazole,	  
clindamycin,	  amoxicillin	  and	  ciprofloxacin	  for	  3	  weeks	  each)	  or	  placebo,	  where	  
there	  was	  48%	  symptomatic	  improvement	  in	  the	  treatment	  group	  and	  24%	  in	  
the	   placebo	   group	   but	   in	   the	   treatment	   group	   80%	   reported	   adverse	   effects	  
(52).	  
	  
Intravesical	  Resiniferatoxin	  was	  evaluated	  in	  a	  systematic	  review	  of	  8	  RCTS	  but	  
failed	   to	   show	   symptomatic	   improvement	   and	   caused	   pain,	   which	   reduced	  
treatment	  compliance	  (53).	  
	  
Intravesical	  Bacillus	  Calmette-­‐Guerin	  (BCG)	  has	  been	  studied	  in	  2	  RCTS	  on	  282	  
patients	   compared	   to	   a	   placebo	   (54,	   55).	  While	   it	   has	   variable	   effectiveness	  
there	   are	   a	   large	   number	   of	   adverse	   effects	   including	   arthralgia,	   headaches	  
and	  infection.	  	  
	  
High-­‐pressure	  long	  duration	  hydrodistension	  with	  pressures	  over	  80-­‐100cm	  of	  
water	  over	  more	  than	  10	  minutes	  may	  cause	  sepsis	  or	  bladder	  rupture.	  Three	  
observational	  studies	  showed	  a	  wide	  range	  of	  efficacy	  rates	  between	  22–67%	  
with	  at	   least	  one	  case	  of	  bladder	   rupture	   in	  each	   study	   (56,	  57).	   The	   risks	  of	  
this	  treatment	  far	  outweigh	  the	  benefits.	  
	  
Long-­‐term	   oral	   glucorticoid	   administration	   is	   not	   recommended	   due	   to	   its	  
long-­‐term	  side	  effect	  profile.	  	  
	  
Evidence	  
Level:	  	  
2+	  
	  
8.	   Further	  management	   	  
8.1	   Who	  should	  manage	  bladder	  pain	  syndrome?	   	  
	   Recommendation:	  
A	  history,	  urinalysis	  and	  possible	  physical	  examination	  should	  be	  carried	  out	  
in	  primary	  care.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
Patients	   should	   be	   commenced	   on	   first-­‐line	   conservative	   treatments	   and	   if	  
these	  fail	  to	  resolve	  or	  improve	  symptoms,	  a	  referral	  to	  secondary	  care	  should	  
be	  considered.	  If	  the	  patient’s	  symptoms	  are	  prevalently	  urinary,	  referral	  to	  a	  
urogynaecologist	  would	  be	  preferable.	  	  	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
Treatments	  for	  Hunner's	  lesions
	  
	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
Hunner’s	   lesions,	   or	   ulcers,	   do	   not	   respond	   to	   oral	   treatments	   and	   need	  
surgical	   management.	   They	   are	   usually	   diagnosed	   by	   cystoscopy	   with	   the	  
appearance	  of	  a	  well-­‐demarcated	  reddish	  mucosal	  lesion	  lacking	  in	  the	  normal	  
capillary	   structure,	   which	   usually	   bleeds	   (49).	   Two	   observational	   studies	  
reported	   success	   when	   using	   Nd:YAG	   laser	   under	   cystoscopic	   control	   in	  
patients	   with	   BPS	   with	   Hunner’s	   ulcers.	   Fifty-­‐one	   patients	   were	   treated,	  
Evidence	  
Level:	  	  
2–	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resulting	  in	  88	  %	  symptomatic	  relief	  within	  2–3	  days	  of	  treatment;	  however,	  45	  
%	  needed	  additional	  treatment	  within	  23	  months	  (58,	  59).	  
	   Recommendation:	  
Referral	  to	  a	  physiotherapist	  should	  be	  considered	  as	  BPS	  symptoms	  may	  be	  
improved	  with	  physical	  therapy.	  	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
An	   RCT	   comparing	   global	   massage	   and	   myofascial	   physical	   therapy	   showed	  
that	   both	   forms	   of	   treatment	   were	   beneficial	   at	   improving	   pain,	   urinary	  
frequency	  and	  urgency	  (41).	  
Evidence	  
Level:	  	  
2+	  
	  
	   Recommendation:	  
Oral	   cyclosporin	   A	  may	   be	   considered	   after	   conservative,	   oral,	   intravesical	  
and	  neuromodulation	  treatments	  have	  failed.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
One	  observational	  study	  of	  23	  patients	  treated	  with	  low	  dose	  oral	  cyclosporine	  
showed	   improvements	   in	   bladder	   capacity,	   voiding	   volumes,	   pain	   and	  
decreased	   urinary	   frequency,	   however,	   symptoms	   recurred	   with	   treatment	  
cessation	   (60).	   Side	   effects	   include	   hypertension,	   gingival	   hyperplasia,	   and	  
facial	  hair	  growth.	  
Evidence	  
Level:	  	  
2–	  
	  
8.2	   Who	  should	  be	  referred	  to	  secondary	  care?	   	  
	   Recommendation:	  
Patients	  who	  fail	  to	  respond	  to	  conservative	  treatment	  should	  be	  referred	  to	  
secondary	  care.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
The	   pain	   and	   urinary	   symptoms	   of	   BPS	   can	   be	   debilitating	   and	   primary	   care	  
physicians	   or	   general	   practitioners	   should	   not	   wait	   for	   definite	   diagnosis	   or	  
treatments	  to	  be	  commenced	  in	  secondary	  care.	  However,	  after	  commencing	  
conservative	   treatments	   if	   symptoms	   are	   unchanged	   or	   having	   a	   negative	  
impact	   on	   the	   patient’s	   quality	   of	   life,	   they	   should	   be	   referred	   to	   secondary	  
care.	  
Evidence	  
Level:	  	  
4	  
	  
8.3	   Surgical	  treatments	  (efficacy	  and	  safety)	   	  
	   Recommendation:	  
Intravesical	  Dimethyl	  sulfoxide	  (DMSO)	  should	  be	  considered	  if	  conservative	  
and	  oral	  treatments	  have	  failed.	  
Grade:	  
B	  
	   Supporting	  Text:	  
A	   systematic	   review	  of	   1	   randomised	   cross-­‐over	   study	   evaluated	   33	   patients	  
given	  placebo	  (saline)	  or	  50%	  DMSO	  for	  2	  sessions	  each	  week	  for	  2	  weeks	  (61).	  
53%	  of	  the	  treatment	  group	  had	  marked	  symptomatic	  improvement	  compared	  
to	  18%	  of	   the	  placebo	  group	  (62).	  Side	  effects	   include	  a	  garlic-­‐like	  odour	  and	  
bladder	  spasm.	  
Evidence	  
Level:	  	  
2++	  
	  
	   Recommendation:	  
Intravesical	   heparin	  may	  be	   considered	   if	   conservative	   and	  oral	   treatments	  
have	  failed.	  
Grade:	  
D	  
	   Supporting	  Text:	  
One	   observational	   study	   evaluated	   48	   patients	   treated	   with	   10,000	   Units	   of	  
heparin	   in	  10	  ml	   sterile	  water	   instilled	   three	   times	  a	  week	   for	  3	  months	  and	  
reported	  that	  56%	  of	  patients	  achieved	  clinical	  remission	  over	  3	  months	  and	  50	  
%	  of	  patients	  had	  symptomatic	  control	  after	  1	  year	  (63).	  
Evidence	  
Level:	  	  
2–	  
	  
	   Recommendation:	  
Intravesical	  lidocaine	  may	  be	  considered	  if	  conservative	  and	  oral	  treatments	  
have	  failed.	  
Grade:	  
C	  
	   Supporting	  Text:	   Evidence	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Lidocaine	  is	  a	  local	  anaesthetic	  that	  acts	  by	  blocking	  sensory	  nerve	  fibres	  in	  the	  
bladder.	  1	  RCT	  reported	  on	  102	  patients	  treated	  with	  a	  5-­‐day	  course	  of	  200	  mg	  
intravesically	   administered	   lidocaine	   with	   alkalinised	   instillation	   of	   8.4%	  
sodium	   bicarbonate	   to	   a	   final	   volume	   of	   10ml	   versus	   placebo	   (64).	   30%	   of	  
treated	  patients	  compared	  to	  9.6%	  of	  the	  control	  group	  reported	  symptomatic	  
improvement	  over	  a	  29-­‐day	  follow	  up	  period	  (65).	  	  
Level:	  	  
2+	  
	  
	   Recommendation:	  
Botulinum	   toxin	   A	   may	   be	   considered	   when	   conservative	   and	   oral	  
treatments	  have	  failed.	  	  
Grade:	  
B	  
	   Supporting	  Text:	  
A	  systematic	  review	  evaluating	  botulinum	  toxin	  A	  in	  BPS	  patients	  found	  three	  
RCTs	  and	  seven	  prospective	  cohort	  studies	  with	  a	   total	  of	  260	  patients.	  Eight	  
studies	  reported	  symptomatic	   improvement,	  although	  7%	  of	  patients	  needed	  
post-­‐treatment	  self-­‐catheterisation	  (66).	  
Evidence	  
Level:	  	  
2++	  
	  
	   Recommendation:	  
Intravesical	  chondroitin	  sulphate	  may	  be	  considered	  if	  conservative	  and	  oral	  
treatments	  have	  failed.	  	  
Grade:	  
A	  
	   Supporting	  Text:	  
An	   individual	   participant	  meta-­‐analysis	   of	   213	  patients	   showed	   some	  benefit	  
using	   2%	   intravesical	   chondroitin	   sulphate	   (67).	   Small	   studies	   have	   shown	  
symptomatic	  improvement	  using	  a	  combination	  of	  intravesical	  hyaluronic	  acid	  
and	  chondroitin	  sulphate	  (68-­‐70).	  
Evidence	  
Level:	  	  
1–	  
	  
	   Recommendation:	  
Neuromodulation	  (nerve	  stimulation),	  in	  the	  form	  of	  posterior	  tibial	  or	  sacral	  
neuromodultaion	   may	   be	   considered	   after	   conservative,	   oral	   and/or	  
intravesical	  treatments	  have	  failed.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
Posterior	   tibial	   nerve	   stimulation	   (PTNS)	   involves	   insertion	  of	   a	   fine	  needle	  5	  
cm	  cephalad	  from	  the	  medial	  malleolus	  and	  posterior	  to	  the	  margin	  of	  the	  tibia	  
at	   the	   site	   of	   the	   posterior	   tibial	   nerve.	   The	   treatment	   regimen	   is	   usually	  
weekly	   for	  10–12	  weeks	   (71).	   Sacral	   nerve	   stimulation	   involves	   an	   initial	   test	  
phase	  with	   insertion	  of	  a	   test	   lead	   tunneled	  under	   the	   skin	   transmitted	  onto	  
the	  nerve	  roots	  exiting	  the	  S3	  foramen,	  so	  stimulating	  the	  pelvic	  and	  pudendal	  
nerves,	   and	   connected	   to	   a	   stimulator	   which	   is	   exchanged	   for	   a	   permanent	  
implant	   if	   successful	   (72).	   There	   are	   no	   RCTs	   evaluating	   either	   form	   of	  
neuromodulation.	   Effectiveness	   data	   comes	   from	   observational	   studies.	   One	  
study	  reported	  efficacy	  of	  posterior	  tibial	  nerve	  stimulation	  in	  18	  patients,	  and	  
six	   studies	   reported	   on	   sacral	   nerve	   stimulation	   in	   150	   patients,	   all	   studies	  
showing	  improvements	  in	  symptoms	  and	  quality	  of	  life	  (73-­‐78).	  Whereas	  both	  
forms	  of	  neuromodulation	  are	  effective,	   they	  are	   invasive	  procedures,	  which	  
may	  deter	  patients.	  
Evidence	  
Level:	  	  
2–	  
	  
	   Recommendation:	  
Cystoscopy+/-­‐	   hydrodistension	  may	   be	   considered	   if	   conservative	   and	   oral	  
treatments	  have	  failed	  or	  if	  there	  is	  suspicion	  of	  Hunner’s	  ulcers.	  
Grade:	  
D	  
	   Supporting	  Text:	  
Cystoscopy	  is	  recommended	  as	  a	  treatment	  rather	  than	  solely	  as	  a	  diagnostic	  
tool.	   Three	  observational	   studies	  with	  a	   total	   of	   265	  patients	  have	  described	  
variable	   symptomatic	   improvement.	   However,	   within	   6	   months,	   symptoms	  
had	   recurred	   in	   the	   majority	   of	   patients	   (19,	   79,	   80).	   Rupture	   is	   a	   possible	  
complication	   of	   prolonged	   distension	   of	   a	   diseased	   bladder;	   hence,	   low-­‐
pressure	  distension	  is	  advised	  (81).	  
Evidence	  
Level:	  	  
2–	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   Recommendation:	  
Major	  surgery	  may	  be	  considered	  as	  last-­‐line	  treatment	  in	  refractory	  BPS.	  
Grade:	  
D	  
	   Supporting	  Text:	  
Total	   cystectomy	   and	   urinary	   diversion	   will	   lead	   to	   the	   need	   for	   self-­‐
catheterisation,	   and	   patients	   must	   be	   aware	   of	   persistent	   pelvic	   and	   pouch	  
pain	  post	  surgery	  (49).	  A	  retrospective	  observational	  study	  of	  47	  patients	  who	  
had	   reconstructive	   surgery,	   including	   cystectomy,	   ileocystoplasty	   and	   urinary	  
diversion,	   for	   BPS	   found	   that	   82%	   of	   patients	  with	   Hunner’s	   ulcerations	   had	  
symptomatic	   relief	   after	   surgery	   compared	  with	   23%	  with	   non-­‐ulcer	   disease	  
after	  an	  average	  89-­‐month	  follow-­‐up	  period	  (82,	  83).	  
Evidence	  
Level:	  	  
3	  
	  
8.4	   What	   is	   the	   role	   of	   the	   multidisciplinary	   team	   –	   physiotherapist,	   pain	   team,	  
clinical	  psychologist?	  
	  
	   Recommendation:	  
Consider	   referring	  patients	  with	   refractory	  BPS	   for	  psychological	   support	  or	  
counselling	  if	  it	  is	  impacting	  on	  their	  quality	  of	  life	  or	  the	  patient’s	  requests	  a	  
referral.	  	  	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
It	  is	  a	  well-­‐known	  fact	  that	  some	  patients	  benefit	  from	  speaking	  to	  a	  counsellor	  
or	   clinical	   psychologist	   and	   engaging	   in	   behavioural	   therapy	   to	   modify	   their	  
lifestyle	  and	  improve	  their	  quality	  of	  life.	  	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
Patients	  with	   refractory	  BPS	   should	  be	   referred	   to	   a	  multidisciplinary	   team	  
(MDT)	  in	  order	  to	  explore	  alternative	  treatment	  options.	  Those	  patients	  who	  
may	   benefit	   for	   neuromodulation	   should	   be	   referred	   to	   an	   MDT	   before	  
treatment	  is	  commenced.	  	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
Referrals	  to	  pain	  clinics	  or	  clinical	  psychologists	  may	  need	  to	  be	  considered	   if	  
conservative	  and	  oral	  treatments	  have	  failed.	  	  
Evidence	  
Level:	  	  
4	  
	  
8.5	   What	  is	  the	  role	  of	  support	  groups?	   	  
	   Recommendation:	  
Support	   groups	   can	   provide	   invaluable	   information,	   support	   and	   advocate	  
patient-­‐centred	  care.	  	  	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
These	  groups	  provide	  a	  platform	  to	  share	  experiences,	  exchange	  information,	  
raise	  awareness	  and	  promote	  patient	  self-­‐help	  management	  (84).	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
Patients	   should	   be	   given	   written	   information	   about	   patient	   organisations	  
that	  provide	  evidence-­‐based	  information.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
There	   are	   many	   patient	   organisations	   with	   variable	   quality	   information	   and	  
resources,	   which	   help	   patients	   find	   information	   that	   is	   relevant	   to	   them	  
personally	  using	  existing	  guidelines	  as	  well	  as	  patient	  experience	  as	  a	  basis	  (85,	  
86).	  
Evidence	  
Level:	  	  
4	  
	  
9.	   Long-­‐term	  management	  and	  prognosis	   	  
9.1	   Which	  patients	  need	  follow-­‐up?	   	  
	   Recommendation:	  
Patients	  whose	  symptoms	  are	  not	  adequately	  controlled	  need	  to	  be	  followed	  
up	  after	  each	  new	  treatment	  has	  been	  tried	  for	  6-­‐12	  weeks.	  
Grade:	  
D	  
	   Supporting	  Text:	   Evidence	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Long-­‐term	   follow	   up	   is	   needed	   in	   poorly	   controlled	   BPS.	   Clemens	   et	   al.	  
reported	   that	   the	  mean	   yearly	   costs	  were	   2.4-­‐fold	   greater	   for	   treating	   these	  
patients	   than	   for	   controls	   in	   a	   managed	   care	   population	   with	   130%	   higher	  
direct	  costs	  (87).	  	  	  
Level:	  	  
2+	  
	  
	   Recommendation:	  
Comorbidities	  should	  be	  addressed	  in	  order	  to	  provide	  holistic	  management.	  
Grade:	  
C	  
	   Supporting	  Text:	  
Due	  to	  the	  multifactorial	  nature	  of	  pelvic	  pain,	  these	  patients	  often	  suffer	  from	  
multiple	   co-­‐morbidities	   that	   need	   to	   be	   addressed.	   Multiple-­‐regression-­‐
analyses	  of	  a	  National	  Health	   Insurance	  Database	  study	   from	  Taiwan	  showed	  
that	  the	  patients	  with	  BPS	  had	  significantly	  higher	  total	  costs	  for	  all	  healthcare	  
services	   than	   the	   controls,	   which	   could	   partly	   be	   due	   to	   higher	   medical	   co-­‐
morbidities	  (88).	  
Evidence	  
Level:	  	  
2+	  
	  
9.2	   What	  should	  be	  the	  duration	  of	  follow-­‐up?	   	  
	   Recommendation:	  
Patients	   should	   be	   followed	   up	   periodically	   until	   their	   symptoms	   become	  
controlled	  to	  the	  extent	  that	  they	  are	  happy	  to	  be	  discharged.	  
Grade:	  
GPP	  
	   Supporting	  Text:	  
It	   is	   difficult	   to	   estimate	   a	   finite	   time	   for	   follow	   up	   as	   it	   is	   often	   difficult	   to	  
achieve	  symptomatic	  control	  to	  an	  extent	  where	  the	  patient	  may	  be	  happy	  so	  
individualised	  management	  plans	  need	  to	  take	  into	  consideration	  response	  to	  
treatment,	  effects	  on	  quality	  of	   life	  and	  other	  existing	  comorbidities.	  Patients	  
may	  benefit	  from	  regular	  appointments	  as	  most	  may	  find	  it	  takes	  time	  to	  find	  a	  
suitable	  treatment	  and	  for	  them	  to	  respond	  to	  these.	  	  
Evidence	  
Level:	  	  
2–	  
	  
	   Recommendation:	  
The	  effect	  of	  pregnancy	  on	  the	  severity	  of	  symptoms	  can	  be	  variable	  
Grade:	  
D	  
	   Supporting	  Text:	  
There	  is	  little	  published	  information	  about	  the	  changes	  in	  symptoms	  that	  may	  
occur	   during	   pregnancy	   (89).	   The	   Interstitial	   Cystitis	   Association	   conducted	   a	  
patient	   survey	   about	   symptoms	   and	  pregnancy	   in	   1989,	  where	   patients	  who	  
described	  their	  symptoms	  as	  ‘‘mild’’	  experienced	  worsening	  symptoms	  during	  
pregnancy,	  which	  persisted	  up	  to	  6	  months	  after	  delivery.	  In	  contrast,	  patients	  
who	  described	   their	   symptoms	  as	   ‘‘severe’’	  had	  a	   significant	   improvement	   in	  
symptoms	   during	   the	   second	   trimester,	   which	   lasted	   up	   to	   6	   months	   after	  
delivery	   or	   for	   the	   duration	   of	   breastfeeding.	   BPS	   was	   not	   affected	   by	   the	  
mode	   of	   delivery.	   Another	   study	   found	   that	   only	   7%	   of	   patients	   stated	   that	  
their	  BPS	  symptoms	  had	  improved	  during	  pregnancy	  (90).	  
Evidence	  
Level:	  	  
3	  
	  
	   Recommendation:	  
Pregnancy	  outcomes	  appear	  to	  be	  good	  following	  1	  course	  of	  DMSO.	  
Grade:	  
D	  
	   Supporting	  Text:	  
A	   prospective	   study	   included	   12	   patients	   who	   had	   a	   course	   of	  
dimethylsulfoxide	   (DMSO)	   (every	   two	   weeks	   for	   12	   weeks)	   and	   all	   had	  
symptom	  remission.	  Pregnancy	  occurred	  6	  months	  to	  5	  years	  after	  the	  DMSO	  
treatment.	   Nine	   patients	   continued	   to	   have	   good	   symptom	   remission	  
throughout	  pregnancy.	  The	  other	  3	  had	  worsening	  symptoms,	  and	  2	  patients	  
terminated	   the	   pregnancy	   because	   of	   severe	   symptoms.	   Because	   this	   small	  
group	  of	  patients	  was	  more	  homogeneous	  than	  the	  general	  IC	  population,	  with	  
all	  patients	  having	  chronic	  inflammation	  on	  bladder	  biopsy	  and	  good	  remission	  
after	  DMSO,	  it	  is	  unclear	  how	  the	  results	  of	  this	  study	  apply	  to	  the	  general	  BPS	  
population	  (91).	  
Evidence	  
Level:	  	  
2–	  
	  
	   Recommendation:	   Grade:	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A	   patient	   who	   is	   experiencing	   significant	   symptom	   relief	   with	   PPS	   	   might	  
choose	  to	  continue	  it	  during	  pregnancy.	  
GPP	  
	   Supporting	  Text:	  
Of	  the	  commonly	  used	  oral	  treatments,	  pentosan	  polysulfate	  and	  amitriptyline	  
have	  the	  lowest	  risks,	  and	  hydroxyzine	  has	  more	  risks	  (89).	  	  
	  
Of	  the	  usual	  intravesical	  treatments,	  heparin	  is	  the	  safest	  because	  it	  is	  unlikely	  
to	  be	  absorbed	  from	  the	  bladder	  or	  to	  cross	  the	  placenta.	  Lidocaine	  does	  cross	  
the	  placenta	  and	  there	  is	  no	  information	  about	  the	  safety	  of	  chronic	  exposure	  
to	   the	   fetus.	   DMSO	   and	   systemic	   corticosteroids	   have	   known	   teratogenic	  
effects,	   but	   the	   absorption	   of	   intravesical	   corticosteroids	   is	   unknown.	   Sacral	  
nerve	   stimulators	   should	   not	   be	   placed	   during	   pregnancy	   and,	   if	   present	  
already,	   should	  be	   turned	  off	   for	   the	  duration	  of	   pregnancy	   as	   the	   effect	   on	  
fetus	  is	  unknown	  (92)	  
Evidence	  
Level:	  	  
4	  
	  
	   Recommendation:	  
The	  pregnant	  patient	  can	  be	  reassured	  that	  the	  risk	  of	  passing	  the	  condition	  
to	  her	  child	  is	  very	  low.	  
Grade:	  
D	  
	   Supporting	  Text:	  
In	  a	   few	  cases,	  multiple	  members	  of	  the	  same	  family	  have	  BPS.	  This	  suggests	  
that	  some	  patients	  may	  have	  a	  genetic	  predisposition.	  Unless	  she	  belongs	  to	  a	  
family	  that	  has	  multiple	  members	  with	  the	  condition,	  the	  pregnant	  patient	  can	  
be	  reassured	  that	  the	  risk	  for	  passing	  it	  on	  to	  her	  child	  is	  low	  (89).	  
Evidence	  
Level:	  	  
4	  
	  
10.	   Recommendations	  for	  future	  research	   	  
	   •	   Create	   a	   single	   standardised	   validated	   assessment	   questionnaire	   and	  
patient	  related	  outcome	  measures	  for	  BPS	  
•	   Assess	  the	  role	  of	  conservative	  treatment	  versus	  placebo	  for	  BPS	  
•	   Assess	  the	  role	  of	  the	  clinical	  psychologist	  	  
•	   Assess	  the	  number	  of	  patients	  with	  co-­‐existing	  conditions	  	  
	  
	  
11.	   Auditable	  topics	   	  
	   •	   What	  proportion	  of	  patients	  presenting	  with	  BPS	  have	  a	  positive	  urine	  
dipstick	  or	  cytology?	  
•	   What	   proportion	   of	   patients	  with	   BPS	   symptoms	   are	   commenced	  on	  
conservative	  treatments	  in	  primary	  care?	  
•	   What	   proportion	   of	   patients	   with	   BPS	   are	   referred	   to	   a	   general	  
gynaecologist	  versus	  a	  urogynaecologist?	  
•	   What	   proportion	   of	   patients	   have	   a	   symptomatic	   improvement	   with	  
conservative	  treatment	  options?	  
•	   What	   proportion	   of	   patients	   have	   a	   cystoscopy	   to	   either	   diagnose	  
symptoms	  or	  as	  a	  treatment	  option?
	  
	  
	  
12.	   Useful	  links	  and	  support	  groups	   	  
	   The	  following	  organisations	  provide	  support	  for	  BPS:	  	  
	  
Cystitis	  and	  overactive	  bladder	  foundation:	  www.cobfoundation.org	  
Pelvic	  pain	  support	  network:	  www.pelvicpain.org.uk	  
International	  painful	  bladder	  foundation:	  http://www.painful-­‐bladder.org	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Appendix	  I.	  Proposed	  treatment	  algorithm	  for	  BPS	  
	  
Bladder'pain'syndrome'(BPS):"Pain/pressure/discomfort"in"the"pelvis/bladder,"associated"with"urinary"symptoms"
"(frequency,"urgency,"nocturia,"bladder"ﬁlling"pain)"las?ng"at"least"6"months,""with"no"iden?ﬁable"cause."
Ini$al'assessment'
•  History:)assess)urinary)
symptoms,)pain,)QoL)
•  Urine)dips5ck)+/:)MSU)
•  Physical)examina5on)
•  Frequency/volume)charts))
1st-line'treatments:'
•  Conserva5ve:)analgesia,)stress)relief,)dietary)modiﬁca5on,)exercise,)physical)therapy,)support)groups))
*"If"treatment"fails"–"refer"to"secondary"care"
2nd-line'treatments:'
•  Oral)amitriptyline,)cime5dine,)hydroxyzine,)pentosan)polysulfate)(PPS))
3rd'-line'treatments:'
•  )))Intravesical)dimethyl)sulfoxide)(DMSO),)heparin,)botulinum)toxin)A,)lidocaine,)chondroi5n)sulphate)
*)If"treatment"fails"–"consider"referral"to"an"MDT"or"clinical"psychologist"
If)urinary)tract)infec5on:)treat)and)reassess)
Consider)other)causes:)
Malignancy,)infec5on,)overac5ve)bladder,))bladder)
calculi,)bladder)outlet)obstruc5on,)prolapse,)
endometriosis,))radia5on/drug:related)cys55s)
4th-line'treatments:'
•  Neuromodula5on)–)posterior)5bial)nerve)or)sacral)nerve)s5mula5on)
•  Oral)cyclosporin)A)
5th-line'treatments:'
•  Cystoscopy)and)hydrodistension)
*"If"Hunner’s"ulcers"are"noted"or"if"major"surgery"is"considered"–"refer"to"a"ter?ary"centre"
Treatments'that'are'not'recommended:'Long-term'an$bio$cs,'intravesical'Resiniferatoxin,'intravesical'Bacillus'
CalmeDe-Guerin'(BCG),'high-pressure'long-dura$on'hydrodistension'and'long-term'oral'glucocor$coids'' 	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Appendix	  II.	  Explanation	  of	  guidelines	  and	  evidence	  levels	  
	  
Clinical	  guidelines	  are:	   ‘systematically	  developed	  statements	  which	  assist	   clinicians	  and	  patients	   in	  
making	   decisions	   about	   appropriate	   treatment	   for	   specific	   conditions’.	   Each	   guideline	   is	  
systematically	   developed	   using	   a	   standardised	   methodology.	   Exact	   details	   of	   this	   process	   can	   be	  
found	  in	  Clinical	  Governance	  Advice	  No.1	  Development	  of	  RCOG	  Green-­‐top	  Guidelines	  (available	  on	  
the	  RCOG	  website	  at	  http://www.rcog.org.uk/green-­‐top-­‐development).	  These	  recommendations	  are	  
not	   intended	  to	  dictate	  an	  exclusive	  course	  of	  management	  or	  treatment.	  They	  must	  be	  evaluated	  
with	   reference	   to	   individual	  patient	  needs,	   resources	  and	   limitations	  unique	   to	   the	   institution	  and	  
variations	   in	   local	   populations.	   It	   is	   hoped	   that	   this	   process	   of	   local	   ownership	   will	   help	   to	  
incorporate	  these	  guidelines	  into	  routine	  practice.	  Attention	  is	  drawn	  to	  areas	  of	  clinical	  uncertainty	  
where	  further	  research	  may	  be	  indicated.	  	  
	  
The	  evidence	  used	  in	  this	  guideline	  was	  graded	  using	  the	  scheme	  below	  and	  the	  recommendations	  
formulated	  in	  a	  similar	  fashion	  with	  a	  standardised	  grading	  scheme.	  
	  
Classification	  of	  evidence	  levels	  	  
1++	   High-­‐quality	  meta-­‐analyses,	  systematic	  reviews	  of	  randomised	  controlled	  trials	  or	  randomised	  
controlled	  trials	  with	  a	  very	  low	  risk	  of	  bias	  
1+	   Well-­‐conducted	   meta-­‐analyses,	   systematic	   reviews	   of	   randomised	   controlled	   trials	   or	  
randomised	  controlled	  trials	  with	  a	  low	  risk	  of	  bias	  
1	  –	   Meta-­‐analyses,	  systematic	  reviews	  of	  randomised	  controlled	  trials	  or	  randomised	  controlled	  
trials	  with	  a	  high	  risk	  of	  bias	  
2++	   High-­‐quality	  systematic	  reviews	  of	  case–control	  or	  cohort	  studies	  or	  high-­‐quality	  
case–control	  or	  cohort	  studies	  with	  a	  very	  low	  risk	  of	  confounding,	  bias	  or	  chance	  and	  a	  
high	  probability	  that	  the	  relationship	  is	  causal	  
2+	   Well-­‐conducted	  case–control	  or	  cohort	  studies	  with	  a	  low	  risk	  of	  confounding,	  bias	  or	  chance	  
and	  a	  moderate	  probability	  that	  the	  relationship	  is	  causal	  
2–	   Case–control	  or	  cohort	  studies	  with	  a	  high	  risk	  of	  confounding,	  bias	  or	  chance	  and	  a	  
significant	  risk	  that	  the	  relationship	  is	  not	  causal	  
3	   Non-­‐analytical	  studies,	  e.g.	  case	  reports,	  case	  series	  
4	   Expert	  opinion	  
	  
Grades	  of	  Recommendation	  
At	  least	  one	  meta-­‐analysis,	  systematic	  reviews	  or	  RCT	  rated	  as	  1++,	  and	  directly	  applicable	  to	  
the	  target	  population;	  or	  a	  systematic	  review	  of	  RCTs	  or	  a	  body	  of	  evidence	  consisting	  
principally	  of	  studies	  rated	  as	  1+,	  directly	  applicable	  to	  the	  target	  population	  and	  
demonstrating	  overall	  consistency	  of	  results	  
	  
A	  body	  of	  evidence	  including	  studies	  rated	  as	  2++	  directly	  applicable	  to	  the	  target	  
population,	  and	  demonstrating	  overall	  consistency	  of	  results;	  or	  	  
	   Extrapolated	  evidence	  from	  studies	  rated	  as	  1++	  or	  1+	  
	  
A	  body	  of	  evidence	  including	  studies	  rated	  as	  2+	  directly	  applicable	  to	  the	  target	  population,	  
and	  demonstrating	  overall	  consistency	  of	  results;	  or	  	  
	   Extrapolated	  evidence	  from	  studies	  rated	  as	  2++	  
	  
	   Evidence	  level	  3	  or	  4;	  or	  	  
	   Extrapolated	  evidence	  from	  studies	  rated	  as	  2+	   	  
	  
Good	  Practice	  Points	  
A	  
B	  
C	  
D	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Recommended	  best	  practice	  based	  on	  the	  clinical	  experience	  of	  the	  guideline	  development	  
group	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
This	  guideline	  was	  produced	  on	  behalf	  of	  the	  Royal	  College	  of	  Obstetricians	  and	  Gynaecologists	  by:	  	  
Dr	  SA	  Tirlapur,	  London;	  Ms	  J	  Birch,	  Pelvic	  Pain	  Support	  Network;	  Dr	  CL	  Carberry	  MD,	  Rhode	  Island,	  
USA;	  Professor	  KS	  Khan	  MRCOG,	  London;	  Dr	  P	  Latthe	  MRCOG,	  Birmingham;	  Dr	  S	  Jha	  FRCOG,	  
Sheffield,	  British	  Society	  of	  Urogynaecology;	  Dr	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  Ward	  MRCOG,	  Manchester,	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  Society	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  Ms	  A	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  Foundation,	  UK	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  unless	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DISCLAIMER	  
	  
The	  Royal	  College	  of	  Obstetricians	  and	  Gynaecologists	  produces	  guidelines	  as	  an	  educational	  aid	  to	  
good	  clinical	  practice.	  They	  present	  recognised	  methods	  and	  techniques	  of	  clinical	  practice,	  based	  on	  
published	  evidence,	  for	  consideration	  by	  obstetricians	  and	  gynaecologists	  and	  other	  relevant	  health	  
professionals.	  The	  ultimate	  judgement	  regarding	  a	  particular	  clinical	  procedure	  or	  treatment	  plan	  
must	  be	  made	  by	  the	  doctor	  or	  other	  attendant	  in	  the	  light	  of	  clinical	  data	  presented	  by	  the	  patient	  
and	  the	  diagnostic	  and	  treatment	  options	  available.	  
	  
This	  means	  that	  RCOG	  Guidelines	  are	  unlike	  protocols	  or	  guidelines	  issued	  by	  employers,	  as	  they	  are	  
not	  intended	  to	  be	  prescriptive	  directions	  defining	  a	  single	  course	  of	  management.	  Departure	  from	  
the	  local	  prescriptive	  protocols	  or	  guidelines	  should	  be	  fully	  documented	  in	  the	  patient’s	  case	  notes	  
at	  the	  time	  the	  relevant	  decision	  is	  taken.	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a b s t r a c t
Background: Chronic pelvic pain (CPP), a common gynaecological presentation, may be due to bladder
pain syndrome (BPS) or the co-existence of BPS and endometriosis, known as the ‘evil twins syndrome’.
Objectives: To estimate the prevalence of BPS and the co-existence of BPS and endometriosis in women
with CPP.
Data sources: We searched until March 2012: The Cochrane Library, DARE (1997e2012), EMBASE (1980
e2012), Medline (1950e2012), PSYCHINFO (1806e2012), Web of knowledge (1900e2012), LILACS
(1982e2012) and SIGLE (1990e2012) with no language restrictions. We manually searched through
bibliographies and conference proceedings of the International Continence Society.
Study selection: Observational studies of women suffering from CPP, who were not pregnant or suffering
from cancer, who underwent a laparoscopy and cystoscopy to investigate their symptoms. Study se-
lection, data extraction and quality assessment was performed independently by two reviewers. Sta-
tistical analysis was performed to estimate prevalence and conﬁdence intervals (CI).
Results: Nine studies were included with 1016 patients with CPP. Study quality and diagnostic assessment
varied. The mean prevalence of BPS was 61% (range 11e97%, CI 58e64%, I2 ¼ 98%). The mean prevalence
of endometriosis was 70% (range 28e93%, CI 67e73%, I2 ¼ 93%) and co-existing BPS and endometriosis
was 48% (range 16e78%, CI 44e51%, I2 ¼ 96%).
Conclusion: Almost two thirds of women presenting with CPP have BPS. Large variations in prevalence
may be due to variable study selection and quality. Clinicians need to actively investigate patients for BPS,
a condition that appears to co-exist with endometriosis.
! 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Background
The diagnosis and treatment of chronic pelvic pain (CPP) has a
large ﬁnancial burden on health care economies. Bladder pain
syndrome (BPS) is a recognised cause of CPP. It can have a huge
impact on quality of life and sexual function.1
BPS is deﬁned as the symptoms of CPP, bladder pressure or
discomfort along with at least one other urinary symptom in the
absence of any identiﬁable pathology or infection.2,3 This deﬁnition
was proposed by the European Society for the Study of Interstitial
Cystitis/Painful Bladder Syndrome (ESSIC) in 2008. The condition
can be further classiﬁed by cystoscopy grading and biopsy results.
BPS was formerly known as interstitial cystitis (IC) and painful
bladder syndrome (PBS). It has an unknown aetiology with a re-
ported prevalence between 5 and 16 per 100,000 of the popula-
tion.4,5 The prevalence of BPS amongst women with CPP is
unknown. The co-existence of diseases in CPP, such as BPS and
endometriosis, described by Chung et al. as the ‘evil twins syn-
drome’6,7 can make management very difﬁcult.8 While the term
‘the evil twin syndrome’ is not a medical deﬁnition, it conveys the
misery of the co-existence of these two chronic pain conditions.
The purpose of this systematic review was to estimate the
prevalence of BPS in women suffering from CPP. Secondarily we
Abbreviations: BPS, bladder pain syndrome; CI, conﬁdence interval; CPP, chronic
pelvic pain; ESSIC, European Society for the Study of Interstitial Cystitis/Painful
Bladder Syndrome; IC, interstitial cystitis; NIDDK, National Institute of diabetes and
digestive and kidney diseases; OLS, O’Leary-Sant; PBS, painful bladder syndrome;
PRISMA, preferred reporting items for systematic reviews and meta-analyses; PUF,
pelvic pain urgency/frequency; SD, standard deviation.
* Corresponding author. Women’s Health Research Unit, Queen Mary, University
of London, 58 Turner Street, London E1 2AB, United Kingdom. Tel.: þ44 207 882
5883; fax: þ44 207 882 2552.
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Contents lists available at SciVerse ScienceDirect
International Journal of Surgery
journal homepage: www.thei js .com
1743-9191/$ e see front matter ! 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ijsu.2013.02.003
International Journal of Surgery 11 (2013) 233e237
REVIEW
	   	  
	   	  
	   199	  
 
	   	  
	   	  
	   200	  
 
	   	  
	   	  
	   201	  
	   	  
	   	  
	   202	  
	   	  
	   	  
	   203	  
 
REVIEWARTICLE
Quality of information on the internet related to bladder pain
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Abstract
Introduction and hypothesis Bladder pain syndrome (BPS)
has an impact on quality of life and available treatments often
only provide temporary symptomatic relief. The information
provided by websites can be valuable for patient education and
management. The hypothesis was to assess medical informa-
tion available on the internet related to bladder pain syndrome
in terms of accuracy, credibility, readability and quality.
Methods A search was performed in the meta-search engine
Copernic Agent, using the search terms “bladder pain syn-
drome, interstitial cystitis, painful bladder syndrome and pelvic
pain”, which simultaneously captured websites from a range of
engines. Websites in the English language that were open-
access were included. The four quality assessments used were:
credibility using a ten-point scale, accuracy based on the
American Urological Association guidelines, quality using
the DISCERN questionnaire and readability using the Flesch
Reading Ease Score. Inter-rater agreement was tested by intra-
class coefficient (ICC).
Results Eighteen suitable websites were identified; 7 (39%)
were specialist or specific to BPS. The combined mean
scores for accuracy, quality, credibility and readability
ranged from 83 to 144 for specialist websites and 76 to
137 for non-specialist ones, with a maximum possible score
of 208. There was good inter-observer agreement for the
assessments performed with an ICC ranging from 0.80 for
DISCERN to 0.53 for readability. Specialist websites had
higher quality scores (median difference 10, p=0.07) and
readability scores (median difference 5.4, p=0.05) com-
pared with non-specialist websites whereas credibility and
accuracy scores were no different.
Conclusion We found four websites that fulfilled our
criteria for good quality information.
Keywords Accuracy . Bladder pain syndrome . Credibility .
Internet . Interstitial cystitis . Readability
Abbreviations
AUA American Urological Association
BPS Bladder pain syndrome
CI Confidence interval
DMSO Dimethyl sulfoxide
FRE Flesch Reading Ease test
ICC Intra-class co-efficient
PRISMA Preferred Reporting Items for Systematic
Reviews and Meta-analyses
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Introduction
Bladder pain syndrome (BPS), formerly known as interstitial
cystitis, is defined as chronic pelvic pain, pressure or discom-
fort related to the bladder along with at least one other urinary
Electronic supplementary material The online version of this article
(doi:10.1007/s00192-013-2091-1) contains supplementary material,
which is available to authorized users.
S. A. Tirlapur : C. Leiu :K. S. Khan
Women’s Health Research Unit, Queen Mary, University of
London, Turner Street, London E1 2AB, UK
S. A. Tirlapur :K. S. Khan
Barts Health NHS Trust, The Royal London Hospital, Whitechapel
Road, London E1 1BB, UK
S. A. Tirlapur (*)
Women’s Health Research Unit, Barts and the London School of
Medicine, Queen Mary, University of London, 58 Turner Street,
London E1 2AB, UK
e-mail: s.a.tirlapur@qmul.ac.uk
Int Urogynecol J
DOI 10.1007/s00192-013-2091-1
Author's personal copy
	   	  
	   	  
	   204	  
 
	   	  
	   	  
	   205	  
 
	   	  
	   	  
	   206	  
 
	   	  
	   	  
	   207	  
 
	   	  
	   	  
	   208	  
 
	   	  
	   	  
	   209	  
STUDY PROTOCOL Open Access
Bladder pain syndrome: validation of simple tests
for diagnosis in women with chronic pelvic pain:
BRaVADO study protocol
Seema A Tirlapur1*, Lee Priest2, Daniel Wojdyla3, Khalid S Khan1,4 and On behalf of the MEDAL Study
Abstract
Background: Bladder pain syndrome (BPS), a condition with no gold standard diagnosis, comprises of a cluster of
signs and symptoms. Bladder filling pain and bladder wall tenderness are two basic clinical features, present in a
high number of sufferers. This study will validate the performance of these simple tests for BPS in women with
chronic pelvic pain (CPP).
Methods/design: We will conduct a prospective test validation study amongst women with unexplained CPP
presenting to gynaecology outpatient clinics. Two index tests will be performed: patient reported bladder filling
pain and bladder wall tenderness on internal pelvic bimanual examination. A final diagnosis of BPS will be made by
expert consensus panel. We will assess the rates of index tests in women with CPP; evaluate the correlation
between index tests and Pelvic Pain Urgency/ Frequency (PUF) questionnaire results; and determine index test
sensitivity and specificity using a range of analytical methods. Assuming a 50% prevalence of BPS and an 80%
power approximately 152 subjects will be required exclude sensitivity of < 55% at 70% sensitivity.
Discussion: The results of this test validation study will be used to identify whether a certain combination of signs
and symptoms can accurately diagnose BPS.
Trial registration: ISRCTN13028601
Keywords: Bladder pain syndrome, Chronic pelvic pain, Consensus panel, Latent class analysis, Test validation
Background
Bladder pain syndrome (BPS), formerly known as inter-
stitial cystitis and painful bladder syndrome, is a cause of
chronic pelvic pain (CPP) and is defined as CPP, bladder
pressure or discomfort along with at least one other
urinary symptom in the absence of any identifiable path-
ology or infection [1,2].
The reported prevalence of BPS is between 5 and 16
per 100,000 of the population with 61% of women pre-
senting with CPP being diagnosed with BPS [3-5]. The
condition has a large impact on sexual function and
quality of life [6]. It has an unknown aetiology and impre-
cise characterisation, which makes it difficult to accurately
diagnose clinically [7,8]. The diagnosis of BPS can be
made by symptoms alone and further classified by cyst-
oscopy findings and biopsy results, after exclusion of
other confusable diseases like urinary tract infection or
overactive bladder [2]. Symptoms include urinary fre-
quency, urgency, nocturia and incomplete voiding [9].
Validated questionnaires may be used to help diagnose
patients. The two commonly used are the O’Leary-Sant
Interstitial Cystitis Symptom Index/Problem Index and
the Pelvic Pain Urgency/ Frequency (PUF) question-
naire [10,11]. Neither questionnaire is considered a reli-
able predictor of disease or disease severity [11,12].
There is no gold standard test for BPS, which makes for
difficulty in choice of study design for a diagnostic eva-
luation study (Figure 1).
The most commonly reported symptoms are bladder/
pelvic pain, urgency, frequency and nocturia but this symp-
tom cluster is present in several other urinary conditions
* Correspondence: s.a.tirlapur@qmul.ac.uk
1Women’s Health Research Unit, Barts and the London School of Medicine,
Queen Mary, University of London, 58 Turner Street, London E1 2AB, UK
Full list of author information is available at the end of the article
© 2013 Tirlapur et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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Abstract
Chronic pelvic pain (CPP) and bladder pain syndrome (BPS) can have a negative
impact on quality of life. Neuromodulation has been suggested as a possible
treatment for refractory pain. To assess the effectiveness of tibial and sacral nerve
stimulation in the treatment of BPS and CPP. We searched until July 2012: the
Cochrane Library, EMBASE (1980–2012), Medline (1950–2012), Web of knowl-
edge (1900–2012), LILACS (1982–2012) and SIGLE (1990–2012) with no
language restrictions. We manually searched through bibliographies and confer-
ence proceedings of the International Continence Society. Randomized and pro-
spective quasi-randomized controlled studies vs. sham nerve stimulation
treatment or usual care of patients with CPP and BPS who underwent sacral or
tibial nerve stimulation were included. Any studies involving transcutaneous
stimulation were excluded. The outcome was a cure or improvement in symp-
toms. Three studies with 169 patients treated with tibial nerve stimulation were
included; two for CPP and one for BPS. There were improvements in pain,
urinary and quality of life scores. There were no reported data for sacral nerve
stimulation. There is scanty literature reporting variable success of posterior tibial
nerve stimulation in improving pain, urinary symptoms and quality of life in
CPP and BPS. In view of the dearth of quality literature, a large multi-centered
clinical trial investigating the effectiveness of electrical nerve stimulation to treat
BPS and CPP along with the cost-analysis of this treatment is recommended.
Abbreviations: BPS, bladder pain syndrome; CPP, chronic pelvic pain; GRADE,
Grading of Recommendations, Assessment, Development and Evaluations; NIH
CPSI, chronic prostatitis symptom index; PTNS, posterior tibial nerve
stimulation; SNS, sacral nerve stimulation.
Introduction
Bladder pain syndrome (BPS), formerly known as inter-
stitial cystitis and painful bladder syndrome, is defined as
chronic pelvic pain (CPP), bladder pressure or discomfort
with at least one other urinary symptom in the absence
of any identifiable pathology or infection (1,2). CPP is an
intermittent or constant pain in the lower abdomen for
at least 6 months, not associated with pregnancy and not
occurring exclusively with menstruation or sexual inter-
course (3). BPS and CPP can have a negative impact on
quality of life and sexual function (4). The prevalence of
BPS is between 5 and 16 per 100 000 of the population
and that of CPP is 3800 per 100 000 (5–7).
Key Message
Neuromodulation is a treatment for patients with
chronic pelvic pain and bladder pain syndrome. This
systematic review assessing the effectiveness of poster-
ior tibial nerve and sacral nerve stimulation showed
variable success and the need for a large multi-
centered clinical trial.
ª 2013 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 92 (2013) 881–887 881
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Grading of evidence for bladder pain syndrome:
a comparative review of study quality assessment methods
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Abstract
Introduction and hypothesis Clinical guidelines on bladder
pain syndrome (BPS) report quality ratings for evidence based
on study design. The Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system takes
into account several domains in addition to limitations of
study design for assigning quality ratings. We compared the
quality of evidence described in current BPS literature.
Methods All existing systematic reviews and guidelines on
BPS management were reviewed, and included evidence was
rated according to GRADE on a four-point scale (1–4, from
very low to high). These ratings were compared to the two
reported quality assessments that assigned levels or strengths
to evidence; both had a four-point scale: level of evidence 1–4
from meta-analysis of randomised studies to expert opinion;
and strength of evidence 1–4 from very low to high.
Results Of the 19 treatments for BPS with GRADE ratings,
comparison with level of evidence ratings showed that, on
average, the latter overestimated quality by 1.8 points [1.1 v
2.9; 95 % confidence interval (CI) 1.2–2.3; p =<0.0001).
Comparison of GRADE ratings with strength of evidence
ratings showed that, on average, the latter overestimated qual-
ity by 1.7 points (1.1 v 2.8; 95 % CI 1.3–2.1; p =<0.0001).
Conclusion GRADE, a refined method of assigning quality to
evidence, provided a more conservative gauge, giving a real-
istic assessment of the value of recommendations for consid-
eration in practice.
Keywords Bladder pain syndrome . GRADE . Guidelines .
Evidence . Quality
Abbreviations
AUA American Urological Association
BCG Bacillus Calmette-Guerin
BPS Bladder pain syndrome
CPP Chronic pelvic pain
CI Confidence interval
DMSO Dimethyl sulfoxide
EAU European Association of Urology
EGF Epidermal growth factor
GRADE Grading, Recommendations, Assessment,
Development and Evaluation
IC Interstitial cystitis
PPS Pentosan polysulfate sodium
RCT Randomised controlled trials
Introduction
Bladder pain syndrome (BPS), formerly known as interstitial
cystitis (IC), is a chronic condition defined as chronic pelvic
pain (CPP), pressure or discomfort related to the bladder,
along with at least one other urinary symptom, such as urgen-
cy or frequency, in the absence of any other pathology [1]. It is
associated with negative cognitive, behavioural, sexual or
emotional consequences, as well as with lower urinary tract
and sexual dysfunction [2]. There is often difficulty in
assessing the value of treatments proposed for BPS. Different
organisations use different scoring systems to rate quality of
evidence, which can be confusing. The Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) system was developed in 2000 by the GRADE
working group to establish transparency over the reporting
S. A. Tirlapur (*) :K. S. Khan
Women’s Health Research Unit, Barts and the London School of
Medicine, Queen Mary University of London, 58 Turner Street,
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Variations in the reporting of outcomes used in systematic reviews of
treatment effectiveness research in bladder pain syndrome
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A B S T R A C T
This paper investigates the quality of outcomes reported in systematic reviews and randomised
controlled trials (RCTs) of bladder pain syndrome and its relationship with study quality and journal
impact factor. We searched until August 2013 the Cochrane Library, EMBASE, Medline, CINAHL, LILACS
and SIGLE, without language restrictions. Quality of outcome reporting in systematic reviews and
constituent RCTs was assessed using a 6-point scale. Overall study quality was assessed using the
AMSTAR and Jadad scoring systems, and impact factor in the year of publication was noted. Spearman's
rank correlation was calculated. There were 8 systematic reviews, with a total of 28 RCTs (1732 patients),
reporting 5 outcomes using 19 different measurement scales. The outcomes reported in individual RCTs
were urinary symptoms (100%), pain (64%), quality of life (39%), general wellbeing (36%) and bladder
capacity (36%). The mean quality of outcomes reported was 1.63 (95% CI 0.29–2.96) for systematic
reviews and 3.25 (95% CI 2.80–3.70) for RCTs. The quality of outcomes reported showed correlation with
overall study quality (0.90, 95% CI 0.79–0.95, p < 0.0001) but not with journal impact factor (0.07, 95% CI
!0.31–0.43, p = 0.35). Multivariable linear regression showed a relationship between quality of outcome
reporting and study quality (b = 0.05, p < 0.0001), adjusting for effects of study type, impact factor and
journal type. There is a need to generate consensus over a set of core outcomes in bladder pain syndrome
using standardised reporting tools and to disseminate these through good publication practice.
ã 2014 Published by Elsevier Ireland Ltd.
Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Search strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Study selection and data extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Quality assessments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Data synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Abbreviations: AMSTAR, assessment of multiple systematic reviews; BPS, bladder pain syndrome; CI, conﬁdence intervals; COMET, core outcome measures in
effectiveness trials; COS, core outcome sets; GRADE, grading, recommendations, assessment, development and evaluation; PRISMA, preferred reporting items for systematic
reviews and meta-analyses; RCT, randomised controlled trial.
* Corresponding author. Tel.: +44 207 882 5883; fax: +44 207 882 2552.
E-mail address: s.a.tirlapur@qmul.ac.uk (S.A. Tirlapur).
http://dx.doi.org/10.1016/j.ejogrb.2014.06.003
0301-2115/ã 2014 Published by Elsevier Ireland Ltd.
European Journal of Obstetrics & Gynecology and Reproductive Biology 180 (2014) 61–67
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
Reproductive Biology
journal homepage: www.elsevier .com/ locate /e jogrb
 
	   	  
	   	  
	   234	  
 
	   	  
	   	  
	   235	  
 
	   	  
	   	  
	   236	  
 
	   	  
	   	  
	   237	  
 
	   	  
	   	  
	   238	  
 
	   	  
	   	  
	   239	  
	   	  
	   	  
	   240	  
References 
1.	   Hunner	   GL.	   A	   rare	   type	   of	   bladder	   ulcer	   in	  women:	   A	   report	   of	   cases.	   Boston	  Medical	  and	  Surgical	  Journal.	  1915(172):660-­‐5.	  2.	   Messing	   EM,	   Stamey	   TA.	   Interstitial	   cystitis:	   early	   diagnosis,	   pathology,	   and	  treatment.	  Urology.	  1978;12(4):381-­‐92.	  3.	   Gillenwater	  JY,	  Wein	  AJ.	  Summary	  of	  the	  National	  Institute	  of	  Arthritis,	  Diabetes,	  Digestive	  and	  Kidney	  Diseases	  Workshop	  on	   Interstitial	  Cystitis,	  National	   Institutes	  of	  Health,	  Bethesda,	  Maryland,	  August	  28-­‐29,	  1987.	  J	  Urol.	  1988;140(1):203-­‐6.	  4.	   Hanno	   PM,	   Landis	   JR,	   Matthews-­‐Cook	   Y,	   Kusek	   J,	   Nyberg	   L.	   The	   diagnosis	   of	  interstitial	   cystitis	   revisited:	   lessons	   learned	   from	   the	   National	   Institutes	   of	   Health	  Interstitial	  Cystitis	  Database	  study.	  J	  Urol.	  1999;161(2):553-­‐7.	  5.	   Butrick	   CW.	   Interstitial	   cystitis	   and	   chronic	   pelvic	   pain:	   new	   insights	   in	  neuropathology,	  diagnosis,	  and	  treatment.	  Clin	  Obstet	  Gynecol.	  2003;46(4):811-­‐23.	  6.	   Hanno	  P,	  Keay	  S,	  Moldwin	  R,	  Van	  Ophoven	  A.	  International	  Consultation	  on	  IC	  -­‐	  Rome,	   September	   2004/Forging	   an	   International	   Consensus:	   progress	   in	   painful	  bladder	   syndrome/interstitial	   cystitis.	   Report	   and	   abstracts.	   Int	   Urogynecol	   J	   Pelvic	  Floor	  Dysfunct.	  2005;16	  Suppl	  1:S2-­‐S34.	  7.	   van	  de	  Merwe	  JP,	  Nordling	  J,	  Bouchelouche	  P,	  Bouchelouche	  K,	  Cervigni	  M,	  Daha	  LK,	   et	   al.	   Diagnostic	   criteria,	   classification,	   and	   nomenclature	   for	   painful	   bladder	  syndrome/interstitial	  cystitis:	  an	  ESSIC	  proposal.	  Eur	  Urol.	  2008;53(1):60-­‐7.	  8.	   Homma	  Y,	  Ueda	  T,	  Ito	  T,	  Takei	  M,	  Tomoe	  H.	  Japanese	  guideline	  for	  diagnosis	  and	  treatment	  of	  interstitial	  cystitis.	  International	  Journal	  of	  Urology.	  2009;16(1):4-­‐16.	  9.	   Baranowski	  A,	   Abrams	  P,	   Berger	  R,	   Buffington	  T,	   Collett	   B,	   Emmanuel	  A,	   et	   al.	  Classification	   of	   Chronic	   Pain.	   2	   ed.	   International	   Association	   for	   the	   Study	   of	   Pain.	  2011.	  10.	   Oravisto	   KJ.	   Epidemiology	   of	   interstitial	   cystitis.	   Ann	   Chir	   Gynaecol	   Fenn.	  1975;64(2):75-­‐7.	  11.	   Temml	   C,	   Wehrberger	   C,	   Riedl	   C,	   Ponholzer	   A,	   Marszalek	   M,	   Madersbacher	   S.	  Prevalence	  and	  correlates	  for	  interstitial	  cystitis	  symptoms	  in	  women	  participating	  in	  a	  health	  screening	  project.	  Eur	  Urol.	  2007;51(3):803-­‐8;	  discussion	  9.	  12.	   Ito	  T,	  Miki	  M,	  Yamada	  T.	  Interstitial	  cystitis	  in	  Japan.	  BJU	  Int.	  2000;86(6):634-­‐7.	  13.	   Homma	  Y,	  Yamaguchi	  O,	  Hayashi	  K,	  Committee	  NBS.	  An	  epidemiological	  survey	  of	  overactive	  bladder	  symptoms	  in	  Japan.	  BJU	  Int.	  2005;96(9):1314-­‐8.	  14.	   Ito	   T,	   Ueda	   T,	   Honma	   Y,	   Takei	  M.	   Recent	   trends	   in	   patient	   characteristics	   and	  therapeutic	  choices	  for	  interstitial	  cystitis:	  analysis	  of	  282	  Japanese	  patients.	  Int	  J	  Urol.	  2007;14(12):1068-­‐70.	  15.	   Konkle	  KS,	  Berry	  SH,	  Elliott	  MN,	  Hilton	  L,	  Suttorp	  MJ,	  Clauw	  DJ,	  et	  al.	  Comparison	  of	   an	   Interstitial	   Cystitis/Bladder	   Pain	   Syndrome	   Clinical	   Cohort	   With	   Symptomatic	  Community	   Women	   From	   the	   RAND	   Interstitial	   Cystitis	   Epidemiology	   Study.	   J	   Urol.	  2012;187(2):508-­‐12.	  16.	   Dyer	  AJ,	  Twiss	  CO.	  Painful	  bladder	  syndrome:	  an	  update	  and	  review	  of	  current	  management	  strategies.	  Curr	  Urol	  Rep.	  2014;15(2):384.	  17.	   Parsons	   CL,	   Lilly	   JD,	   Stein	   P.	   Epithelial	   dysfunction	   in	   nonbacterial	   cystitis	  (interstitial	  cystitis).	  J	  Urol.	  1991;145(4):732-­‐5.	  18.	   Peeker	   R,	   Enerbäck	   L,	   Fall	   M,	   Aldenborg	   F.	   Recruitment,	   distribution	   and	  phenotypes	  of	  mast	  cells	  in	  interstitial	  cystitis.	  J	  Urol.	  2000;163(3):1009-­‐15.	  
	   	  
	   	  
	   241	  
19.	   Ochs	  RL,	  Stein	  TW,	  Peebles	  CL,	  Gittes	  RF,	  Tan	  EM.	  Autoantibodies	   in	   interstitial	  cystitis.	  J	  Urol.	  1994;151(3):587-­‐92.	  20.	   Pontari	   MA,	   Hanno	   PM,	   Ruggieri	   MR.	   Comparison	   of	   bladder	   blood	   flow	   in	  patients	  with	  and	  without	  interstitial	  cystitis.	  J	  Urol.	  1999;162(2):330-­‐4.	  21.	   Cheng	   C,	   Rosamilia	   A,	   Healey	   M.	   Diagnosis	   of	   interstitial	   cystitis/bladder	   pain	  syndrome	   in	  women	  with	   chronic	   pelvic	   pain:	   a	   prospective	   observational	   study.	   Int	  Urogynecol	  J.	  2012. Oct;23(10):1361-­‐6	  22.	   Wyndaele	   JJ,	   Van	   Dyck	   J,	   Toussaint	   N.	   Cystoscopy	   and	   bladder	   biopsies	   in	  patients	   with	   bladder	   pain	   syndrome	   carried	   out	   following	   ESSIC	   guidelines.	   Scand	   J	  Urol	  Nephrol.	  2009;43(6):471-­‐5.	  23.	   Hanno	  PM,	  Burks	  DA,	  Clemens	  JQ,	  Dmochowski	  RR,	  Erickson	  D,	  Fitzgerald	  MP,	  et	  al.	   AUA	   guideline	   for	   the	   diagnosis	   and	   treatment	   of	   interstitial	   cystitis/bladder	   pain	  syndrome.	  J	  Urol.	  2011;185(6):2162-­‐70.	  24.	   Fall	   M,	   Oberpenning	   F,	   Peeker	   R.	   Treatment	   of	   bladder	   pain	  syndrome/interstitial	   cystitis	  2008:	   can	  we	  make	  evidence-­‐based	  decisions?	  Eur	  Urol.	  2008;54(1):65-­‐75.	  25.	   Castro-­‐Diaz	   D,	   Cardozo	   L,	   Chapple	   CR,	   Espuña	   M,	   Kelleher	   C,	   Kirby	   M,	   et	   al.	  Urgency	  and	  pain	  in	  patients	  with	  overactive	  bladder	  and	  bladder	  pain	  syndrome.	  What	  are	  the	  differences?	  Int	  J	  Clin	  Pract.	  2014;68(3):356-­‐62.	  26.	   O'Leary	  MP,	  Sant	  GR,	  Fowler	  FJ,	  Whitmore	  KE,	  Spolarich-­‐Kroll	   J.	  The	  interstitial	  cystitis	  symptom	  index	  and	  problem	  index.	  Urology.	  1997;49(5A	  Suppl):58-­‐63.	  27.	   Lubeck	   DP,	   Whitmore	   K,	   Sant	   GR,	   Alvarez-­‐Horine	   S,	   Lai	   C.	   Psychometric	  validation	   of	   the	   O'leary-­‐Sant	   interstitial	   cystitis	   symptom	   index	   in	   a	   clinical	   trial	   of	  pentosan	  polysulfate	  sodium.	  Urology.	  2001;57(6	  Suppl	  1):62-­‐6.	  28.	   Parsons	   CL,	   Dell	   J,	   Stanford	   EJ,	   Bullen	   M,	   Kahn	   BS,	   Waxell	   T,	   et	   al.	   Increased	  prevalence	   of	   interstitial	   cystitis:	   previously	   unrecognized	   urologic	   and	   gynecologic	  cases	   identified	   using	   a	   new	   symptom	   questionnaire	   and	   intravesical	   potassium	  sensitivity.	  Urology.	  2002;60(4):573-­‐8.	  29.	   Brewer	  ME,	  White	  WM,	  Klein	  FA,	  Klein	  LM,	  Waters	  WB.	  Validity	  of	  Pelvic	  Pain,	  Urgency,	   and	   Frequency	   questionnaire	   in	   patients	   with	   interstitial	   cystitis/painful	  bladder	  syndrome.	  Urology.	  2007;70(4):646-­‐9.	  30.	   Hanno	  P,	  Lin	  A,	  Nordling	  J,	  Nyberg	  L,	  van	  Ophoven	  A,	  Ueda	  T,	  et	  al.	  Bladder	  Pain	  Syndrome	   Committee	   of	   the	   International	   Consultation	   on	   Incontinence.	   Neurourol	  Urodyn.	  2010;29(1):191-­‐8.	  31.	   Rapariz-­‐González	  M,	   Castro-­‐Díaz	  D,	  Mejía-­‐Rendón	  D,	   EURCIS.	   Evaluation	  of	   the	  impact	   of	   the	   urinary	   symptoms	   on	   quality	   of	   life	   of	   patients	   with	   painful	   bladder	  syndrome/chronic	   pelvic	   pain	   and	   radiation	   cystitis:	   EURCIS	   study.	   Actas	   Urol	   Esp.	  2014;38(4):224-­‐31.	  32.	   Fall	  M,	  Baranowski	  AP,	  Fowler	  CJ,	  Lepinard	  V,	  Malone-­‐Lee	  JG,	  Messelink	  EJ,	  et	  al.	  EAU	  guidelines	  on	  chronic	  pelvic	  pain.	  33.	   Chung	   MK,	   Chung	   RP,	   Gordon	   D.	   Interstitial	   cystitis	   and	   endometriosis	   in	  patients	   with	   chronic	   pelvic	   pain:	   The	   "Evil	   Twins"	   syndrome. JSLS.	   2005	   Jan-­‐Mar;9(1):25-­‐9.	  34.	   Chung	  MK,	  Chung	  RR,	  Gordon	  D,	  Jennings	  C.	  The	  evil	  twins	  of	  chronic	  pelvic	  pain	  syndrome:	  endometriosis	  and	  interstitial	  cystitis.	  JSLS.	  2002;6(4):311-­‐4.	  35.	   Latthe	   P,	   Latthe	  M,	   Say	   L,	   Gülmezoglu	  M,	   Khan	   KS.	  WHO	   systematic	   review	   of	  prevalence	   of	   chronic	   pelvic	   pain:	   a	   neglected	   reproductive	   health	   morbidity.	   BMC	  Public	  Health.	  2006;6:177.	  
	   	  
	   	  
	   242	  
36.	   Liberati	  A,	  Altman	  DG,	  Tetzlaff	  J,	  Mulrow	  C,	  Gøtzsche	  PC,	  Ioannidis	  JP,	  et	  al.	  The	  PRISMA	  statement	   for	  reporting	  systematic	  reviews	  and	  meta-­‐analyses	  of	  studies	   that	  evaluate	   health	   care	   interventions:	   explanation	   and	   elaboration.	   PLoS	   Med.	  2009;6(7):e1000100.	  37.	   Royal	   College	   of	   Obstetricians	   and	   Gynaecologists.	   Green-­‐top	   guideline:	  Management	  of	  Chronic	  Pelvic	  Pain.	  London.	  April	  2005.	  38.	   Villegas-­‐Echeverri,	   Lopez-­‐Jaramillo,	   Leon-­‐Avellaneda,	   Restrepo-­‐Santa.	   The	   role	  of	   cystoscopy	   when	   studying	   patients	   suffering	   from	   chronic	   pelvic	   pain:an	  observational	  study.	  .	  Columbia:	  Rev	  Colomb	  Obstet	  Ginecol;	  2011.	  p.	  161-­‐6.	  39.	   Shahmohamady	   B,	   Berker	   B,	   Lashay	   N,	   Saberi	   N,	   Kazerooni	   T,	   Nezhat	   C.	  Interstitial	   cystitis	   in	   the	   setting	   of	   chronic	   pelvic	   pain.	   Obstetrics	   and	   Gynecology.	  2005;105(4):101S-­‐S.	  40.	   Glasziou	  P,	  Irwig	  L,	  Bain	  C,	  Colditz	  G.	  Frequency	  and	  Rate.	  In	  systematic	  Reviews	  in	  Health	  Care:	  A	  practical	  guide.	  2nd	  edition:	  Cambridge	  University	  Press;	  2001.	  p.	  67-­‐73.	  41.	   Khan	   KS,	   Kunz	   R,	   Kleijnen	   J,	   Antes	   G.	   Five	   steps	   to	   conducting	   a	   systematic	  review.	  J	  R	  Soc	  Med.	  2003;96(3):118-­‐21.	  42.	   Streiner	  DL,	  Norman	  GR.	  Measurement.	  London:	  PDQ	  Epidemiology;	  1998.	  43.	   Zamora	  J,	  Abraira	  V,	  Muriel	  A,	  Khan	  K,	  Coomarasamy	  A.	  Meta-­‐DiSc:	  a	  software	  for	  meta-­‐analysis	  of	  test	  accuracy	  data.	  BMC	  Med	  Res	  Methodol.	  2006;6:31.	  44.	   Chung	   MK,	   Chung	   RP,	   Gordon	   D.	   Interstitial	   cystitis	   and	   endometriosis	   in	  patients	  with	  chronic	  pelvic	  pain:	  The	  "Evil	  Twins"	  syndrome.	  JSLS.	  2005;9(1):25-­‐9.	  45.	   Blum	  M,	  Rho	  M.	  A	  multidisciplinary	  approach	  to	  managing	  lumbar	  radiculopathy	  throughout	  pregnancy:	  A	  unique	  case	  report.	  PM&R.	  2012;	  vol	  4	  (10)	  suppl	  263.	  46.	   Paulson	   JD,	  Paulson	   JN.	  Anterior	  vaginal	  wall	   tenderness	   (AVWT)	  as	  a	  physical	  symptom	  in	  chronic	  pelvic	  pain.	  JSLS.	  2011;15(1):6-­‐9.	  47.	   Rackow	  BW,	  Novi	   JM,	   Arya	   LA,	   Pfeifer	   SM.	   Interstitial	   cystitis	   is	   an	   etiology	   of	  chronic	  pelvic	  pain	  in	  young	  women.	  J	  Pediatr	  Adolesc	  Gynecol.	  2009;22(3):181-­‐5.	  48.	   Stanford	  EJ,	  Koziol	  J,	  Feng	  A.	  The	  prevalence	  of	  interstitial	  cystitis,	  endometriosis,	  adhesions,	   and	   vulvar	   pain	   in	   women	   with	   chronic	   pelvic	   pain.	   J	   Minim	   Invasive	  Gynecol.	  2005;12(1):43-­‐9.	  49.	   Clemons	   JL,	   Arya	   LA,	  Myers	   DL.	   Diagnosing	   interstitial	   cystitis	   in	  women	  with	  chronic	  pelvic	  pain.	  Obstet	  Gynecol.	  2002;100(2):337-­‐41.	  50.	   Cao	  W,	  Zhang	  D,	  Gan	  J.	  [Effects	  of	  microwave	  baking	  on	  the	  immunological	  cells	  in	  primary	  lymphedema	  patients].	  Chung-­‐Hua	  Cheng	  Hsing	  Shao	  Shang	  Wai	  Ko	  Tsa	  Chih	  -­‐	  Chinese	  Journal	  of	  Plastic	  Surgery	  &	  Burns.15(5):357-­‐9.	  51.	   Kushner	   L,	   Moldwin	   RM.	   Efficiency	   of	   questionnaires	   used	   to	   screen	   for	  interstitial	  cystitis.	  J	  Urol.	  2006;176(2):587-­‐92.	  52.	   Clemens	   JQ,	   Link	   CL,	   Eggers	   PW,	   Kusek	   JW,	   Nyberg	   LM,	   McKinlay	   JB,	   et	   al.	  Prevalence	  of	  painful	  bladder	  symptoms	  and	  effect	  on	  quality	  of	   life	   in	  black,	  Hispanic	  and	  white	  men	  and	  women.	  J	  Urol.	  2007;177(4):1390-­‐4.	  53.	   Sant	   GR.	   Interstitial	   cystitis	   in	   minority	   women.	   J	   Assoc	   Acad	   Minor	   Phys.	  1993;4(3):89-­‐92.	  54.	   Jacoby	  VL,	  Fujimoto	  VY,	  Giudice	  LC,	  Kuppermann	  M,	  Washington	  AE.	  Racial	  and	  ethnic	   disparities	   in	   benign	   gynecologic	   conditions	   and	   associated	   surgeries.	   Am	   J	  Obstet	  Gynecol.	  2010;202(6):514-­‐21.	  55.	   Suskind	  AM,	  Berry	  SH,	  Suttorp	  MJ,	  Elliott	  MN,	  Hays	  RD,	  Ewing	  BA,	  et	  al.	  Health-­‐related	   quality	   of	   life	   in	   patients	  with	   interstitial	   cystitis/bladder	   pain	   syndrome	   and	  frequently	  associated	  comorbidities.	  Qual	  Life	  Res.	  2013;22(7):1537-­‐41.	  
	   	  
	   	  
	   243	  
56.	   Cervigni	   M,	   Natale	   F.	   Gynecological	   disorders	   in	   bladder	   pain	  syndrome/interstitial	  cystitis	  patients.	  Int	  J	  Urol.	  2014;21	  Suppl	  1:85-­‐8.	  57.	   Tirlapur	   SA,	   Kuhrt	   K,	   Chaliha	   C,	   Ball	   E,	   Meads	   C,	   Khan	   KS.	   The	   'evil	   twin	  syndrome'	  in	  chronic	  pelvic	  pain:	  a	  systematic	  review	  of	  prevalence	  studies	  of	  bladder	  pain	  syndrome	  and	  endometriosis.	  Int	  J	  Surg.	  2013. 2013;11(3):233-­‐7	  58.	   McMullan	  M.	  Patients	  using	  the	   Internet	   to	  obtain	  health	   information:	  how	  this	  affects	   the	   patient-­‐health	   professional	   relationship.	   Patient	   Educ	   Couns.	   2006;63(1-­‐2):24-­‐8.	  59.	   Benigeri	  M,	  Pluye	  P.	  Shortcomings	  of	  health	  information	  on	  the	  Internet.	  Health	  Promot	  Int.	  2003;18(4):381-­‐6.	  60.	   Temml	   C,	   Wehrberger	   C,	   Riedl	   C,	   Ponholzer	   A,	   Marszalek	   M,	   Madersbacher	   S.	  Prevalence	  and	  correlates	  for	  interstitial	  cystitis	  symptoms	  in	  women	  participating	  in	  a	  health	  screening	  project.	  Eur	  Urol.	  2007;51(3):803-­‐8;	  discussion	  9.	  61.	   Chien	  PF,	  Khan	  KS,	  Siassakos	  D.	  Registration	  of	  systematic	  reviews:	  PROSPERO.	  BJOG.	  2012;119(8):903-­‐5.	  62.	   Liberati	  A,	  Altman	  DG,	  Tetzlaff	  J,	  Mulrow	  C,	  Gøtzsche	  PC,	  Ioannidis	  JP,	  et	  al.	  The	  PRISMA	  statement	   for	  reporting	  systematic	  reviews	  and	  meta-­‐analyses	  of	  studies	   that	  evaluate	   health	   care	   interventions:	   explanation	   and	   elaboration.	   J	   Clin	   Epidemiol.	  2009;62(10):e1-­‐34.	  63.	   Silberg	  WM,	   Lundberg	   GD,	   Musacchio	   RA.	   Assessing,	   controlling,	   and	   assuring	  the	   quality	   of	  medical	   information	   on	   the	   Internet:	   Caveant	   lector	   et	   viewor-­‐-­‐Let	   the	  reader	  and	  viewer	  beware.	  JAMA.	  1997;277(15):1244-­‐5.	  64.	   Latthe	  PM,	  Latthe	  M,	  Khan	  KS.	  Quality	  of	  medical	  information	  about	  menorrhagia	  on	  the	  worldwide	  web.	  BJOG.	  2000;107(1):39-­‐43.	  65.	   Winker	   MA,	   Flanagin	   A,	   Chi-­‐Lum	   B,	   White	   J,	   Andrews	   K,	   Kennett	   RL,	   et	   al.	  Guidelines	   for	   medical	   and	   health	   information	   sites	   on	   the	   internet:	   principles	  governing	  AMA	  web	  sites.	  American	  Medical	  Association.	  JAMA.	  2000;283(12):1600-­‐6.	  66.	   Groot	   D,	   ter	   Riet	   G,	   Khan	   KS,	   Misso	   K.	   Comparison	   of	   search	   strategies	   and	  quality	  of	  medical	   information	  of	   the	   Internet:	  a	  study	  relating	  to	  ankle	  sprain.	   Injury.	  2001;32(6):473-­‐6.	  67.	   Kunst	   H,	   Groot	   D,	   Latthe	   PM,	   Latthe	   M,	   Khan	   KS.	   Accuracy	   of	   information	   on	  apparently	   credible	   websites:	   survey	   of	   five	   common	   health	   topics.	   BMJ.	  2002;324(7337):581-­‐2.	  68.	   Murphy	   R,	   Frost	   S,	   Webster	   P,	   Schmidt	   U.	   An	   evaluation	   of	   web-­‐based	  information.	  Int	  J	  Eat	  Disord.	  2004;35(2):145-­‐54.	  69.	   Ambre	   J,	   Guard	   R,	   Perveiler	   FM,	   Renner	   J,	   Rippen	   H.	   White	   paper:	   Criteria	  for	  assessing	  the	  quality	  of	  health	  information	  on	  the	  internet.	  1997.	  70.	   Bernstam	  EV,	  Shelton	  DM,	  Walji	  M,	  Meric-­‐Bernstam	  F.	  Instruments	  to	  assess	  the	  quality	  of	  health	   information	  on	   the	  World	  Wide	  Web:	  what	   can	  our	  patients	  actually	  use?	  Int	  J	  Med	  Inform.	  2005;74(1):13-­‐9.	  71.	   Routh	  JC,	  Gong	  EM,	  Cannon	  GM,	  Nelson	  CP.	  Does	  a	  controversial	  topic	  affect	  the	  quality	  of	  urologic	  information	  on	  the	  Internet?	  Urology.	  2011;78(5):1051-­‐6.	  72.	   Kaicker	  J,	  Debono	  VB,	  Dang	  W,	  Buckley	  N,	  Thabane	  L.	  Assessment	  of	  the	  quality	  and	   variability	   of	   health	   information	   on	   chronic	   pain	   websites	   using	   the	   DISCERN	  instrument.	  BMC	  Med.	  2010;8:59.	  73.	   Henderson	   EM,	   Rosser	   BA,	   Keogh	   E,	   Eccleston	   C.	   Internet	   sites	   offering	  adolescents	  help	  with	  headache,	  abdominal	  pain,	  and	  dysmenorrhoea:	  a	  description	  of	  content,	  quality,	  and	  peer	  interactions.	  J	  Pediatr	  Psychol.	  2012;37(3):262-­‐71.	  
	   	  
	   	  
	   244	  
74.	   Landis	   JR,	   Koch	   GG.	   The	   measurement	   of	   observer	   agreement	   for	   categorical	  data.	  Biometrics.	  1977;33(1):159-­‐74.	  75.	   Henry	   JL.	  The	  need	   for	  knowledge	   translation	   in	  chronic	  pain.	  Pain	  Res	  Manag.	  2008;13(6):465-­‐76.	  76.	   Corcoran	   TB,	   Haigh	   F,	   Seabrook	   A,	   Schug	   SA.	   The	   quality	   of	   internet-­‐sourced	  information	  for	  patients	  with	  chronic	  pain	  is	  poor.	  Clin	  J	  Pain.	  2009;25(7):617-­‐23.	  77.	   de	  Boer	  MJ,	  Versteegen	  GJ,	   van	  Wijhe	  M.	  Patients'	  use	  of	   the	   Internet	   for	  pain-­‐related	  medical	  information.	  Patient	  Educ	  Couns.	  2007;68(1):86-­‐97.	  78.	   Sajadi	   KP,	   Goldman	   HB.	   Social	   networks	   lack	   useful	   content	   for	   incontinence.	  Urology.	  2011;78(4):764-­‐7.	  79.	   Clemens	  JO,	  Calhoun	  EA,	  Litwin	  MS,	  Collins	  MM.	  Primary	  care	  physician	  practice	  patterns	   in	   the	   management	   of	   interstitial	   cystitis/painful	   bladder	   syndrome.	  Neurourology	  and	  Urodynamics.	  2008;27(2):140-­‐1.	  80.	   Cline	  RJ,	  Haynes	  KM.	  Consumer	  health	   information	  seeking	  on	  the	  Internet:	   the	  state	  of	  the	  art.	  Health	  Educ	  Res.	  2001;16(6):671-­‐92.	  81.	   Tirlapur	  SA,	  Vlismas	  A,	  Ball	  E,	  Khan	  KS.	  Nerve	  stimulation	  for	  chronic	  pelvic	  pain	  and	   bladder	   pain	   syndrome:	   a	   systematic	   review.	   Acta	   Obstet	   Gynecol	   Scand.	  2013;92(8):881-­‐7.	  82.	   Tincello	  DG,	  Walker	  AC.	  Interstitial	  cystitis	  in	  the	  UK:	  results	  of	  a	  questionnaire	  survey	   of	   members	   of	   the	   Interstitial	   Cystitis	   Support	   Group.	   Eur	   J	   Obstet	   Gynecol	  Reprod	  Biol.	  2005;118(1):91-­‐5.	  83.	   Tirlapur	   SA,	   Khan	   KS.	   Grading	   of	   evidence	   for	   bladder	   pain	   syndrome:	   a	  comparative	  review	  of	  study	  quality	  assessment	  methods.	  Int	  Urogynecol	  J.	  2013.	  84.	   Poldrack	   RA.	   Can	   cognitive	   processes	   be	   inferred	   from	   neuroimaging	   data?	  Trends	  Cogn	  Sci.	  2006;10(2):59-­‐63.	  85.	   Kelley	  K,	  Clark	  B,	  Brown	  V,	  Sitzia	  J.	  Good	  practice	  in	  the	  conduct	  and	  reporting	  of	  survey	  research.	  Int	  J	  Qual	  Health	  Care.	  2003;15(3):261-­‐6.	  86.	   Latthe	  PM,	  Braunholtz	  DA,	  Hills	  RK,	  Khan	  KS,	  Lilford	  R.	  Measurement	  of	  beliefs	  about	  effectiveness	  of	  laparoscopic	  uterosacral	  nerve	  ablation.	  BJOG.	  2005;112(2):243-­‐6.	  87.	   Mahendru	  AA,	  Al-­‐Taher	  H.	  Cystodistension:	  certainly	  no	  standards	  and	  possibly	  no	  benefits-­‐-­‐survey	  of	  UK	  practice.	  Int	  Urogynecol	  J.	  2010;21(2):135-­‐9.	  88.	   Keller	   JJ,	   Chen	  YK,	  Lin	  HC.	  Comorbidities	  of	  bladder	  pain	   syndrome/interstitial	  cystitis:	  a	  population-­‐based	  study.	  BJU	  Int.	  2012;110(11	  Pt	  C):E903-­‐9.	  89.	   Hepner	   KA,	  Watkins	   KE,	   Elliott	   MN,	   Clemens	   JQ,	   Hilton	   LG,	   Berry	   SH.	   Suicidal	  ideation	   among	   patients	   with	   bladder	   pain	   syndrome/interstitial	   cystitis.	   Urology.	  2012;80(2):280-­‐5.	  90.	   Watkins	   KE,	   Eberhart	   N,	   Hilton	   L,	   Suttorp	   MJ,	   Hepner	   KA,	   Clemens	   JQ,	   et	   al.	  Depressive	   disorders	   and	   panic	   attacks	   in	   women	   with	   bladder	   pain	  syndrome/interstitial	   cystitis:	   a	   population-­‐based	   sample.	   Gen	   Hosp	   Psychiatry.	  2011;33(2):143-­‐9.	  91.	   Clemens	  JQ,	  Calhoun	  EA,	  Litwin	  MS,	  Walker-­‐Corkery	  E,	  Markossian	  T,	  Kusek	  JW,	  et	  al.	  A	  survey	  of	  primary	  care	  physician	  practices	  in	  the	  diagnosis	  and	  management	  of	  women	  with	  interstitial	  cystitis/painful	  bladder	  syndrome.	  Urology.	  2010;76(2):323-­‐8.	  92.	   Mishra	   N,	   Meijlink	   J.	   International	   survey	   on	   interstitial	   cystitis.	   Int	   J	   Urol.	  2003;10	  Suppl:S59-­‐60.	  93.	   Bogart	   LM,	   Berry	   SH,	   Clemens	   JQ.	   Symptoms	   of	   interstitial	   cystitis,	   painful	  bladder	   syndrome	   and	   similar	   diseases	   in	   women:	   a	   systematic	   review.	   J	   Urol.	  2007;177(2):450-­‐6.	  
	   	  
	   	  
	   245	  
94.	   Warren	   JW,	  Diggs	   C,	   Horne	   L,	   Greenberg	   P.	   Interstitial	   cystitis/painful	   bladder	  syndrome:	   what	   do	   patients	   mean	   by	   "perceived"	   bladder	   pain?	   Urology.	  2011;77(2):309-­‐12.	  95.	   Reitsma	   JB,	   Rutjes	   AW,	   Khan	   KS,	   Coomarasamy	   A,	   Bossuyt	   PM.	   A	   review	   of	  solutions	   for	   diagnostic	   accuracy	   studies	   with	   an	   imperfect	   or	   missing	   reference	  standard.	  J	  Clin	  Epidemiol.	  2009;62(8):797-­‐806.	  96.	   Bossuyt	   PM,	   Reitsma	   JB,	   Bruns	   DE,	   Gatsonis	   CA,	   Glasziou	   PP,	   Irwig	   LM,	   et	   al.	  Towards	  complete	  and	  accurate	  reporting	  of	  studies	  of	  diagnostic	  accuracy:	  the	  STARD	  initiative.	  BMJ.	  2003;326(7379):41-­‐4.	  97.	   Liu	  B,	  Su	  M,	  Zhan	  H,	  Yang	  F,	  Li	  W,	  Zhou	  X.	  Adding	  a	  Sexual	  Dysfunction	  Domain	  to	  UPOINT	   System	   Improves	   Association	   With	   Symptoms	   in	   Women	   With	   Interstitial	  Cystitis	  and	  Bladder	  Pain	  Syndrome.	  Urology.	  2014. Oct	  11.	  98.	   Bogart	  LM,	  Suttorp	  MJ,	  Elliott	  MN,	  Clemens	  JQ,	  Berry	  SH.	  Validation	  of	  a	  quality-­‐of-­‐life	  scale	   for	  women	  with	  bladder	  pain	  syndrome/interstitial	  cystitis.	  Qual	  Life	  Res.	  2012;21(9):1665-­‐70.	  99.	   Chung	  SD,	  Liu	  SP,	  Li	  HC,	  Lin	  HC.	  Health	  care	  service	  utilization	  among	  patients	  with	   bladder	   pain	   syndrome/interstitial	   cystitis	   in	   a	   single	   payer	   healthcare	   system.	  PLoS	  One.	  2014;9(1):e87522.	  100.	   Tirlapur	  SA,	  Priest	  L,	  Wojdyla	  D,	  Khan	  KS.	  Bladder	  pain	  syndrome:	  validation	  of	  simple	  tests	  for	  diagnosis	  in	  women	  with	  chronic	  pelvic	  pain:	  BRaVADO	  study	  protocol.	  Reprod	  Health.	  2013;10(1):61.	  101.	   Zondervan	   KT,	   Yudkin	   PL,	   Vessey	   MP,	   Dawes	   MG,	   Barlow	   DH,	   Kennedy	   SH.	  Prevalence	   and	   incidence	   of	   chronic	   pelvic	   pain	   in	   primary	   care:	   evidence	   from	   a	  national	  general	  practice	  database.	  Br	  J	  Obstet	  Gynaecol.	  1999;106(11):1149-­‐55.	  102.	   Royal	  College	  of	  Obstetricians	  and	  Gynaecologists.	  Initial	  management	  of	  chronic	  pelvic	  pain.	  2012.	  103.	   Engeler	   D,	   Baranowski	   AP,	   Elneil	   S,	   Hughes	   J,	   Messelink	   EJ,	   Oliveira	   P,	   et	   al.	  Guidelines	  on	  Chronic	  Pelvic	  Pain.	  2012.	  104.	   Howard	  FM.	  The	  role	  of	  laparoscopy	  in	  chronic	  pelvic	  pain:	  promise	  and	  pitfalls.	  Obstet	  Gynecol	  Surv.	  1993;48(6):357-­‐87.	  105.	   Hebbar	   S,	   Chawla	  C.	  Role	   of	   laparoscopy	   in	   evaluation	  of	   chronic	  pelvic	  pain.	   J	  Minim	  Access	  Surg.	  2005;1(3):116-­‐20.	  106.	   Tirlapur	   SA,	   Khan	   KS,	   Ball	   E.	   The	   role	   of	   laparoscopy	   and	   cystoscopy	   in	   the	  diagnosis	   and	   management	   of	   pelvic	   and	   bladder	   pain.	   In:	   Ledger,	   editor.	   Recent	  advances	  in	  obstetrics	  and	  gynaecology.	  1.	  1	  ed2014.	  p.	  1-­‐8.	  107.	   Wykes	   CB,	   Clark	   TJ,	   Khan	   KS.	   Accuracy	   of	   laparoscopy	   in	   the	   diagnosis	   of	  endometriosis:	  a	  systematic	  quantitative	  review.	  BJOG.	  2004;111(11):1204-­‐12.	  108.	   Freedman	   J,	   Ganeshan	   A,	   Crowe	   PM.	   Pelvic	   congestion	   syndrome:	   the	   role	   of	  interventional	   radiology	   in	   the	   treatment	   of	   chronic	   pelvic	   pain.	   Postgrad	   Med	   J.	  2010;86(1022):704-­‐10.	  109.	   Munday	   PE.	   Clinical	   aspects	   of	   pelvic	   inflammatory	   disease.	   Hum	   Reprod.	  1997;12(11	  Suppl):121-­‐6.	  110.	   Ahmad	   G,	   O'Flynn	   H,	   Duffy	   JM,	   Phillips	   K,	   Watson	   A.	   Laparoscopic	   entry	  techniques.	  Cochrane	  Database	  Syst	  Rev.	  2012;2:CD006583.	  111.	   Ball	  E,	  Koh	  C,	  Janik	  G,	  Davis	  C.	  Gynaecological	  laparoscopy:	  'see	  and	  treat'	  should	  be	  the	  gold	  standard.	  Curr	  Opin	  Obstet	  Gynecol.	  2008;20(4):325-­‐30.	  112.	   Okaro	  E,	  Condous	  G,	  Khalid	  A,	  Timmerman	  D,	  Ameye	  L,	  Huffel	  SV,	  et	  al.	  The	  use	  of	  ultrasound-­‐based	   'soft	  markers'	   for	   the	  prediction	  of	  pelvic	  pathology	   in	  women	  with	  chronic	  pelvic	  pain-­‐-­‐can	  we	  reduce	  the	  need	  for	  laparoscopy?	  BJOG.	  2006;113(3):251-­‐6.	  
	   	  
	   	  
	   246	  
113.	   Byrne	   H,	   Ball	   E,	   Davis	   C.	   The	   role	   of	   magnetic	   resonance	   imaging	   in	   minimal	  access	  surgery. Curr	  Opin	  Obstet	  Gynecol.	  2006	  Aug;18(4):369-­‐73.	  114.	   Griffiths	   AN,	   Koutsouridou	   RN,	   Penketh	   RJ.	   Rectovaginal	   endometriosis	   -­‐-­‐	   a	  frequently	  missed	  diagnosis.	  J	  Obstet	  Gynaecol.	  2007;27(6):605-­‐7.	  115.	   Wright	   J,	   Lotfallah	   H,	   Jones	   K,	   Lovell	   D.	   A	   randomized	   trial	   of	   excision	   versus	  ablation	  for	  mild	  endometriosis.	  Fertil	  Steril.	  2005;83(6):1830-­‐6.	  116.	   Swank	  DJ,	  Swank-­‐Bordewijk	  SC,	  Hop	  WC,	  van	  Erp	  WF,	  Janssen	  IM,	  Bonjer	  HJ,	  et	  al.	   Laparoscopic	   adhesiolysis	   in	   patients	   with	   chronic	   abdominal	   pain:	   a	   blinded	  randomised	  controlled	  multi-­‐centre	  trial.	  Lancet.	  2003;361(9365):1247-­‐51.	  117.	   Dunker	  MS,	  Bemelman	  WA,	  Vijn	  A,	   Jansen	  FW,	  Peters	  AA,	   Janss	  RA,	  et	  al.	  Long-­‐term	  outcomes	  and	  quality	  of	  life	  after	  laparoscopic	  adhesiolysis	  for	  chronic	  abdominal	  pain.	  J	  Am	  Assoc	  Gynecol	  Laparosc.	  2004;11(1):36-­‐41.	  118.	   Elcombe	   S,	   Gath	  D,	  Day	  A.	   The	   psychological	   effects	   of	   laparoscopy	   on	  women	  with	  chronic	  pelvic	  pain.	  Psychol	  Med.	  1997;27(5):1041-­‐50.	  119.	   Levy	  G,	  Dehaene	  A,	  Laurent	  N,	  Lernout	  M,	  Collinet	  P,	  Lucot	  JP,	  et	  al.	  An	  update	  on	  adenomyosis.	  Diagn	  Interv	  Imaging.	  2013;94(1):3-­‐25.	  120.	   Yasmin	   H,	   Bombieri	   L,	   Hollingworth	   J.	   What	   happens	   to	   women	   with	   chronic	  pelvic	  pain	  after	  a	  negative	  [normal]	  laparoscopy?	  J	  Obstet	  Gynaecol.	  2005;25(3):283-­‐5.	  121.	   Offiah	   I,	  McMahon	   SB,	   O'Reilly	   BA.	   Interstitial	   cystitis/bladder	   pain	   syndrome:	  diagnosis	  and	  management.	  Int	  Urogynecol	  J.	  2013. Aug;24(8):1243-­‐56.	  122.	   Latthe	   P,	   Mignini	   L,	   Gray	   R,	   Hills	   R,	   Khan	   K.	   Factors	   predisposing	   women	   to	  chronic	  pelvic	  pain:	  systematic	  review.	  BMJ.	  2006;332(7544):749-­‐55.	  123.	   Butrick	   CW.	   Patients	   with	   chronic	   pelvic	   pain:	   endometriosis	   or	   interstitial	  cystitis/painful	  bladder	  syndrome?	  JSLS.	  2007;11(2):182-­‐9.	  124.	   Baranowski	   AP,	   Lee	   J,	   Price	   C,	   Hughes	   J.	   Pelvic	   pain:	   a	   pathway	   for	   care	  developed	   for	   both	   men	   and	   women	   by	   the	   British	   Pain	   Society.	   Br	   J	   Anaesth.	  2014;112(3):452-­‐9.	  125.	   Daniels	  JP,	  Khan	  KS.	  Chronic	  pelvic	  pain	  in	  women.	  BMJ.	  2010;341:c4834.	  126.	   Burton	  C,	  Sajja	  A,	  Latthe	  PM.	  Effectiveness	  of	  percutaneous	  posterior	  tibial	  nerve	  stimulation	   for	  overactive	  bladder:	  A	   systematic	   review	  and	  meta-­‐analysis.	  Neurourol	  Urodyn.	  2012. Nov;31(8):1206-­‐16.	  127.	   Giannantoni	   A,	   Bini	   V,	   Dmochowski	   R,	   Hanno	   P,	   Nickel	   JC,	   Proietti	   S,	   et	   al.	  Contemporary	   management	   of	   the	   painful	   bladder:	   a	   systematic	   review.	   Eur	   Urol.	  2012;61(1):29-­‐53.	  128.	   Marcelissen	   T,	   Jacobs	   R,	   van	   Kerrebroeck	   P,	   de	   Wachter	   S.	   Sacral	  Neuromodulation	   as	   a	   Treatment	   for	   Chronic	   Pelvic	   Pain.	   Journal	   of	   Urology.	  2011;186(2):387-­‐93.	  129.	   Bosch	   J.	  Electrical	  neuromodulatory	   therapy	   in	   female	  voiding	  dysfunction.	  Bju	  International.	  2006;98:43-­‐8.	  130.	   Hassouna	  MM,	  Siegel	  SW,	  Nyeholt	  A,	  Elhilali	  MM,	  van	  Kerrebroeck	  PEV,	  Das	  AK,	  et	   al.	   Sacral	   neuromodulation	   in	   the	   treatment	   of	   urgency-­‐frequency	   symptoms:	   A	  multicenter	  study	  on	  efficacy	  and	  safety.	  Journal	  of	  Urology.	  2000;163(6):1849-­‐54.	  131.	   Fariello	  JY,	  Whitmore	  K.	  Sacral	  neuromodulation	  stimulation	  for	  IC/PBS,	  chronic	  pelvic	   pain,	   and	   sexual	   dysfunction.	   International	   Urogynecology	   Journal.	  2010;21(12):1553-­‐8.	  132.	   Downs	  SH,	  Black	  N.	  The	   feasibility	  of	  creating	  a	  checklist	   for	   the	  assessment	  of	  the	  methodological	  quality	  both	  of	   randomised	  and	  non-­‐randomised	   studies	  of	  health	  care	  interventions.	  J	  Epidemiol	  Community	  Health.	  1998;52(6):377-­‐84.	  
	   	  
	   	  
	   247	  
133.	   Jadad	   AR,	   Moore	   RA,	   Carroll	   D,	   Jenkinson	   C,	   Reynolds	   DJ,	   Gavaghan	   DJ,	   et	   al.	  Assessing	   the	   quality	   of	   reports	   of	   randomized	   clinical	   trials:	   is	   blinding	   necessary?	  Control	  Clin	  Trials.	  1996;17(1):1-­‐12.	  134.	   Kennelley	  J.	  Methodological	  approach	  to	  assessing	  the	  evidence.	  Reducing	  racial	  and	   ethnic	   disparities	   in	   reproductive	   and	   perinatal	   outcomes:	   the	   evidence	   from	  population-­‐based	  interventions.	  2011.	  p.	  7-­‐20.	  135.	   Guyatt	   GH,	   Oxman	   AD,	   Vist	   GE,	   Kunz	   R,	   Falck-­‐Ytter	   Y,	   Alonso-­‐Coello	   P,	   et	   al.	  GRADE:	   an	   emerging	   consensus	   on	   rating	   quality	   of	   evidence	   and	   strength	   of	  recommendations.	  BMJ.	  2008;336(7650):924-­‐6.	  136.	   Sharma	  M,	  Ansari	  MT,	  Abou-­‐Setta	  AM,	   Soares-­‐Weiser	  K,	  Ooi	  TC,	   Sears	  M,	   et	   al.	  Systematic	   review:	   comparative	   effectiveness	   and	   harms	   of	   combination	   therapy	   and	  monotherapy	  for	  dyslipidemia.	  Ann	  Intern	  Med.	  2009;151(9):622-­‐30.	  137.	   Gokyildiz	   S,	   Kizilkaya	   Beji	   N,	   Yalcin	   O,	   Istek	   A.	   Effects	   of	   percutaneous	   tibial	  nerve	  stimulation	  therapy	  on	  chronic	  pelvic	  pain.	  Gynecol	  Obstet	  Invest.	  2012;73(2):99-­‐105.	  138.	   O'Reilly	   BA,	   Dwyer	   PL,	   Hawthorne	   G,	   Cleaver	   S,	   Thomas	   E,	   Rosamilia	   A,	   et	   al.	  Transdermal	   posterior	   tibial	   nerve	   laser	   therapy	   is	   not	   effective	   in	   women	   with	  interstitial	  cystitis.	  Journal	  of	  Urology.	  2004;172(5):1880-­‐3.	  139.	   Kabay	   S,	   Kabay	   SC,	   Yucel	   M,	   Ozden	   H.	   Efficiency	   of	   posterior	   tibial	   nerve	  stimulation	   in	  category	  IIIB	  chronic	  prostatitis/chronic	  pelvic	  pain:	  a	  Sham-­‐Controlled	  Comparative	  Study.	  Urol	  Int.	  2009;83(1):33-­‐8.	  140.	   Lee	   SH,	   Lee	   BC.	   Electroacupuncture	   relieves	   pain	   in	   men	   with	   chronic	  prostatitis/chronic	   pelvic	   pain	   syndrome:	   three-­‐arm	   randomized	   trial.	   Urology.	  2009;73(5):1036-­‐41.	  141.	   Guyatt	  GH,	  Oxman	  AD,	  Kunz	  R,	  Vist	  GE,	  Falck-­‐Ytter	  Y,	  Schünemann	  HJ,	  et	  al.	  What	  is	  "quality	  of	  evidence"	  and	  why	  is	  it	  important	  to	  clinicians?	  BMJ.	  2008;336(7651):995-­‐8.	  142.	   Brozek	  JL,	  Akl	  EA,	  Alonso-­‐Coello	  P,	  Lang	  D,	  Jaeschke	  R,	  Williams	  JW,	  et	  al.	  Grading	  quality	  of	  evidence	  and	  strength	  of	  recommendations	  in	  clinical	  practice	  guidelines.	  Part	  1	   of	   3.	   An	   overview	   of	   the	   GRADE	   approach	   and	   grading	   quality	   of	   evidence	   about	  interventions.	  Allergy.	  2009;64(5):669-­‐77.	  143.	   Baxter	  C,	  Kim	   JH.	  Contrasting	   the	  percutaneous	  nerve	  evaluation	  versus	  staged	  implantation	  in	  sacral	  neuromodulation.	  Curr	  Urol	  Rep.	  2010;11(5):310-­‐4.	  144.	   Diokno	  AC,	  Burgess	  S,	  Mulholland	  T.	  Complication	  of	  the	  sacral	  neuromodulator:	  lead	  avulsion	  and	  wire	  disruption.	  J	  Urol.	  2003;169(1):283-­‐4.	  145.	   Mowatt	  G,	  Glazener	  C,	  Jarrett	  M.	  Sacral	  nerve	  stimulation	  for	  faecal	  incontinence	  and	   constipation	   in	   adults.	   Cochrane	   Database	   of	   Systematic	   Reviews.	   2007(3).	   Jul	  18;(3):CD004464.	  146.	   van	  de	  Merwe	  JP.	  Interstitial	  cystitis	  and	  systemic	  autoimmune	  diseases.	  Nat	  Clin	  Pract	  Urol.	  2007;4(9):484-­‐91.	  147.	   Quillin	   RB,	   Erickson	   DR.	   Practical	   Use	   of	   the	   New	   American	   Urological	  Association	  Interstitial	  Cystitis	  Guidelines.	  Curr	  Urol	  Rep.	  2012. Oct;13(5):394-­‐401.	  148.	   Bernstein	   AJ,	   Peters	   KM.	   Expanding	   indications	   for	   neuromodulation.	   Urologic	  Clinics	  of	  North	  America.	  2005;32(1):59.	  149.	   Peters	  K,	  Carrico	  D,	  Burks	  F.	  Validation	  of	  a	  Sham	  for	  Percutaneous	  Tibial	  Nerve	  Stimulation	  (PTNS).	  Neurourology	  and	  Urodynamics.	  2009;28(1):58-­‐61.	  150.	   Butrick	   CW,	   Howard	   FM,	   Sand	   PK.	   Diagnosis	   and	   treatment	   of	   interstitial	  cystitis/painful	   bladder	   syndrome:	   a	   review.	   Journal	   of	  Women's	   Health	   (15409996).	  2010;19(6):1185-­‐94.	  
	   	  
	   	  
	   248	  
151.	   Dudding	  TC.	  Future	  indications	  for	  sacral	  nerve	  stimulation.	  Colorectal	  Dis.	  2011	  Mar;13	  Suppl	  2:23-­‐8	  152.	   van	  Balken	  MR,	  Vandoninck	  V,	  Messelink	  BJ,	  Vergunst	  H,	  Heesakkers	  J,	  Debruyne	  FMJ,	   et	   al.	   Percutaneous	   tibial	   nerve	   stimulation	   as	   neuromodulative	   treatment	   of	  chronic	  pelvic	  pain.	  European	  Urology.	  2003;43(2):158-­‐63.	  153.	   Kirkham	  JJ,	  Gargon	  E,	  Clarke	  M,	  Williamson	  PR.	  Can	  a	  core	  outcome	  set	  improve	  the	  quality	   of	   systematic	   reviews?-­‐-­‐a	   survey	  of	   the	  Co-­‐ordinating	  Editors	   of	   Cochrane	  Review	  Groups.	  Trials.	  2013;14:21.	  154.	   Williamson	   PR,	   Altman	   DG,	   Blazeby	   JM,	   Clarke	   M,	   Devane	   D,	   Gargon	   E,	   et	   al.	  Developing	  core	  outcome	  sets	  for	  clinical	  trials:	  issues	  to	  consider.	  Trials.	  2012;13:132.	  155.	   Harman	  NL,	  Bruce	  IA,	  Callery	  P,	  Tierney	  S,	  Sharif	  MO,	  O'Brien	  K,	  et	  al.	  MOMENT	  -­‐	  Management	   of	   Otitis	   Media	   with	   Effusion	   in	   Cleft	   Palate:	   protocol	   for	   a	   systematic	  review	  of	  the	  literature	  and	  identification	  of	  a	  core	  outcome	  set	  using	  a	  Delphi	  survey.	  Trials.	  2013;14:70.	  156.	   Shea	   BJ,	   Grimshaw	   JM,	   Wells	   GA,	   Boers	   M,	   Andersson	   N,	   Hamel	   C,	   et	   al.	  Development	  of	  AMSTAR:	  a	  measurement	   tool	   to	  assess	   the	  methodological	  quality	  of	  systematic	  reviews.	  BMC	  Med	  Res	  Methodol.	  2007;7:10.	  157.	   Dawson	   TE,	   Jamison	   J.	   Intravesical	   treatments	   for	   painful	   bladder	   syndrome/	  interstitial	  cystitis.	  Cochrane	  Database	  Syst	  Rev.	  2007	  Oct	  17;(4):CD006113.	  158.	   Dimitrakov	  J,	  Kroenke	  K,	  Steers	  WD,	  Berde	  C,	  Zurakowski	  D,	  Freeman	  MR,	  et	  al.	  Pharmacologic	   management	   of	   painful	   bladder	   syndrome/interstitial	   cystitis:	   a	  systematic	  review.	  Arch	  Intern	  Med.	  2007;167(18):1922-­‐9.	  159.	   Mangera	  A,	  Andersson	  KE,	  Apostolidis	  A,	  Chapple	  C,	  Dasgupta	  P,	  Giannantoni	  A,	  et	  al.	  Contemporary	  management	  of	  lower	  urinary	  tract	  disease	  with	  botulinum	  toxin	  A:	  a	  systematic	  review	  of	  botox	  (onabotulinumtoxinA)	  and	  dysport	  (abobotulinumtoxinA).	  Eur	  Urol.	  2011	  Oct;60(4):784-­‐95.	  160.	   Matsuoka	   PK,	   Haddad	   JM,	   Pacetta	   AM,	   Baracat	   EC.	   Intravesical	   treatment	   of	  painful	   bladder	   syndrome:	   a	   systematic	   review	   and	   meta-­‐analysis.	   Int	   Urogynecol	   J.	  2012;23(9):1147-­‐53.	  161.	   Mourtzoukou	   EG,	   Iavazzo	   C,	   Falagas	   ME.	   Resiniferatoxin	   in	   the	   treatment	   of	  interstitial	   cystitis:	   A	   systematic	   review.	   Int	   Urogynecol	   J	   Pelvic	   Floor	  Dysfunct.	   2008	  Nov;19(11):1571-­‐6.	  162.	   Srivastava	  D.	  Efficacy	  of	  sacral	  neuromodulation	  in	  treating	  chronic	  pain	  related	  to	   painful	   bladder	   syndrome/interstitial	   cystitis	   in	   adults. J	   Anaesthesiol	   Clin	  Pharmacol.	  2012	  Oct;28(4):428-­‐35.	  163.	   Tirlapur	  SA,	  Vlismas	  A,	  Ball	  E,	  Khan	  KS.	  Nerve	  stimulation	  for	  chronic	  pelvic	  pain	  and	   bladder	   pain	   syndrome:	   a	   systematic	   review.	   Acta	   Obstet	   Gynecol	   Scand.	   2013	  Aug;92(8):881-­‐7.	  164.	   Tirumuru	  S,	  Al-­‐Kurdi	  D,	  Latthe	  P.	  Intravesical	  botulinum	  toxin	  A	  injections	  in	  the	  treatment	   of	   painful	   bladder	   syndrome/interstitial	   cystitis:	   a	   systematic	   review.	   Int	  Urogynecol	  J.	  2010;21(10):1285-­‐300.	  165.	   Cody	   JD,	   Nabi	   G,	   Dublin	   N,	   McClinton	   S,	   Neal	   DE,	   Pickard	   R,	   et	   al.	   Urinary	  diversion	   and	   bladder	   reconstruction/replacement	   using	   intestinal	   segments	   for	  intractable	   incontinence	   or	   following	   cystectomy.	   Cochrane	   Database	   Syst	   Rev.	   2012	  Feb	  15;2:CD003306	  166.	   Vilar	   DG,	   Fadrique	   GG,	   Martin	   IJP,	   Aguado	   JM,	   Perello	   CG,	   Verdu	   LS,	   et	   al.	  Hypebaric	  oxygen	  treatment	  in	  urology.	  Arch	  Esp	  Urol.	  2011	  Nov;64(9):869-­‐74.	  
	   	  
	   	  
	   249	  
167.	   Yokoyama	  T,	  Chancellor	  MB,	  Oguma	  K,	  Yamamoto	  Y,	   Suzuki	  T,	  Kumon	  H,	   et	   al.	  Botulinum	   toxin	   typeA	   for	   the	   treatment	   of	   lower	   urinary	   tract	   disorders.	   Int	   J	   Urol.	  2012	  Mar;19(3):202-­‐15.	  168.	   Bade	   JJ,	   Laseur	  M,	   Nieuwenburg	   A,	   van	   der	  Weele	   LT,	  Mensink	   HJ.	   A	   placebo-­‐controlled	   study	   of	   intravesical	   pentosanpolysulphate	   for	   the	   treatment	   of	   interstitial	  cystitis.	  Br	  J	  Urol.	  1997;79(2):168-­‐71.	  169.	   Barbalias	  GA,	  Liatsikos	  EN,	  Athanasopoulos	  A,	  Nikiforidis	  G.	   Interstitial	  cystitis:	  bladder	  training	  with	  intravesical	  oxybutynin.	  J	  Urol.	  2000;163(6):1818-­‐22.	  170.	   Chen	  TY,	  Corcos	   J,	  Camel	  M,	  Ponsot	  Y,	  Tu	   lM.	  Prospective,	   randomized,	  double-­‐blind	  study	  of	  safety	  and	  tolerability	  of	  intravesical	  resiniferatoxin	  (RTX)	  in	  interstitial	  cystitis	  (IC).	  Int	  Urogynecol	  J	  Pelvic	  Floor	  Dysfunct.	  2005;16(4):293-­‐7.	  171.	   Mayer	  R,	  Propert	  KJ,	  Peters	  KM,	  Payne	  CK,	  Zhang	  Y,	  Burks	  D,	  et	  al.	  A	  randomized	  controlled	   trial	   of	   intravesical	   bacillus	   calmette-­‐guerin	   for	   treatment	   refractory	  interstitial	  cystitis.	  J	  Urol.	  2005;173(4):1186-­‐91.	  172.	   Payne	   CK,	   Mosbaugh	   PG,	   Forrest	   JB,	   Evans	   RJ,	   Whitmore	   KE,	   Antoci	   JP,	   et	   al.	  Intravesical	   resiniferatoxin	   for	   the	   treatment	   of	   interstitial	   cystitis:	   a	   randomized,	  double-­‐blind,	  placebo	  controlled	  trial.	  J	  Urol.	  2005;173(5):1590-­‐4.	  173.	   Peeker	   R,	   Haghsheno	   MA,	   Holmäng	   S,	   Fall	   M.	   Intravesical	   bacillus	   Calmette-­‐Guerin	  and	  dimethyl	  sulfoxide	  for	  treatment	  of	  classic	  and	  nonulcer	  interstitial	  cystitis:	  a	  prospective,	   randomized	  double-­‐blind	   study.	   J	  Urol.	  2000;164(6):1912-­‐5;	  discussion	  5-­‐6.	  174.	   Perez-­‐Marrero	  R,	  Emerson	  LE,	  Feltis	  JT.	  A	  controlled	  study	  of	  dimethyl	  sulfoxide	  in	  interstitial	  cystitis.	  J	  Urol.	  1988;140(1):36-­‐9.	  175.	   Peters	  K,	  Diokno	  A,	  Steinert	  B,	  Yuhico	  M,	  Mitchell	  B,	  Krohta	  S,	  et	  al.	  The	  efficacy	  of	  intravesical	  Tice	  strain	  bacillus	  Calmette-­‐Guerin	  in	  the	  treatment	  of	  interstitial	  cystitis:	  a	  double-­‐blind,	  prospective,	  placebo	  controlled	  trial.	  J	  Urol.	  1997;157(6):2090-­‐4.	  176.	   Kuo	   HC,	   Chancellor	   MB.	   Comparison	   of	   intravesical	   botulinum	   toxin	   type	   A	  injections	   plus	   hydrodistention	   with	   hydrodistention	   alone	   for	   the	   treatment	   of	  refractory	  interstitial	  cystitis/painful	  bladder	  syndrome.	  BJU	  Int.	  2009;104(5):657-­‐61.	  177.	   Nickel	   JC,	   Moldwin	   R,	   Lee	   S,	   Davis	   EL,	   Henry	   RA,	   Wyllie	   MG.	   Intravesical	  alkalinized	   lidocaine	   (PSD597)	   offers	   sustained	   relief	   from	   symptoms	   of	   interstitial	  cystitis	  and	  painful	  bladder	  syndrome.	  BJU	  Int.	  2009;103(7):910-­‐8.	  178.	   Irani	   D,	   Heidari	   M,	   Khezri	   AA.	   The	   efficacy	   and	   safety	   of	   intravesical	   Bacillus-­‐Calmette-­‐Guerin	  in	  the	  treatment	  of	  female	  patients	  with	  interstitial	  cystitis:	  a	  double-­‐blinded	  prospective	  placebo	  controlled	  study.	  Urol	  J.	  2004;1(2):90-­‐3.	  179.	   Lazzeri	  M,	   Beneforti	   P,	   Spinelli	  M,	   Zanollo	   A,	   Barbagli	   G,	   Turini	   D.	   Intravesical	  resiniferatoxin	   for	   the	   treatment	   of	   hypersensitive	   disorder:	   a	   randomized	   placebo	  controlled	  study.	  J	  Urol.	  2000;164(3	  Pt	  1):676-­‐9.	  180.	   El-­‐Bahnasy	   A,	   Farahat	   Y,	   El-­‐Bendary	   M,	   Taha	   M,	   El-­‐Damhogy	   M,	   Mourad	   S.	   A	  Randomized	  Controlled	  Trial	  of	  Bacillus	  Calmette-­‐Guerin	  and	  Botulinum	  Toxin-­‐A	  for	  the	  Treatment	  of	  Refractory	  Interstitial	  Cystitis.	  UroToday	  International	  Journal	  [Internet].	  2009;	  2(1).	  181.	   Manning	   JA,	  Dwyer	  P,	  Rosamilia	  A,	  Murray	  C,	  Thomas	  E,	  Beattie	  K.	  Prospective	  randomized	  double	  blind	  study	  of	  the	  effectiveness	  of	  botulinum	  a	  toxin	  for	  treatment	  of	   refractory	   painful	   bladder	   syndrome.	   International	   Urogynecology	   Journal.	  2009;20:S87-­‐S8.	  182.	   van	   Ophoven	   A,	   Pokupic	   S,	   Heinecke	   A,	   Hertle	   L.	   A	   prospective,	   randomized,	  placebo	  controlled,	  double-­‐blind	  study	  of	  amitriptyline	  for	  the	  treatment	  of	   interstitial	  cystitis.	  J	  Urol.	  2004;172(2):533-­‐6.	  
	   	  
	   	  
	   250	  
183.	   van	  Ophoven	  A,	  Rossbach	  G,	  Pajonk	  F,	  Hertle	  L.	  Safety	  and	  efficacy	  of	  hyperbaric	  oxygen	  therapy	  for	  the	  treatment	  of	  interstitial	  cystitis:	  a	  randomized,	  sham	  controlled,	  double-­‐blind	  trial.	  J	  Urol.	  2006;176(4	  Pt	  1):1442-­‐6.	  184.	   Warren	   JW,	   Horne	   LM,	   Hebel	   JR,	   Marvel	   RP,	   Keay	   SK,	   Chai	   TC.	   Pilot	   study	   of	  sequential	   oral	   antibiotics	   for	   the	   treatment	   of	   interstitial	   cystitis.	   J	   Urol.	  2000;163(6):1685-­‐8.	  185.	   Thilagarajah	   R,	   Witherow	   RO,	   Walker	   MM.	   Oral	   cimetidine	   gives	   effective	  symptom	   relief	   in	   painful	   bladder	   disease:	   a	   prospective,	   randomized,	   double-­‐blind	  placebo-­‐controlled	  trial.	  BJU	  Int.	  2001;87(3):207-­‐12.	  186.	   Sairanen	  J,	  Tammela	  TL,	  Leppilahti	  M,	  Multanen	  M,	  Paananen	  I,	  Lehtoranta	  K,	  et	  al.	   Cyclosporine	   A	   and	   pentosan	   polysulfate	   sodium	   for	   the	   treatment	   of	   interstitial	  cystitis:	  a	  randomized	  comparative	  study.	  J	  Urol.	  2005;174(6):2235-­‐8.	  187.	   Sant	   GR,	   Propert	   KJ,	   Hanno	   PM,	   Burks	   D,	   Culkin	   D,	   Diokno	   AC,	   et	   al.	   A	   pilot	  clinical	   trial	   of	   oral	   pentosan	   polysulfate	   and	   oral	   hydroxyzine	   in	   patients	   with	  interstitial	  cystitis.	  J	  Urol.	  2003;170(3):810-­‐5.	  188.	   Korting	  GE,	  Smith	  SD,	  Wheeler	  MA,	  Weiss	  RM,	  Foster	  HE.	  A	  randomized	  double-­‐blind	   trial	   of	   oral	   L-­‐arginine	   for	   treatment	   of	   interstitial	   cystitis.	   J	   Urol.	  1999;161(2):558-­‐65.	  189.	   Cartledge	  JJ,	  Davies	  AM,	  Eardley	  I.	  A	  randomized	  double-­‐blind	  placebo-­‐controlled	  crossover	   trial	  of	   the	  efficacy	  of	  L-­‐arginine	   in	   the	   treatment	  of	   interstitial	   cystitis.	  BJU	  Int.	  2000;85(4):421-­‐6.	  190.	   Mulholland	  SG,	  Hanno	  P,	  Parsons	  CL,	  Sant	  GR,	  Staskin	  DR.	  Pentosan	  polysulfate	  sodium	   for	   therapy	   of	   interstitial	   cystitis.	   A	   double-­‐blind	   placebo-­‐controlled	   clinical	  study.	  Urology.	  1990;35(6):552-­‐8.	  191.	   Gottsch	   HP,	   Yang	   CC,	   Berger	   RE.	   A	   pilot	   study	   of	   botulinum	   toxin	   A	   for	   male	  chronic	  pelvic	  pain	  syndrome.	  Scand	  J	  Urol	  Nephrol.	  2011;45(1):72-­‐6.	  192.	   Nickel	  JC,	  Egerdie	  RB,	  Steinhoff	  G,	  Palmer	  B,	  Hanno	  P.	  A	  multicenter,	  randomized,	  double-­‐blind,	   parallel	   group	   pilot	   evaluation	   of	   the	   efficacy	   and	   safety	   of	   intravesical	  sodium	   chondroitin	   sulfate	   versus	   vehicle	   control	   in	   patients	   with	   interstitial	  cystitis/painful	  bladder	  syndrome.	  Urology.	  2010;76(4):804-­‐9.	  193.	   Holm-­‐Bentzen	  M,	  Jacobsen	  F,	  Nerstrøm	  B,	  Lose	  G,	  Kristensen	  JK,	  Pedersen	  RH,	  et	  al.	   A	   prospective	   double-­‐blind	   clinically	   controlled	   multicenter	   trial	   of	   sodium	  pentosanpolysulfate	  in	  the	  treatment	  of	   interstitial	  cystitis	  and	  related	  painful	  bladder	  disease.	  J	  Urol.	  1987;138(3):503-­‐7.	  194.	   Parsons	   CL,	   Mulholland	   SG.	   Successful	   therapy	   of	   interstitial	   cystitis	   with	  pentosanpolysulfate.	  J	  Urol.	  1987;138(3):513-­‐6.	  195.	   Simpson	  R,	  Thomas	  K,	  Murphy	  R.	  Outcome	  measures	  for	  vulval	  skin	  conditions:	  A	   systematic	   review	   of	   randomised	   controlled	   trials.	   British	   Journal	   of	   Dermatology.	  2013;In	  press.	  196.	   Tugwell	   P,	   Boers	   M,	   Brooks	   P,	   Simon	   L,	   Strand	   V,	   Idzerda	   L.	   OMERACT:	   an	  international	   initiative	   to	   improve	   outcome	   measurement	   in	   rheumatology.	   Trials.	  2007;8:38.	  197.	   Williamson	  P,	   Clarke	  M.	   The	  COMET	   (Core	  Outcome	  Measures	   in	   Effectiveness	  Trials)	  Initiative:	  Its	  Role	  in	  Improving	  Cochrane	  Reviews.	  Cochrane	  Database	  Syst	  Rev.	  2012;5:ED000041.	  198.	   Rahn	   DD,	   Abed	   H,	   Sung	   VW,	   Matteson	   KA,	   Rogers	   RG,	   Morrill	   MY,	   et	   al.	  Systematic	   review	   highlights	   difficulty	   interpreting	   diverse	   clinical	   outcomes	   in	  abnormal	  uterine	  bleeding	  trials.	  J	  Clin	  Epidemiol.	  2011;64(3):293-­‐300.	  
	   	  
	   	  
	   251	  
199.	   Haylen	   BT,	   Freeman	   RM,	   Swift	   SE,	   Cosson	   M,	   Davila	   GW,	   Deprest	   J,	   et	   al.	   An	  International	   Urogynecological	   Association	   (IUGA)	   /	   International	   Continence	   Society	  (ICS)	   joint	   terminology	   and	   classification	   of	   the	   complications	   related	   directly	   to	   the	  insertion	  of	  prostheses	  (meshes,	  implants,	  tapes)	  &	  grafts	  in	  female	  pelvic	  floor	  surgery.	  Int	  Urogynecol	  J.	  2011;22(1):3-­‐15.	  200.	   Toozs-­‐Hobson	  P,	  Freeman	  R,	  Barber	  M,	  Maher	  C,	  Haylen	  B,	  Athanasiou	  S,	  et	  al.	  An	  International	   Urogynecological	   Association	   (IUGA)/International	   Continence	   Society	  (ICS)	  joint	  report	  on	  the	  terminology	  for	  reporting	  outcomes	  of	  surgical	  procedures	  for	  pelvic	  organ	  prolapse.	  Neurourol	  Urodyn.	  2012;31(4):415-­‐21.	  201.	   Smyth	  RM,	  Kirkham	  JJ,	  Jacoby	  A,	  Altman	  DG,	  Gamble	  C,	  Williamson	  PR.	  Frequency	  and	  reasons	  for	  outcome	  reporting	  bias	  in	  clinical	  trials:	  interviews	  with	  trialists.	  BMJ.	  2011;342:c7153.	  202.	   Dwan	   K,	   Gamble	   C,	   Williamson	   PR,	   Altman	   DG.	   Reporting	   of	   clinical	   trials:	   a	  review	  of	  research	  funders'	  guidelines.	  Trials.	  2008;9:66.	  203.	   Kirkham	  JJ,	  Dwan	  KM,	  Altman	  DG,	  Gamble	  C,	  Dodd	  S,	  Smyth	  R,	  et	  al.	  The	  impact	  of	  outcome	   reporting	   bias	   in	   randomised	   controlled	   trials	   on	   a	   cohort	   of	   systematic	  reviews.	  BMJ.	  2010;340:c365.	  204.	   Khan	  K.	  The	  CROWN	  Initiative:	  journal	  editors	  invite	  researchers	  to	  develop	  core	  outcomes	  in	  women's	  health.	  BJOG.	  2014.	  Sep;121(10):1181-­‐2.	  205.	   Tirlapur	  SA,	  Riordain	  RN,	  Khan	  KS,	  Collaboration	  E-­‐C.	  Variations	  in	  the	  reporting	  of	  outcomes	  used	  in	  systematic	  reviews	  of	  treatment	  effectiveness	  research	  in	  bladder	  pain	  syndrome.	  Eur	  J	  Obstet	  Gynecol	  Reprod	  Biol.	  2014;180C:61-­‐7.	  206.	   Guyatt	  G,	  Oxman	  AD,	  Akl	  EA,	  Kunz	  R,	  Vist	  G,	  Brozek	  J,	  et	  al.	  GRADE	  guidelines:	  1.	  Introduction-­‐GRADE	  evidence	  profiles	  and	  summary	  of	  findings	  tables.	  J	  Clin	  Epidemiol.	  2011;64(4):383-­‐94.	  207.	   Guyatt	   GH,	   Oxman	   AD,	   Schünemann	   HJ,	   Tugwell	   P,	   Knottnerus	   A.	   GRADE	  guidelines:	   a	   new	   series	   of	   articles	   in	   the	   Journal	   of	   Clinical	   Epidemiology.	   J	   Clin	  Epidemiol.	  2011;64(4):380-­‐2.	  208.	   Roos	  C,	  Borowiack	  E,	  Kowalska	  M,	  Zapalska	  A,	  Mol	  B,	  Mignini	  L,	  et	  al.	  What	  do	  we	  know	  about	  tocolytic	  effectiveness	  and	  how	  do	  we	  use	  this	  information	  in	  guidelines?	  A	  comparison	  of	  evidence	  grading.	  BJOG.	  2013	  Dec;120(13):1588-­‐96	  209.	   Guyatt	  GH,	  Oxman	  AD,	  Kunz	  R,	  Woodcock	   J,	   Brozek	   J,	  Helfand	  M,	   et	   al.	   GRADE	  guidelines:	   7.	   Rating	   the	   quality	   of	   evidence-­‐-­‐inconsistency.	   J	   Clin	   Epidemiol.	  2011;64(12):1294-­‐302.	  210.	   Guyatt	  GH,	  Oxman	  AD,	  Kunz	  R,	  Woodcock	   J,	   Brozek	   J,	  Helfand	  M,	   et	   al.	   GRADE	  guidelines:	   8.	   Rating	   the	   quality	   of	   evidence-­‐-­‐indirectness.	   J	   Clin	   Epidemiol.	  2011;64(12):1303-­‐10.	  211.	   Guyatt	  GH,	  Oxman	  AD,	  Kunz	  R,	  Brozek	   J,	  Alonso-­‐Coello	  P,	  Rind	  D,	   et	   al.	  GRADE	  guidelines	   6.	   Rating	   the	   quality	   of	   evidence-­‐-­‐imprecision.	   J	   Clin	   Epidemiol.	  2011;64(12):1283-­‐93.	  212.	   O'Hare	   PG,	   Hoffmann	   AR,	   Allen	   P,	   Gordon	   B,	   Salin	   L,	   Whitmore	   K.	   Interstitial	  cystitis	  patients'	  use	  and	  rating	  of	  complementary	  and	  alternative	  medicine	  therapies.	  Int	  Urogynecol	  J.	  2013.	  Jun;24(6):977-­‐82.	  213.	   Hertle	   L,	   van	   Ophoven	   A.	   Long-­‐term	   results	   of	   amitriptyline	   treatment	   for	  interstitial	  cystitis.	  Aktuelle	  Urol.	  2010;41	  Suppl	  1:S61-­‐5.	  214.	   Parsons	  CL,	  Benson	  G,	  Childs	  SJ,	  Hanno	  P,	  Sant	  GR,	  Webster	  G.	  A	  quantitatively	  controlled	   method	   to	   study	   prospectively	   interstitial	   cystitis	   and	   demonstrate	   the	  efficacy	  of	  pentosanpolysulfate.	  J	  Urol.	  1993;150(3):845-­‐8.	  
	   	  
	   	  
	   252	  
215.	   Parsons	   CL,	   Housley	   T,	   Schmidt	   JD,	   Lebow	   D.	   Treatment	   of	   interstitial	   cystitis	  with	  intravesical	  heparin.	  Br	  J	  Urol.	  1994;73(5):504-­‐7.	  216.	   Erickson	  DR,	  Kunselman	  AR,	  Bentley	  CM,	  Peters	  KM,	  Rovner	  ES,	  Demers	  LM,	  et	  al.	   Changes	   in	   urine	   markers	   and	   symptoms	   after	   bladder	   distention	   for	   interstitial	  cystitis.	  J	  Urol.	  2007;177(2):556-­‐60.	  217.	   Cole	  EE,	  Scarpero	  HM,	  Dmochowski	  RR.	  Are	  patient	  symptoms	  predictive	  of	  the	  diagnostic	   and/or	   therapeutic	   value	   of	   hydrodistention?	   Neurourol	   Urodyn.	  2005;24(7):638-­‐42.	  218.	   Ottem	  DP,	  Teichman	   JM.	  What	   is	   the	  value	  of	   cystoscopy	  with	  hydrodistension	  for	  interstitial	  cystitis?	  Urology.	  2005;66(3):494-­‐9.	  219.	   Higson	  RH,	  Smith	   JC,	  Whelan	  P.	  Bladder	  rupture:	  an	  acceptable	  complication	  of	  distension	  therapy?	  Br	  J	  Urol.	  1978;50(7):529-­‐34.	  220.	   Malloy	  TR,	   Shanberg	  AM.	   Laser	   therapy	   for	   interstitial	   cystitis.	  Urol	   Clin	  North	  Am.	  1994;21(1):141-­‐4.	  221.	   Rofeim	  O,	  Hom	  D,	  Freid	  RM,	  Moldwin	  RM.	  Use	  of	  the	  neodymium:	  YAG	  laser	  for	  interstitial	  cystitis:	  a	  prospective	  study.	  J	  Urol.	  2001;166(1):134-­‐6.	  222.	   Zhao	  J,	  Bai	  J,	  Zhou	  Y,	  Qi	  G,	  Du	  L.	  Posterior	  tibial	  nerve	  stimulation	  twice	  a	  week	  in	  patients	  with	  interstitial	  cystitis.	  Urology.	  2008;71(6):1080-­‐4.	  223.	   Whitmore	   KE,	   Payne	   CK,	   Diokno	   AC,	   Lukban	   JC.	   Sacral	   neuromodulation	   in	  patients	   with	   interstitial	   cystitis:	   a	   multicenter	   clinical	   trial.	   Int	   Urogynecol	   J	   Pelvic	  Floor	  Dysfunct.	  2003;14(5):305-­‐8;	  discussion	  8-­‐9.	  224.	   Maher	   CF,	   Carey	   MP,	   Dwyer	   PL,	   Schluter	   PL.	   Percutaneous	   sacral	   nerve	   root	  neuromodulation	  for	  intractable	  interstitial	  cystitis.	  J	  Urol.	  2001;165(3):884-­‐6.	  225.	   Comiter	  CV.	  Sacral	  neuromodulation	  for	  the	  symptomatic	  treatment	  of	  refractory	  interstitial	  cystitis:	  A	  prospective	  study.	  Journal	  of	  Urology.	  2003;169(4):1369-­‐73.	  226.	   Steinberg	  AC,	  Oyama	   IA,	  Whitmore	  KE.	  Bilateral	  S3	  Stimulator	   in	  Patients	  with	  Interstitial	  Cystitis.	  Urology.	  2007	  Mar;69(3):441-­‐3.	  227.	   Powell	   CR,	   Kreder	   KJ.	   Long-­‐Term	   Outcomes	   of	   Urgency-­‐Frequency	   Syndrome	  Due	  to	  Painful	  Bladder	  Syndrome	  Treated	  With	  Sacral	  Neuromodulation	  and	  Analysis	  of	  Failures.	  Journal	  of	  Urology.	  2010;183(1):173-­‐6.	  228.	   Sairanen	   J,	   Leppilahti	   M,	   Tammela	   T,	   Ruutu	   M,	   Finn	   ICSG.	   Quality	   of	   life	   in	  patients	  with	  interstitial	  cystitis/painful	  bladder	  syndrome	  after	  treatment	  with	  DMSO,	  BCG,	   cyclosporine	   and	   pentosan	   polysulfate	   sodium.	   European	   Urology	   Supplements.	  2007;6(2):169-­‐.	  229.	   Sairanen	  J,	  Hotakainen	  K,	  Tammela	  TL,	  Stenman	  UH,	  Ruutu	  M.	  Urinary	  epidermal	  growth	   factor	   and	   interleukin-­‐6	   levels	   in	   patients	   with	   painful	   bladder	  syndrome/interstitial	   cystitis	   treated	   with	   cyclosporine	   or	   pentosan	   polysulfate	  sodium.	  Urology.	  2008;71(4):630-­‐3.	  230.	   Sairanen	   J,	   Leppilahti	   M,	   Tammela	   TL,	   Paananen	   I,	   Aaltomaa	   S,	   Taari	   K,	   et	   al.	  Evaluation	   of	   health-­‐related	   quality	   of	   life	   in	   patients	   with	   painful	   bladder	  syndrome/interstitial	   cystitis	   and	   the	   impact	   of	   four	   treatments	   on	   it.	   Scand	   J	   Urol	  Nephrol.	  2009;43(3):212-­‐9.	  231.	   Tirumuru	  S,	  Al	  Kurdi	  D,	  Latthe	  P.	  Intravesical	  botulinum	  toxin	  a	  injections	  in	  the	  treatment	   of	   painful	   bladder	   syndrome/interstitial	   cystitis:	   a	   systematic	   review.	  International	  Urogynecology	  Journal.	  2010;21:S343-­‐S4.	  232.	   Rössberger	   J,	   Fall	  M,	   Jonsson	   O,	   Peeker	   R.	   Long-­‐term	   results	   of	   reconstructive	  surgery	   in	   patients	   with	   bladder	   pain	   syndrome/interstitial	   cystitis:	   subtyping	   is	  imperative.	  Urology.	  2007;70(4):638-­‐42.	  
	   	  
	   	  
	   253	  
233.	   Propert	  KJ,	  Mayer	  R,	  Nickel	   JC,	  Payne	  CK,	  Peters	  KM,	  Teal	  V,	   et	   al.	   Followup	  of	  patients	   with	   interstitial	   cystitis	   responsive	   to	   treatment	   with	   intravesical	   bacillus	  Calmette-­‐Guerin	  or	  placebo.	  J	  Urol.	  2008;179(2):552-­‐5.	  234.	   McCahy	  PJ,	  Styles	  RA.	  Prolonged	  bladder	  distension:	  experience	  in	  the	  treatment	  of	  detrusor	  overactivity	  and	  interstitial	  cystitis.	  Eur	  Urol.	  1995;28(4):325-­‐7.	  235.	   Glemain	  P,	  Rivière	  C,	  Lenormand	  L,	  Karam	  G,	  Bouchot	  O,	  Buzelin	  JM.	  Prolonged	  hydrodistention	   of	   the	   bladder	   for	   symptomatic	   treatment	   of	   interstitial	   cystitis:	  efficacy	  at	  6	  months	  and	  1	  year.	  Eur	  Urol.	  2002;41(1):79-­‐84.	  236.	   Badenoch	  AW.	  Chronic	  interstitial	  cystitis.	  Br	  J	  Urol.	  1971;43(6):718-­‐21.	  237.	   Tirlapur	   SA,	   Khan	   KS.	   Grading	   of	   evidence	   for	   bladder	   pain	   syndrome:	   a	  comparative	   review	   of	   study	   quality	   assessment	   methods.	   Int	   Urogynecol	   J.	  2014;25(8):1005-­‐13.	  238.	   Moher	  D,	  Liberati	  A,	  Tetzlaff	  J,	  Altman	  DG,	  Group	  P.	  Preferred	  reporting	  items	  for	  systematic	   reviews	   and	   meta-­‐analyses:	   the	   PRISMA	   statement.	   PLoS	   Med.	  2009;6(7):e1000097.	  	  
